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ABSTRACT 
The hypothalamus is a region of the central nervous system that is important in the regulation 
energy homeostasis. Thyroid hormone action within the hypothalamus has been shown to 
influence food intake and body weight and these effects may be mediated through the nuclear 
WUDQVFULSWLRQIDFWRU WK\URLGKRUPRQHUHFHSWRUEHWD 75ȕ, which is highly expressed within the 
ventromedial nucleus (VMN) of the hypothalamus. 
Recombinant adeno-associated virus (rAAV) expressing Cre recombinase (rAAV-Cre) was 
synthesised. This was injected bilaterally into the VMN of adult mice which were bred for locus 
of crossover of phage P1 (LoxP) sites within the THRB gene 75ȕflox/flox) ZKLFKHQFRGHV75ȕ. 
Cre recombination in these mice introduces a frame shift, so that only truncated products are 
encoded. This UHVXOWV LQ 75ȕ NQRFN GRZQ LQ WKH 901 Recombinant AAV encoding green 
fluorescent protein (GFP) (rAAV-GFP) was injected bilaterally into the VMN of control mice.  
Cre PHGLDWHG WLVVXH VSHFLILF NQRFNGRZQ RI 75ȕ LQ WKH901 UHVXOWHG LQ D highly significant 
increase in body weight over sixty three days. The cumulative food intake over the course of the 
VWXG\ ZDV VLJQLILFDQWO\ JUHDWHU LQ PLFH ZLWK 75ȕ NQRFN GRZQ LQ WKH 901 FRPSDUHG ZLWK
controls. Furthermore, mice with intra-VMN 75ȕ NQRFN GRZQmice failed to become obese 
when pair-fed to the food intake of control animals, but when allowed to ad libitum feed once 
again, gained significantly more weight and ate significantly more than controls. The importance 
of hyperphagia to the obese phenotype was further underscored by the level of uncoupling 
protein-1 mRNA in brown adipose tissue which was unaltered in intra-VMN 75ȕNQRFNGRZQ
mice. 
This work is the first to show WKHHVVHQWLDOIXQFWLRQRI75ȕLQWKH901LQWKHUHJXODWLRQRIIRRG
intake and body weight by demonstrating that 75ȕ NQRFN GRZQ LQ WKH 901 UHVXOts in 
hyperphagia and obesity. 
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1 CHAPTER ONE 
 
1.1 INTRODUCTION 
The neuroendocrine mechanisms that regulate food intake and body weight are highly conserved 
between mammalian species. These signalling pathways promote the storage of energy-dense 
triglycerides in adipose tissue, thereby permitting survival during the frequent periods of food 
deprivation that occurred during evolution (Neel, 1962). However, in modern times, the ready 
availability of energy-dense food and the reduced necessity for energy expenditure have resulted 
in the excess storage of adipose tissue and an increased prevalence of obesity (having a body 
mass index (BMI) of greater than 30 kgm2) that the World Health Organisation considers to be 
DQµHSLGHPLF¶(World Health Organisation, 2006). 
Obesity is an important public health problem. A prospective epidemiological study of more than 
one million people has established that obesity is an independent risk factor for increased 
mortality (Calle et al., 1999). In addition, overweight (having a BMI of 25-30 kgm2) and obesity 
cause significant morbidity, including type II diabetes mellitus, coronary heart disease, 
hypertension, sleep apnoea, certain cancers, psychological morbidity and societal stigmatisation 
and it has been shown that these health risks are greatly diminished when even modest amounts 
of weight (that is, five percent of total body weight) are lost (Blackburn, 1995, Calle et al., 1999, 
National Audit Office, 2001, Sjostrom et al., 1997). However, although lifestyle modification 
remains the cornerstone of weight reduction, dieting, by itself, is only rarely effective for the 
long term maintenance of weight loss (Wadden, 1993). Furthermore, the lack of effective 
pharmacotherapy for the treatment of obesity makes the management of this condition clinically 
challenging.  
Thyroid hormones play an essential role in the regulation of food intake and metabolic rate, 
which in turn influence body weight. Historically, the effects of thyroid hormones on energy 
homeostasis have been attributed to thyroid hormone action in the periphery. However, in more 
recent years the important effects of thyroid hormones in the central nervous system (CNS) have 
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also been described. One area of the CNS that has a well-defined role in the regulation of feeding 
and body weight is the hypothalamus (Hetherington and Ranson, 1940, Schwartz et al., 2000). 
The ventromedial nucleus (VMN) is situated within the mediobasal hypothalamus (MBH) and 
both the VMN, and more generally, the MBH have been particularly implicated in the central 
regulation of energy homeostasis by thyroid hormones. It has been shown that both 
pharmacological and physiological changes in thyroid hormones levels within the VMN and the 
MBH modulate food intake in mice, rats and hamsters (Barrett et al., 2007, Coppola et al., 2007, 
Ishii et al., 2003, Kong et al., 2004). However, the central mechanisms through which thyroid 
hormones regulate food intake and body weight are not well-defined.  
It is known that thyroid hormones regulate gene transcription via thyroid hormone receptors, a 
group of nuclear transcription factors which are part of the steroid hormone receptor superfamily. 
7KH WK\URLGKRUPRQH UHFHSWRUEHWD 75ȕ LVRIRUP LVKLJKO\ H[SUHVVHGZLWKLQ WKH901EXW LWV
role in energy homeostasis has not previously been characterised (Bradley et al., 1989, Cook et 
al., 1992). The aim of the work described in this thesis was to investigate the role of 
K\SRWKDODPLF75ȕLQWKHSK\VLRORJLFDOUHJXODWLRQRIfood intake and body weight. 
Progress in our understanding of the physiological systems which control energy homeostasis 
will result in improvements in the clinical management of obesity, the archetypal outcome of an 
imbalance between food intake and energy expenditure. Given the increasing worldwide 
prevalence of obesity, this would clearly bring significant public health benefits. 
35 
 
1.2 THE HYPOTHALAMUS 
The hypothalamus is a midline structure situated at the base of the brain below the thalamus and 
above the anterior pituitary gland (adenohypophysis) (FIGURE 1.1) (FIGURE 1.2). 
The hypothalamus plays a critical role in the maintenance of whole body homeostasis regulating 
feeding, energy homeostasis, glucose homeostasis, thermoregulation, circadian rhythms, sexual 
function, stress responses, the cardiovascular system and the abdominal viscera. It also controls 
the synthesis and secretion of hormones from the anterior pituitary gland through the release of 
regulatory peptides into the hypophyseal portal circulation, which act upon discrete cellular 
populations within the adenohypophysis. In addition, the posterior pituitary gland 
(neurohypophysis) which produces the hormones oxytocin and anti-diuretic hormone consists of 
neural tissue which is in direct continuity with the hypothalamus. 
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FI GURE 1.1  SCHEMATIC REPRESENTATION OF A MIDLINE SAGITTAL SECTION THROUGH THE 
MOUSE HYPOTHALAMUS 
Hypothalamic nuclei that are important in the control of food intake and energy homeostasis are 
depicted: Arc, arcuate nucleus; DMN, dorsomedial nucleus; LH, lateral hypothalamus; PVN, 
paraventricular nucleus; VMN, ventromedial nucleus.  
AC denotes the anterior commissure; PC posterior commissure; OC optic chiasm. 
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1.2.1 THE HYPOTHALAMUS AND THE REGULATION OF ENERGY HOMEOSTASIS 
Nutritional signals and neurotransmitters, which convey information about the metabolic milieu, 
converge within the hypothalamus. Here, they effect changes in neuronal activity, culminating in 
alterations in food intake and metabolic rate. These signalling pathways are composed of both 
short-term and long-term components. The short-term system, comprising changes in plasma gut 
hormones, plasma glucose and insulin concentration, body temperature and plasma amino acids, 
can all modulate meal patterns and feeding throughout the day (Dhillo, 2007). The long-term 
system balances food intake and energy expenditure and therefore plays a dominant role in 
UHJXODWLQJWKHVL]HRIWKHERG\¶VHQHUJ\VWRUHV 
The adipocyte derived peptide hormone leptin is a key component of this long-term metabolic 
regulatory system. Leptin is a sixteen kilodalton secreted protein that is a member of the cytokine 
family (Zhang et al., 1997). Leptin is synthesised and released by adipocytes and serum leptin 
levels are proportional to body fat mass (Pelleymounter et al., 1995a, Zhang et al., 1994). This 
makes leptin an important signal of stored energy and of nutritional status. 
 
1.2.2 HYPOTHALAMIC NUCLEI WHICH REGULATE FOOD INTAKE AND BODY WEIGHT  
The hypothalamic nuclei which are implicated in the regulation of food intake and body weight 
include the arcuate nucleus (Arc), the paraventricular nucleus (PVN), the VMN, the lateral 
hypothalamus (LH) and the dorsomedial nucleus (DMN) (FIGURE 1.1) (FIGURE 1.2). 
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FI GURE 1.2  SCHEMATIC REPRESENTATION OF CORONAL SECTIONS THROUGH THE MOUSE 
BRAIN AT ±0.82MM FROM BREGMA (A) AND -1.46MM FROM BREGMA (B) 
Key hypothalamic nuclei involved in the regulation of food intake and energy homeostasis are 
depicted; ARC, arcuate nucleus; DMN, dorsomedial nucleus; LHA, lateral hypothalamic area; 
PVN, paraventricular nucleus; VMN, ventromedial nucleus. 
Other abbreviations in the figures denote anatomical structures seen on coronal section at these 
two levels; 3V, third ventricle; AM, amygdala; CC, corpus callosum; CCX, cerebral cortex; FX, 
fornix; HI, hippocampus; ME, median eminence; OC, optic chiasm; PFA, pre-fornical area; SE, 
septum; TH, thalamus. Figure adapted from (Schwartz et al., 2000). 
39 
 
1.2.2.1 THE ARCUATE NUCLEUS  
The arcuate nucleus (Arc) of the MBH is located near the median eminence, an area of the CNS 
where the blood brain barrier is incomplete (Fry and Ferguson, 2007) (FIGURE 1.2). The Arc 
contains well-characterised populations of first order leptin responsive neurons which are known 
to have opposing effects on food intake. One population co-expresses the orexigenic peptides 
neuropeptide Y (NPY) and the melanocortin, agouti-related protein (AgRP). Cocaine- and 
amphetamine-regulated transcript (CART) and the anorectic peptide, alpha-melanocyte-
stimulating hormone (D-MSH) derived from the melanocortin pro-opiomelanocortin (POMC) are 
expressed in a separate neuronal subpopulation (Cheung et al., 1997, Elias et al., 1998, Erickson 
et al., 1996b). In combination, these leptin responsive neurons of the Arc respond to changes in 
plasma leptin levels and this results in an alteration in food intake (FIGURE 1.3). 
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FI GURE 1.3  THE RESPONSE OF ARCUATE NUCLEUS NEUROPEPTIDES TO FASTING AND TO 
FOOD INTAKE  
When food intake falls there is a reduction in fat cell mass and a consequent decrease in 
circulating leptin (panel A). This fall in plasma leptin is a potent signal to the Arc of negative 
energy balance. Within the Arc there is a reduction in the synthesis and release of anorectic 
peptides including the melanocortin 4 receptor (MC4R) agonist, alpha-melanocyte-stimulating 
hormone (Į-MSH) derived from the pro-opiomelanocortin (POMC) gene. Reduced leptin levels 
also result in a rise in the orexigenic Arc peptides neuropeptide Y (NPY) and agouti-related 
protein (AgRP), an antagonist at MC4R. An increase in food intake results in the expansion of 
the fat cell mass and an increase in circulating leptin (panel B). In the Arc, leptin inhibits the 
activation of orexigenic NPY/AgRP neurons and activates POMC neurons. These changes are 
relayed to second order neurons of the hypothalamus, notably those of the paraventricular 
nucleus (PVN), a key integrating centre and out flow nucleus with projections to numerous sites 
within the CNS known to modulate motivational behaviours including eating. Figure adapted 
from (Schwartz et al., 2000). 
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1.2.2.2 THE PARAVENTRICULAR NUCLEUS  
The paraventricular nucleus (PVN) is composed of a group of heterogeneous neurons situated on 
either side of the top of the third cerebral ventricle (FIGURE 1.1) (FIGURE 1.2). Both NPY/AgRP 
and POMC/CART neurons of the Arc project directly to the PVN. These connections between 
the Arc and the PVN are formed in the early post-natal period and their development is regulated 
by leptin (Bouret et al., 2004).  
Direct injection of NPY into the PVN of satiated rats induces hyperphagia in a dose-dependent 
manner, whilst administration of an NPY receptor antagonist reduces food intake (Stanley and 
Leibowitz, 1985)%RWK$J53DQGĮ-MSH act at the melanocortin 4 receptor (MC4R), which is 
highly expressed in the PVN (Fan et al., 1997, Huszar et al., 1997). Alpha-MSH mediates a basal 
tonic inhibition of food intake by agonist action at MC4R. Conversely, AgRP stimulates food 
intake by antagonism of the MC4R.  
The PVN controls the secretion of peptides from both the anterior and posterior pituitary gland 
and contains parvicellular neurons which directly innervate autonomic pre-ganglionic neurons in 
the medulla and spinal cord (Luiten et al., 1987, Swanson and Sawchenko, 1983). Therefore, the 
PVN may act as a final common relay, integrating the autonomic and endocrine response to 
changes in the metabolic milieu with projections to numerous sites outside the hypothalamus. 
This PVN output serves to regulate energy homeostasis through effects on the endocrine system, 
the autonomic nervous system and higher brain centres which modulate motivational behaviours 
including feeding.  
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1.2.2.3 THE VENTROMEDIAL NUCLEUS  
The ventromedial nucleus (VMN) is a bilateral group of encapsulated neuronal cell bodies and 
their dendritic branches which sit adjacent to the third ventricle above the Arc and below the 
DMN (FIGURE 1.1) (FIGURE 1.2). 
 
1.2.2.3.1.1 THE VENTROMEDIAL NUCLEUS AND THE REGULATION OF FOOD INTAKE; AN 
HISTORICAL PERSPECTIVE 
The importance of the VMN in the regulation of energy homeostasis was first reported by 
Hetherington and Ranson in the early 1940s (Hetherington and Ranson, 1940, Hetherington and 
Ranson, 1942). These workers demonstrated that bilateral electrolytic lesions of the VMN in rats 
resulted in the development of obesity, with body weight doubling in the first thirty days after 
surgery. The obesity that resulted from lesioning the VMN was thought to be predominantly due 
to hyperphagia which was observed immediately after the surgery (Brobeck, 1946, Brobeck et 
al., 1943, Brooks et al., 1946). In addition, it was found that the natural rodent pattern of feeding 
during the dark phase was abolished in VMN-lesioned rats, such that one third of the food intake 
occurred during the day (Kakolewski et al., 1971).  
 
1.2.2.3.1.2 NEURONAL CIRCUITS WITHIN THE VENTROMEDIAL NUCLEUS WHICH REGULATE 
FOOD INTAKE AND BODY WEIGHT 
The VMN can be subdivided into four sub-nuclear groups, dorsomedial, central, ventrolateral 
and anterior, which are functionally differentiated by receptor and peptide expression (Van 
Houten and Brawer, 1978). This includes the significant expression of a number of receptors and 
neuropeptides important in energy homeostasis, such as leptin, steroidogenic factor-1 (SF-1) and 
brain derived neurotrophic factor (BDNF). In addition, the concentration of plasma glucose has 
been shown to modulate food intake, an effect which may, in part, be mediated in the VMN. 
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1.2.2.3.1.3 LEPTIN 
The leptin receptor (ObR) is highly expressed in the dorsomedial VMN and direct injection of 
leptin into the VMN of rats has been shown to significantly reduce food intake and body weight 
over a three day study period (Jacob et al., 1997, Schwartz et al., 1996). Following peripheral 
administration of leptin, there is a rapid increase in the expression of the immediate early gene 
product c-fos and an increase in the expression of suppressor of cytokine signaling-3 (SOCS-3) 
mRNA, a component of the leptin intra-cellular signalling pathway (Bjorbaek et al., 1999, 
Elmquist et al., 1997). Both of these findings suggest that leptin acts directly within the VMN.   
 
1.2.2.3.1.4 STEROIDOGENIC FACTOR-1  
ObR is expressed in the VMN by a subset of neurons which express the transcription factor 
steroidogenic factor-1 (SF-1), an orphan member of the nuclear receptor superfamily (Dellovade 
et al., 2000). SF-1 is essential for the normal embryonic development of the VMN and SF-1 
knockout mice show marked disruption of the intra-nuclear architecture and develop late-onset 
obesity (Dellovade et al., 2000, Majdic et al., 2002). 
 
1.2.2.3.1.5 BRAIN DERIVED NEUROTROPHIC FACTOR  
Brain derived neurotrophic factor (BDNF) and its receptor, tropomyosin-related kinase B (TrkB) 
are abundantly expressed in the VMN, where BDNF expression is co-localised with SF-1 
expressing neurons. BDNF is a mediator of brain development and plasticity and also has a well-
defined role as an anorectic neuropeptide (Xu et al., 2003). The anorectic action of BDNF has been 
demonstrated following infusion into the lateral ventricle of rats, which results in a dose-dependent 
reduction in food intake and body weight. In addition, BDNF expression in the VMN, but not in 
other brain regions is regulated by nutritional state, with food deprivation resulting in a sixty percent 
reduction in BDNF mRNA in the VMN (Pelleymounter et al., 1995b, Xu et al., 2003). In mice, 
when BDNF is selectively deleted in the VMN and DMN, the mutant animals are hyperphagic and 
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obese with normal energy expenditure (Unger et al., 2007, Xu et al., 2003). This is in agreement 
with the severe hyperphagic obesity described in humans with mutations in the genes for BDNF or 
TrkB, a phenotype that confirms the physiological importance of BDNF signalling in human body 
weight regulation (Gray et al., 2006, Yeo et al., 2004). 
 
1.2.2.3.1.6 GLUCOSE 
Approximately half of VMN neurons are glucose responsive and respond to changes in local 
glucose concentration (Oomura et al., 1969, Oomura et al., 1974, Song et al., 2001). 
Intracerebroventricular (ICV) administration of glucose leads to the rapid induction of BDNF 
mRNA expression in the VMN of adult mice (Unger et al., 2007). This may partly explain the 
glucostatic theory of food intake which proposes that the glucose responsive neurons of the 
VMN promote satiety following glucose administration (Mayer, 1955, Unger et al., 2007). 
 
1.2.2.3.2 NEURONAL CONNECTIONS OF THE VENTROMEDIAL NUCLEUS 
The VMN is innervated by both POMC and AgRP neurons from the Arc and the melanocortin 
system plays a key role in modulating the anorectic effect of BDNF (Xu et al., 2003). The MC4R 
is highly expressed in the VMN and following ICV administration of an MC4R agonist to food 
deprived animals, the expression of BDNF mRNA in the VMN rises rapidly (Harrold et al., 
1999, Xu et al., 2003). Furthermore, BDNF expression is reduced in the obese Ay mouse in 
which the ectopic expression of agouti protein blocks the activation of the MC4R (Lu et al., 
1994, Xu et al., 2003). 
NPY immunoreactive neurons form a dense plexus within the VMN and the nucleus expresses 
the NPY receptor Y1 (Kishi et al., 2005). Direct injection of NPY into the VMN results in an 
increase in food intake, whilst injection of NPY antibodies into the VMN has the opposing effect 
(Stanley and Leibowitz, 1985, Walter et al., 1994). Recently, it has been reported that NPY 
inhibits the electrical activity of ObR expressing neurons of the VMN which raises the 
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possibility that the orexigenic effect of NPY in the VMN may result from the suppression the 
anorectic output of the nucleus (Chee et al., 2010).  
The VMN also has important extra-hypothalamic efferents including those to the brainstem 
which influence the outflow of the sympathetic nervous system to brown adipose tissue (see 
1.5.2) (Canteras et al., 1994, Lopez et al., 2010). 
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1.2.2.4 THE LATERAL HYPOTHALAMUS  
The lateral hypothalamus (LH) is a nucleus of the lateral zone of the hypothalamus (FIGURE 1.1) 
(FIGURE 1.2). To date, two key groups of LH peptides, the orexins and melanin concentrating 
hormone (MCH) have been identified as having a marked orexigenic effect which may be 
physiologically important. Levels of orexin pre-pro mRNA increase during fasting and central 
administration of orexin stimulates food intake (Sakurai et al., 1998). The orexins were originally 
named for their stimulatory effect on food intake from the Greek orexis meaning appetite, 
although subsequent studies have demonstrated that the orexins play a significant role in 
behavioural arousal (Hagan et al., 1999). In addition, a deficiency of orexin or its receptor has 
been shown to be associated with human narcolepsy, a condition of sudden irresistible day time 
somnolence (Lin et al., 1999, Nishino et al., 2000). 
Like the orexins, the expression of MCH mRNA in the LH also increases during starvation and 
returns to baseline after re-feeding (Qu et al., 1996). Furthermore, injection of MCH into the LH 
results in an increase in food intake in rats, whilst MCH knockout mice are hypophagic and have 
a lower body weight than wild type controls (Qu et al., 1996, Shimada et al., 1998). 
 
1.2.2.5 THE DORSOMEDIAL NUCLEUS  
The dorsomedial nucleus (DMN) lies above the VMN within the MBH (FIGURE 1.1) (FIGURE 1.2). 
In rats, destructive lesions of the DMN result in hyperphagia and obesity but this is less pronounced 
than the syndrome seen following ablation of the VMN (see 1.2.2.3.1.1). 
DMN neurons express the orexigenic peptide NPY and the tissue specific over expression of NPY 
in the DMN of rats using adeno-associated virus (AAV) results in an increase in food intake and 
body weight (Yang et al., 2009). Conversely, the knockdown of NPY in the DMN normalises the 
food intake of Otsuka Long-Evans Tokushima Fatty rats, a strain which is hyperphagic and obese 
due to the congenital absence of the receptor for the anorectic gut peptide cholecystokinin (Yang et 
al., 2009). The DMN receives afferent input from the Arc, VMN and LH and efferent fibres project 
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to the PVN (Bai et al., 1985, Swanson and Sawchenko, 1980). The DMN therefore serves as an 
important relay between the appetite circuits of the hypothalamus.  
  
48 
 
1.3 THE HYPOTHALAMO-PITUITARY-THYROID AXIS!
Thyroid hormones play an essential role in the regulation of energy homeostasis and recent 
evidence suggests that these effects may, in part, be mediated within the hypothalamus. 
Thyrotropin releasing hormone (TRH) is synthesised in the PVN. It acts upon thyrotrophs of the 
anterior pituitary gland, stimulating the synthesis and release of thyroid stimulating hormone 
(TSH). TSH governs the production and secretion of thyroxine (T4) and tri-iodothyronine (T3) 
by the thyroid gland. The synthesis and release of both TRH and TSH are regulated by feedback 
from circulating T3. In combination these feed-forward feedback effects are termed the 
hypothalamo-pituitary-thyroid (HPT) axis (FIGURE 1.4). 
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FI GURE 1.4 FEED-FORWARD AND FEEDBACK CONTROL OF THE HYPOTHALAMO-PITUITARY-
THYROID AXIS  
Thyrotropin releasing hormone (TRH) is released by the paraventricular nucleus (PVN) of the 
hypothalamus stimulating the synthesis and release of thyroid stimulating hormone (TSH) from 
thyrotrophs of the anterior pituitary gland. TSH binds to the TSH receptor expressed on 
follicular cells of the thyroid gland. This leads to an increase in the transcription of the 
thyroglobulin gene and thyroxine (T4) and tri-iodothyronine (T3) production and secretion. The 
majority of thyroid hormone released by the thyroid gland is in the form of the pro-hormone T4, 
which is converted to the active T3 by the action of the enzyme deiodinase 2 (D2) within target 
tissues. Circulating T3 feeds back to the anterior pituitary gland and to the PVN down regulating 
TSH and TRH production respectively. 
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1.3.1 THYROTROPIN RELEASING HORMONE  
Thyrotropin Releasing Hormone (TRH) is a modified three amino acid peptide hormone 
(pyroglutamate-histidine-proline-NH2) (Boler et al., 1969). Mature TRH is generated by the post-
translational cleavage of pre-TRH which contains five TRH progenitor sequences. High 
expression of TRH mRNA is found within neurons of the parvocellular division of the PVN 
which have been shown both to synthesise and to secrete the mature tripeptide (Lechan et al., 
1986, Segerson et al., 1987a, Yamada et al., 1997). 
The parvocellular neurons project to the median eminence where TRH is released into the portal 
circulation and is transported to the anterior pituitary gland. Here it binds to cell surface TRH 
receptors (TRHR) on pituitary thyrotrophs (Labrie et al., 1972).  
TRH neurons of the PVN are subject to transcriptional regulation by circulating thyroid 
hormones. The PVN is enclosed by the blood-brain barrier and T3 and T4 must therefore be 
actively transported into the CNS by two thyroid hormone specific transporters, organic anion 
transporting polypeptide 1C1 (OATP1C1) and monocarboxylate transporter 8 (MCT8) (Friesema 
et al., 2003, Sugiyama et al., 2003). 
The transcription of TRH is suppressed by high levels of circulating thyroid hormones and rises 
when levels fall (Koller et al., 1987, Segerson et al., 1987b). This negative feedback is mediated 
by the binding of T3 to the beta-LVRIRUPRIWKHWK\URLGKRUPRQHUHFHSWRU75ȕZKLFKWKHQ
binds to a negative thyroid hormone response element (TRE) in the promoter region of the TRH 
gene (Abel et al., 2001). 
 
1.3.2  THYROID STIMULATING HORMONE  
TRH binds to TRHR on thyrotrophs of the anterior pituitary gland, stimulating both the synthesis 
and release of thyroid stimulating hormone (TSH) (Harris et al., 1978, Straub et al., 1990). TSH 
is a glycoprotein which consists of an alpha and a beta subunit. The alpha subunit is identical to 
the alpha subunit of leutinising hormone, follicle stimulating hormone and human chorionic 
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gonadotropin whilst the beta subunit confers biological specificity (Lapthorn et al., 1994, Liao 
and Pierce, 1970). The expression of the beta subunit gene is confined to thyrotrophs whilst the 
alpha subunit gene is more widely expressed within the anterior pituitary gland. 
Circulating T3 exerts negative feedback control on TSH synthesis and release, with binding of 
7WR75ȕUHVXOWLQJLQWKHUDSLGUHGXFWLRQLQWKHWUDQVFULSWLRQRIERWKWKH76+Į and 76+ȕ genes 
(Chatterjee et al., 1989, Wondisford et al., 1989, Wood et al., 1989). 
 
1.3.3 THE THYROID GLAND 
TSH binds to and activates the membrane bound TSH receptor (TSHR), a G protein-coupled 
receptor which is expressed predominantly by the follicular cells of the thyroid gland. Binding of 
TSH to TSHR results in the synthesis and secretion of T4 and T3, which are released into the 
blood stream in a 4:1 ratio (Parmentier et al., 1989). 
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1.3.4 THE DEIODINASES AND THYROID HORMONE METABOLISM 
Two forms of thyroid hormone, T4 and T3 are released by the thyroid gland but it is the inactive 
pro-hormone T4 which is the major secretory product. T4 has low activity at thyroid hormone 
receptors (TRs) and must be converted into T3 in order to exert its biological activity. The 
activation and the inactivation of thyroid hormones is catalysed by the deiodinases, a group of 
three thioredoxin fold enzymes which have a conserved selenocysteine containing active site. It 
is the selective removal of iodine from T4 and its derivatives by the deiodinases that activates or 
inactivates these hormones (FIGURE 1.5). 
 
1.3.4.1 DEIODINASE 1  
Deiodinase 1 (D1) is predominantly expressed in liver and kidney cells with a preference for 
reverse tri-iodothyronine (rT3) and sulphated iodothyronines as substrates (Moreno et al., 1994). 
D1 can act as an outer ring deiodinase converting T4 to T3 or rT3 to ¶-diiodothyronine (T2). 
D1 can also deiodinate the inner ring of T4 thus converting it to rT3 (Moreno et al., 1994). D1 is 
thought to contribute to the circulating T3 level, although the production of T3 by D1 is 
inefficient compared with D2 which has a 700 fold greater FDWDO\WLF HIILFLHQF\ IRU WKH ¶-
deiodination of T4 (Maia et al., 2005). D1 also plays a role in thyroid hormone metabolism in 
disease states. Raised D1 expression and activity in the thyroid gland is an important contributor 
to the elevated circulating T3 level in hyperthyroidism, whilst impaired hepatic D1 activity 
contributes to the reduced T3 of non-thyroidal illness syndrome (NTIS) (Debaveye et al., 2008, 
Maia et al., 2005). 
 
1.3.4.2 DEIODINASE 2  
Deiodinase 2 (D2) generates the majority of intra-cellular T3 by catalysing outer ring 
deiodination of T4 (Visser et al., 1982). The expression of the deiodinase 2 gene (Dio2) and the 
activity of D2 increase markedly in hypothyroidism and fall in response to T4 administration, 
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thus protecting the tissue from the adverse effects of thyroid deficiency or excess (Visser et al., 
1982). D2 is highly expressed in the CNS and in the periphery where it is found in brown 
adipose tissue, the anterior pituitary gland, skeletal muscle, cardiac myocytes and the thyroid 
gland (Croteau et al., 1996, Salvatore et al., 1996). 
D2 activity is critical for thyroid hormone mediated feedback regulation of TSH and TRH 
production. Within the anterior pituitary gland, D2 converts circulating T4 into the receptor 
binding form of the hormone T3, which down regulates TSH production (see 1.3.2) (Chatterjee 
et al., 1989, Wood et al., 1989). D2 is not expressed in hypothalamic neurons but is highly 
expressed in tanycytes, the specialised endothelial cells which line the third ventricle (Tu et al., 
1997). Within tanycytes, D2 converts circulating T4 to T3 which is transported into the PVN. 
This mechanism ensures that under basal conditions, TRH production is regulated by the 
peripheral T4 concentration (see 1.3.1). 
 
1.3.4.3 DEIODINASE 3  
Deiodinase 3 (D3) catalyses the conversion of T4 to rT3 and T3 to T2 by inner ring deiodination. 
Both rT3 and T2 lack activity at TRs and D3 activity therefore results in the local termination of 
T3 action. The expression of D3 is regulated by the prevailing thyroid hormone level, being 
increased in hyperthyroidism and reduced when local levels of thyroid hormones fall (Tu et al., 
1999). 
D3 is highly expressed in the placenta where its activity regulates the trans-placental passage of 
T4 and T3 from mother to foetus. This serves to protect the developing foetus from maternal 
thyroid hormone levels which may be inappropriate for gestational age (Roti et al., 1982). In 
addition, D3 has also been demonstrated to play a key role in retinal and cochlea development 
(Campos-Barros et al., 2000, Marsh-Armstrong et al., 1999). 
D3 has been identified within the adult CNS where a small amount of D3 mRNA is detectable 
within the hypothalamus of euthyroid rats (Campos-Barros et al., 1996). The expression of D3 in 
other adult tissues is low although its expression may be induced in the liver and skeletal muscle 
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of critically ill patients which could contribute to the pattern of low circulating T3 and high rT3 
levels seen in NTIS (Peeters et al., 2003). 
In summary, the expression and the activity of the deiodinases are highly regulated by thyroid 
status. In particular, the interplay between the expression and activity of D2 and D3 allows an 
individual subpopulation of cells within a tissue to govern the temporal and spatial level of intra-
cellular T3 exposure. 
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FI GURE 1.5  THE METABOLISM OF THE IODOTHYRONINES BY THE DEIODINASE ENZYMES 
The outer phenolic ring of the iodothyronines is shown in grey and the inner tyrosil ring is 
shown in white.  
Abbreviations: D1, deiodinase 1; D2, deiodinase 2; D3, deiodinase 3; rT3, reverse tri-
LRGRWK\URQLQH7¶¶-diiodothyronine; T3, tri-iodothyronine; T4, thyroxine. 
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1.4 !THYROID HORMONE RECEPTORS  
Thyroid hormone receptors (TRs) are intra-nuclear, hormone inducible transcription factors (Sap 
et al., 1986, Weinberger et al., 1986). TRs are members of the nuclear steroid receptor 
superfamily which includes the receptors for steroid hormones, vitamin D, retinoic acid and 
µRUSKDQ UHFHSWRUV¶ IRU ZKLFK QR HQGRJHQRXV OLJDQG KDV EHHQ LGHQWLILHG (Evans, 1988). The 
classic model for steroid/thyroid hormone action proposes that ligand binding to the receptor 
induces an allosteric change that allows the receptor-hormone complex to bind to its DNA 
response element in the promoter region of a target gene. It is this binding that leads to 
modulation of gene expression (Evans, 1988). 
 
1.4.1 STRUCTURE OF THYROID HORMONE RECEPTORS 
Like other members of the steroid receptor family, TRs consist of a single polypeptide chain with 
functionally separate modular domains. All members of the superfamily have an amino terminal 
A/B domain, a central DNA binding domain (DBD), a hinge region containing the nuclear 
translocation signal and a carboxy terminal ligand binding domain (LBD) (Yen, 2001) (FIGURE 
1.6). 
The amino terminal A/B domain is highly variable between TR isoforms and shows poor inter-
species homology (Koenig et al., 1988). The function of this region is not well-characterised but 
a role in transcriptional activation has been suggested (Yen, 2001). 
The DBD recognises the specific DNA response element for the receptor and this region is 
critical for the specificity of the receptor-hormone response element interaction (Evans, 1988, 
Umesono and Evans, 1989). Within the DBD, dimerisation sites have been identified which are 
essential for the heterodimerisation of TR with the retinoid-X receptor (RXR), an interaction 
which serves to stabilise TR-DNA contact (Evans, 1988, Zhang et al., 1992). 
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The hinge region lies between the DBD and the LBD and plays a key role in the import of TR 
into the nucleus following its translation within the cytoplasm (Evans, 1988). Furthermore, the 
hinge region may serve as a co-repressor protein contact domain, resulting in transcriptional 
silencing in the absence of ligand binding (Chen and Evans, 1995, Horlein et al., 1995). 
T3 binds deep within a hydrophobic pocket of the carboxyl-terminal LBD (Wagner et al., 1995). 
Although T4 and rT3 can bind to TRs, their affinity is much lower than that of T3, which is the 
endogenous ligand at the receptor (Sap et al., 1986). In addition to the DBD, the LBD also 
contains interaction sites necessary for the homo- and heterodimerisation of DNA bound TRs 
(Yen, 2001).  
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FI GURE 1.6  SCHEMATIC REPRESENTATION OF THE THYROID HORMONE RECEPTOR ISOFORMS 
75VH[LVWDVWZRGLVWLQFWLVRIRUPVWK\URLGKRUPRQHUHFHSWRUDOSKD75ĮDQGWK\URLGKRUPRQH
UHFHSWRUEHWD75ȕZKLFKDUHHQFRGHGE\WKHTHRA gene on chromosome 17 and THRB gene 
on chromosome 3 respectively. Four thyroid hormone/DNA ELQGLQJLVRIRUPV75Į75ȕ75ȕ
DQG 75ȕ DUH JHQHUDWHG E\ WKH DOWHUQDWLYH VSOLFLQJ RI SULPDU\ WUDQVFULSWV 75V KDYH KLJK
sequence homology in the DNA binding domain (C) (black bar) and the ligand binding domain 
(white bar). The amino-terminal A/B domain varies between isoforms in both length and amino 
acid sequence as indicated by the different coloured bars. The amino acids at the junctions 
between modular domains are indicated by numbers. 
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1.4.2 GENOMIC MECHANISM OF THYROID HORMONE RECEPTOR ACTION 
TRs modulate gene expression by binding to cis-acting DNA sequences in target genes known as 
thyroid hormone response elements (TREs). TREs are located in the promoter region of T3 
target genes and activate or repress transcription in response to TR binding.  
TRs exert an effect on transcription both in the absence of T3, as aporeceptors and when ligand 
is bound as holoreceptors (Chatterjee et al., 1989, Glass et al., 1989). At a positively regulated 
TRE, in the absence of bound ligand, co-repressor proteins are found in association with the 
LBD (Rosenfeld and Glass, 2001). Following T3 binding, TRs undergo a conformational change, 
resulting in the dissociation of the co-repressors and recruitment of co-activator proteins, which 
serves to significantly augment the magnitude of T3 induced changes in transcriptional activity 
(FIGURE 1.7). At a negatively regulated TRE, gene transcription occurs in the absence of bound 
ligand and is silenced following T3 binding to TR. 
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FI GURE 1.7 SCHEMATIC REPRESENTATION OF THYROID HORMONE RECEPTOR REGULATION 
OF TARGET GENE TRANSCRIPTION AT A POSITIVE THYROID HORMONE RESPONSE ELEMENT  
In the absence of bound T3 (panel A) the thyroid hormone response element (TRE) bound 
thyroid receptor-retinoid-X receptor (TR-RXR) heterodimer interacts with nuclear co-repressor 
proteins (CoR). This association results in transcriptional silencing of the target gene. On T3 
binding to TR (panel B), TRs undergo a conformational change resulting in the dissociation of 
CoRs and recruitment of co-activator proteins (CoA). This results in the up-regulation of target 
gene transcription and the production of mRNA.  
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1.4.3 CLASSIFICATION OF THYROID HORMONE RECEPTORS 
75VH[LVWDVWZRGLVWLQFWLVRIRUPVWK\URLGKRUPRQHUHFHSWRUDOSKD75ĮDQGWK\URLGKRUPRQH
UHFHSWRUEHWD75ȕ 
$OO IRUPV RI WKH 75Į LVRIRUP 75Į 75Į 75Į 75ǻĮ DQG 75ǻĮ DUH HQFRGHG RQ WKH
THRA gene on chromosome 17 (Sap et al., 1986, Weinberger et al., 1986)2QO\75ĮKDVEHen 
shown to bind T3 and to have functional activity in vivo75Į75Į75ǻĮDQG75ǻĮGR
not bind T3 and their in vivo function is uncertain although in vitro they have been shown to act 
DVGRPLQDQWQHJDWLYHDQWDJRQLVWVRI75ĮIXQFWLRQ(Koenig et al., 1989, Mitsuhashi et al., 1988).  
The THRB gene on chromosome 3 encodes WKH IRXU 75ȕ LVRIRUPV 75ȕ 75ȕ 75ȕ DQG
75ǻȕ (Hodin et al., 1989, Thompson et al., 1987, Williams, 2000). THRB contains two 
SURPRWHU UHJLRQV DQG 75ȕ DQG 75ȕ DUH WUDQVFULEHG IURP VHSDUDWH SURPRWHUV 75ȕ DULVHV
IURP WKHVSOLFLQJRI WZRQRYHO¶H[RQVRQWR WKH ILUVW H[RQ WKDW LV FRPPRQ WRERWK75ȕDQG
75ȕ(Williams, 2000). 75ȕ75ȕDQG75ȕare bona fide T3 receptors that bind both T3 and 
DNA and regulate expression of T3-responsive target genes, whilst 75ǻȕ3 retains T3 binding 
activity but lacks a DBD and does not activate gene transcription (Harvey et al., 2007).  
 
1.4.4 TISSUE DISTRIBUTION OF THYROID HORMONE RECEPTORS 
TR mRNAs are expressed in a tissue and developmental stage-specific pattern (Forrest et al., 
1990) 75Į WKH VROH 7 ELQGLQJ 75Į LVRIRUP LV FRQVWLWXWLYHO\ H[SUHVVHG GXULQJ HPEU\RQLF
development, with high levels of expression in the developing brain (Bradley et al., 1992). 
In post-QDWDOOLIH75ĮP51$LVXELTXLWRXVO\H[SUHVVHGZLWKLQUDWWLVVXHVDOWKRXJKH[SUHVVLRQ
is highest in the brain, with lower levels present in skeletal muscle, the kidneys, the heart, the 
liver and brown adipose tissue (Cheng et al., 2010, Yen, 2001):LWKLQWKHK\SRWKDODPXV75Į
is expressed within the supraoptic nucleus, PVN and VMN, with low to moderate expression in 
the preoptic nucleus and suprachiasmatic nucleus (Bradley et al., 1989, Lopez et al., 2010). 
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,QFRQWUDVW75ȕLVH[SUHVVHGLQWKHODWHUVWDJHVRIHPEU\RQLFEUDLQGHYHORSPHQWZLWKDVXUJHLQ
its expression that coincides with the period of brain development that is known to be thyroid 
hormone dependent (Forrest et al., 1990)75ȕH[SUHVVLRQLQWKHGHYHORSLQJEUDLQVKRZVUHJLRQDO
specificity, with particularly high expression in the developing anterior pituitary gland, basal 
ganglia, cerebellum, cochlea and retina (Bradley et al., 1992, Bradley et al., 1994, Sjoberg et al., 
1992, Strait et al., 1992). 
:LWKLQ DGXOW WLVVXHV 75ȕ P51$ DQG SURWHLQ are ubiquitously expressed, with highest 
H[SUHVVLRQLQWKHOLYHUEUDLQDQGNLGQH\V75ȕLVOHVVZLGHO\GLVWULEXWHGDQGLVPRVWDEXQGDQW
in the anterior pituitary gland where it plays a critical role in T3 mediated negative feedback on 
TSH production (see 1.3.2) (Hodin et al., 1989)75ȕLVDOVRH[SUHVVHGZLWKLQGLVFUHWHUHJLRQV
of the hypothalamus. Within the PVN, 7ELQGLQJ WR75ȕVXSSUHVses TRH transcription (see 
1.3.1) DQG LQ DGGLWLRQ75ȕ LV DOVRSUHVHQWZLWKLQ WKH901$UF DQGPHGLDQHPLQHQFHZLWK
trace expression found in the DMN (Abel et al., 2001, Bradley et al., 1989, Cook et al., 1992). 
The third 7'1$ ELQGLQJ LVRIRUP 75ȕ shows regional specificity of expression and is 
predominantly found in the liver, lungs and kidneys (Williams, 2000). 
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1.4.5 MOUSE MODELS OF THYROID HORMONE RECEPTOR KNOCKOUT 
The temporo-spatial expression patterns of TRs, suggest either that TR isoforms serve distinct 
physiological functions or that there is significant redundancy between the isoforms. In order to 
improve our understanding of the role of specific TR subtypes, several mouse models of TR gene 
knockout have been developed. These studies have shown that TRs have both subtype specific 
and overlapping functional roles. The genotypes and phenotypes of the key TR knockout models 
are described in TABLE 1.  
However, these knockout models cannot be used to determine the tissue-specific effects of TRs 
since TR knockout in these mice is global. Furthermore, because TR knockout occurs during 
embryonic development, biological compensation undoubtedly occurs, which may mask 
important actions of TRs. This is particularly important when investigating the role of TRs in the 
control of feeding as developmental compensation is known to occur in appetite regulating 
systems (Erickson et al., 1996a, Sun et al., 2003). In addition, global TR knockout mice have 
altered plasma thyroid hormone status which will also impact upon food intake and body weight.  
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KNOCKOUT DELETED 
TR mRNAs 
EXPRESSED 
TR mRNAs 
THYROID 
STATUS 
PHENOTYPE 
75Į0/0  
(Gauthier et al., 
2001, Macchia et al., 
2001, Pelletier et al., 
2008) 
 
$OOĮLVRIRUPV All E isoforms Euthyroid Reduced basal heart rate with reduced 
cardiac sensitivity to T3  
Failure of BAT thermogenesis 
Growth retardation with abnormal bone 
maturation 
Abnormal intestinal development 
High tone deafness 
75Į-/- 
(Fraichard et al., 
1997) 
ĮĮ 'Į'Į 
All E isoforms 
Abnormal 
thyroid gland 
development 
Death after 
weaning unless 
rescued with T3 
replacement 
Small brain with normal architecture 
Growth retardation with abnormal bone 
maturation 
Abnormal intestinal development  
Infertility 
75Į-/-   
(Wikstrom et al., 
1998) 
Į'Į Į'Į 
All E isoforms 
 
Mild 
hypothyroidism 
secondary to 
impaired 76+Į 
gene regulation 
Reduced basal heart rate with reduced 
cardiac sensitivity to T3  
Reduced core body temperature 
75Į-/- 
(Salto et al., 2001) 
Į'Į 
 
ĮRYHU-
expressed), 'Į 
All E isoforms 
Abnormal 
thyroid gland 
morphology  
Low plasma T3 
and T4, with 
inappropriately 
normal TSH 
Obese 
Late onset growth retardation 
Tachycardia 
Raised basal body temperature 
75ȕ-/-  
(Forrest et al., 1996a, 
Forrest et al., 1996b, 
Weiss et al., 1997) 
$OOȕLVRIRUPV $OOĮLVRIRUPV Central 
resistance to 
thyroid hormone 
Cochlea deafness 
Features of hyperthyroidism in specific 
tissues e.g. raised heart rate 
75ȕ-/-  
(Abel et al., 1999, 
Ng et al., 2001) 
ȕ ȕȕ'ȕ 
$OOĮLVRIRUPV 
Central 
resistance to 
thyroid hormone 
Defective colour vision secondary to 
abnormal retinal cone expression 
75Į0/0/75ȕ-/- 
(Gothe et al., 1999) 
$OOĮLVRIRUPV 
All E isoforms 
None Central 
resistance to 
thyroid hormone 
Growth retardation with abnormal bone 
maturation 
TABLE 1  GENOTYPES AND PHENOTYPES OF THYROID HORMONE RECEPTOR KNOCKOUT 
MICE 
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1.4.6 µNON-GENOMIC¶ MECHANISM OF THYROID HORMONE ACTION 
As described above, the binding of T3 to nuclear TRs results in a change in the transcription of a 
WDUJHWJHQHDQHIIHFWNQRZQDVWKHµJHQRPLF¶PHFKDQLVP of thyroid hormone action. In addition, 
thyroid hormones can influence intra-cellular events without binding to TRs within the nucleus. 
7KLVVHFRQGFODVVRIWK\URLGPHGLDWHGHIIHFWVWHUPHGWKHµQRQ-genomic¶PHFKDQLVP of thyroid 
hormone action, may be mediated by the binding of thyroid hormones to receptors expressed 
within the plasma membrane (Bergh et al., 2005, Davis et al., 2000) 7KLV µQRQ-JHQRPLF¶
mechanism could explain the effects of thyroid hormones which are too rapid to be explained by 
a change in gene transcription or which occur in enucleate cells.  
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1.5 THYROID HORMONES AND THE REGULATION OF ENERGY EXPENDITURE 
Thyroid hormones play an important role in the regulation of energy expenditure. Part of this 
effect is on account of their significant role in potentiating the action of the sympathetic nervous 
system (SNS) on brown adipose tissue (BAT). BAT is a key site of adaptive thermogenesis, a 
process which generates heat at the expense of adenosine triphosphate (ATP) production. 
 
1.5.1.1 ACTIONS OF THYROID HORMONES AND THE SYMPATHETIC NERVOUS SYSTEM IN 
BROWN ADIPOSE TISSUE  
BAT is present in small mammals and human neonates and is a key site of adaptive 
thermogenesis. In addition, recent work using fluorodeoxyglucose positron emission tomography 
(FDG PET) scanning has identified a significant amount of BAT in adult humans (Cypess et al., 
2009, Nedergaard et al., 2007). BAT is a mitochondria rich tissue which receives dense 
innervation from the SNS (Wirsen and Hamberger, 1967). In response to a cold stress, 
sympathetic stimulation of the tissue results in the increased expression and activation of 
uncoupling protein-1 (UCP-1) which dissipates the proton gradient across the inner 
mitochondrial membrane leading to the production of heat rather than ATP (Lowell and Flier, 
1997).  
Within BAT, thyroid hormones act in close synergism with the SNS to promote thermogenesis. 
T4 conversion to T3 is catalysed by D2, the activation of which is greatly augmented by 
sympathetic stimulation of the tissue (Bianco and Silva, 1987, Silva and Larsen, 1983). The 
importance of this D2 effect is underscored by the phenotype of Dio2 knockout mice which 
show impaired thermogenesis and can only respond to a cold stimulus by shivering (de Jesus et 
al., 2001). The T3 that is generated within BAT by D2 activity, increases the expression of   
UCP-1 which has a TRE in iWV¶IODQNLQJUHJLRQ(Branco et al., 1999, Rabelo et al., 1995). 
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1.5.2 THE INNERVATION OF BROWN ADIPOSE TISSUE BY THE VENTROMEDIAL NUCLEUS 
Part of the sympathetic innervation to BAT arises from the VMN. Glutamate is the major 
excitatory neurotransmitter of the CNS and glutamate microinjection into the VMN results in an 
increase in the electrical firing rate of the sympathetic nerves that innervate inter-scapular BAT 
(Yoshimatsu et al., 1993). Similarly, electrical stimulation of the VMN results in a threefold 
increase in the turnover of norepinephrine in BAT (Saito et al., 1987). Recently, it has been 
shown in rats, that central administration of T3 into the VMN results in a dose-dependent 
increase in the sympathetic outflow from the VMN to BAT and, in addition, that ICV T3 
administration increases UCP-1 mRNA expression in BAT (Lopez et al., 2010).  
Conversely, animals with lesions of the VMN show a reduction in sympathetic activity in BAT, 
as evidenced by reduced electrical activity in the sympathetic nerves supplying BAT and reduced 
postprandial heat production in the tissue (Monda et al., 1997, Sakaguchi and Bray, 1987). 
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1.6 THYROID HORMONES AND THE REGULATION OF FOOD INTAKE 
Thyroid hormones are known to affect food intake in both rodents and humans. In humans, one 
of the characteristics of thyrotoxicosis is hyperphagia and in rodents peripheral and central 
administration of T3 increases food intake and this occurs at both physiological and supra-
physiological levels of plasma T3 (Ishii et al., 2003, Kong et al., 2004, Luo and MacLean, 2003, 
Pijl et al., 2001). It is noteworthy, that five to ten percent of patients with thyrotoxicosis, have a 
sufficiently increased appetite to gain weight, despite the induced catabolic state, which suggests 
that thyroid hormones may directly stimulate food intake in humans (Gurney et al., 1970).  
Consistent with the hyperphagic state observed in thyrotoxicosis, peripheral administration of T3 
to rats results in an increase in hypothalamic NPY mRNA expression (Ishii et al., 2003, Lopez et 
al., 2010). In addition, ICV administration of a NPY Y1 receptor antagonist to rats has been 
shown to blunt T3 induced hyperphagia (Ishii et al., 2003). It has also been reported that 
expression of AgRP mRNA is increased in the Arc of hyperthyroid rats, whilst POMC and 
CART mRNA levels are reduced (Ishii et al., 2003, Lopez et al., 2010). 
In rats, hypothalamic D2 activity shows marked circadian variation, such that activity peaks 
during the dark phase and falls to a nadir level during the light phase (Campos-Barros et al., 
1997). This results in an increase in hypothalamic T3 levels during the dark phase, which is the 
natural feeding period for rodents and low hypothalamic T3 levels during the day when food 
intake is low. The circadian increase in hypothalamic T3 levels during the feeding period 
supports the proposal that T3 plays a physiological role in the control of food intake. 
Within the CNS, high D2 activity is found in the Arc and the median eminence where it is 
expressed within astrocytes and tanycytes (Riskind et al., 1987). The processes of D2 containing 
tanycytes are in direct apposition to NPY/AgRP neurons of the Arc which also express the inner 
mitochondrial membrane uncoupling protein-2 (UCP-2) (Coppola et al., 2007). Compared with 
UCP-1, which plays a well-characterised role in non-shivering thermogenesis (see 1.5.1.1), UCP-
2 generates less pronounced changes in mitochondrial inner membrane permeability and its 
function is not dependent upon sympathetic activation (Andrews et al., 2005). During fasting, 
there is a marked increase in tanycyte D2 expression and activity (Coppola et al., 2007). This 
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results in an increase in T3 within the Arc, which has been shown to increase UCP-2 activation 
and mitochondrial proliferation in NPY/AgRP neurons (Coppola et al., 2007). This latter effect 
may be critical for the ability of these orexigenic neurons to maintain an increased firing rate 
during fasting. In Dio2 knockout mice, fasting fails to elevate NPY expression which further 
emphasises the significance of intra-Arc T3 production in the response to food deprivation 
(Coppola et al., 2007).  
Evidence from studies on hibernating mammals suggests that in addition to D2, D3 may also 
play a role in the regulation of feeding. Hibernating rodents show marked changes in food intake 
and energy expenditure depending on photoperiod and during short days, which occur in the 
winter months, they enter a catabolic phase. This results in a reduction in food intake and body 
weight and a fall in core body temperature (Ebling and Barrett, 2008). It is during these short 
photoperiod days, that the expression and activity of hypothalamic D3 in Siberian hamsters 
increases, leading to a reduction in locally available T3 (Barrett et al., 2007). This coincides with 
a fall in food intake and body weight which is reversed by the implantation of a T3 pellet into the 
dorsomedial hypothalamus (Barrett et al., 2007).  
In summary, changes in the expression and activity of D2 and D3 within the hypothalamus result 
in tissue specific changes in hypothalamic T3 availability. This in turn plays an important role in 
the regulation of food intake and body weight.  
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1.6.1.1 THE REGULATION OF FOOD INTAKE BY TRI-IODOTHYRONINE ACTION IN THE 
VENTROMEDIAL NUCLEUS 
Peripheral administration of T3 to rats results in a dose-dependent increase in food intake, an 
effect which may be mediated by T3 action in the VMN (Kong et al., 2004). Early growth 
response factor-1 (EGR-1) is an immediate early gene product that is induced by T3 action in the 
CNS (Mellstrom et al., 1994, Mercier et al., 2001). In rats, following peripheral injection of T3, 
there is a rapid increase in EGR-1 immunoreactivity in the VMN, an effect not seen in the Arc or 
the PVN (Kong et al., 2004). Furthermore, direct injection of T3 into the VMN but not the Arc 
results in a significant, T3-dose-dependent increase in food intake (Kong et al., 2004). 
This effect however has not been described by all investigators. Recently, Lopez et al reported 
that neither ICV nor intra-VMN administration of T3 affects food intake in rats (Lopez et al., 
2010). 
Further work is therefore needed to determine the physiological role of thyroid hormone action 
in the VMN in the regulation of feeding. 
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1.7 HYPOTHESIS AND AIMS 
The extensive evidence that has been summarised in this chapter suggests a significant role for 
thyroid hormones in the central regulation of food intake, body weight and energy homeostasis. 
The VMN of the hypothalamus is known to be important in the control of feeding and body 
weight regulation and may be a key area for thyroid hormone action in the regulation of these 
processes7KHQXFOHDUWUDQVFULSWLRQIDFWRU75ȕLVKLJKO\H[SUHVVHGZLWKLQWKH901UDLVLQJWKH
possibility that this receptor may play an important role in the control of food intake and body 
ZHLJKW 7KLV FDQ EH LQYHVWLJDWHG E\ GHYHORSLQJ DPRXVHPRGHO RI 75ȕ knock down 75ȕ LV
ubiquitously expressed and global receptor knockout models result in a myriad of phenotypic 
abnormalities and, in addition, may be subject to developmental compensation (see 1.4.5). Tissue 
specific knock down RI75ȕLQWKH901LQDGXOWPLFHFLUFXPYHQWVWKHVHGUDZbacks and has the 
potential to reveal novel information about the role of thyroid hormone action in the VMN in the 
regulation of food intake, body weight and energy homeostasis. 
 
1.7.1 HYPOTHESIS 
75ȕ LQ WKH901SOD\V D VLJQLILFDQW SK\VLRORJLFDO UROH LQ WKH UHJXOation of food intake, body 
weight and energy homeostasis. 
 
1.7.2 AIMS 
The aims of this work were: 
1. 7R GHYHORS DPRGHO RI FRQGLWLRQDO WLVVXH VSHFLILF NQRFNGRZQ RI75ȕ LQ WKH901 in 
 adult mice. 
2. To examine the effects on food intake, body weight DQG HQHUJ\ KRPHRVWDVLV RI 75ȕ
 knock down in the VMN. 
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2 CHAPTER TWO 
 
2.1 MODELS FOR INVESTIGATING THE ROLE OF THYROID HORMONE RECEPTOR BETA IN THE 
VENTROMEDIAL NUCLEUS IN THE MEDIATION OF ENERGY HOMEOSTASIS 
Extensive evidence suggests a significant role for thyroid hormones and for the VMN in the 
regulation of food LQWDNHDQGHQHUJ\H[SHQGLWXUH7KHVHHIIHFWVPD\EHPHGLDWHGWKURXJK75ȕ
which is highly expressed in the VMN (Bradley et al., 1989, Cook et al., 1992). It is possible to 
LQYHVWLJDWHWKLVE\PDQLSXODWLQJWKHPRXVHJHQRPHLQRUGHUWRFKDQJHWKHH[SUHVVLRQRI75ȕLQ
the VMN. In general, genomic technologies can be classified as those which alter the 
endogenous gene by homologous recombination in embryonic stem cells (targeted transgenesis) 
and those which insert exogenous genes into the genome (additive transgenesis).  
 
2.1.1 GENE TARGETING DURING EMBRYONIC DEVELOPMENT 
 
2.1.1.1 EMBRYONIC STEM CELL TECHNOLOGY 
A modified cloned gene can be introduced into embryonic stem cells in culture, resulting in the 
inactivation of genes in vivo WRSURGXFHµknockoutV¶RU WKHLQVHUWLRQRIIXQFWLRnal mutations to 
SURGXFHµNQRFNLQV¶The resultant change in the genome is then transmitted to the germ line.  
In some models, the gene of interest is placed under the control of a tissue specific promoter, 
which confers spatial control over transgene gene expression. The VMN is unique amongst 
hypothalamic nuclei in that it expresses the SF-1 promoter which is not found in other areas of 
the hypothalamus (Dellovade et al., 2000). However, SF-1 is also expressed in the gonads, the 
adrenal glands and the anterior pituitary gland and the use of the SF-1 promoter to drive 
transgene expression results in the disruption of these tissues and a phenotype which may be 
difficult to interpret (Majdic et al., 2002).  
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Although embryonic stem cell technology can provide valuable insights into gene function, there 
are several drawbacks which limit its use for this work and these have been discussed in 1.4.5. 
 
2.1.1.2 SITE-SPECIFIC DNA RECOMBINATION IN MAMMALIAN CELLS  
Site-specific recombination systems are important tools for the manipulation of the mouse 
genome. These systems utilise the introduction of an integrase enzyme into mammalian cells 
ZKLFK FDWDO\VHV WKH LQWHJUDWLRQ H[FLVLRQ RU LQYHUVLRQ RI GHILQHG '1$ VLWHV 7KH µ&UH-/R[3¶
system has been the most successful and widely used approach, although other systems such as 
WKHµ)/3-)57¶UHFRPELQDWLRQV\VWHPKDYHDOVREHHQHPSOR\HG 
 
2.1.1.2.1 SITE-SPECIFIC RECOMBINATION BY CRE RECOMBINASE 
Cre recombinase is a site-specific recombinase enzyme derived from the bacteriophage P1, 
which is pathogenic to Escherichia coli (E. coli) (Sternberg and Hamilton, 1981). Cre 
recombinase is not naturally expressed by mammalian cells, but when the Cre recombinase gene 
is introduced into the mammalian genome it is expressed in vitro and in vivo and has been widely 
used for site-specific recombination. 
Cre recombinase activity is specific for the thirty four base pair (bp) sequence motif known as 
the locus of crossover of phage P1 (LoxP) site (Austin et al., 1981, Sternberg and Hamilton, 
1981). Transgenic mice can be constructed with LoxP sites positioned on either side of a gene of 
interest, DQDOWHUDWLRQNQRZQDVµIOR[LQJ¶DJHQH(Austin et al., 1981). LoxP sites are composed of 
two, thirteen bp recombinase binding elements (RBEs) arranged as inverted repeats separated by 
an eight bp asymmetric spacer sequence (Blakely et al., 1993). Binding of Cre recombinase to 
LoxP sites results in excision or inversion of the floxed DNA segment, which in most cases 
results in tissue specific knock down or knockout of gene function (FIGURE 2.1). In addition, 
gene expression can be augmented by the Cre-LoxP system following excision of a floxed stop 
cassette of the gene of interest (Lakso et al., 1992). Furthermore, LoxP recombination can restore 
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an open reading frame which was previously interrupted by a floxed sequence. For gene 
expression to occur in this model, the remaining combined LoxP sites must be tolerated as part 
of the open reading frame.  
In the absence of Cre recombinase expression, recombination of LoxP sites cannot occur and the 
floxed gene is therefore a conditional alteration. If a floxed mouse is mated with a mouse that 
expresses Cre recombinase, gene excision will occur in all cells which express the enzyme. If 
transgene expression is widespread then the resultant phenotypic changes may be difficult to 
interpret.  
In order to confer a higher degree of tissue specificity, Cre recombinase can be expressed in 
transgenic mice under the control of a tissue-specific promoter. However the VMN lacks tissue 
specific promoters (see 2.1.1.1) which limits the utility of this approach for this work. 
Furthermore, this strategy does not permit for the temporal control of Cre recombinase activity 
and transgene expression in early life may result in developmental abnormalities and 
compensations (see 1.4.5). 
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FI GURE 2.1  SCHEMA DEPICTING CRE RECOMBINASE MEDIATED EXCISION OF A LOXP 
FLANKED GENE 
Following introduction into the mouse genome of two thirty four bp LoxP sites flanking a gene of 
interest, the genetic modification is quiescent in the absence of Cre recombinase (segment A). 
Cre recombinase binds to the LoxP sites resulting in the excision of the intervening DNA 
(segment B) and the recombination of the two LoxP sites (segment C).  
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2.1.1.2.2 SITE-SPECIFIC RECOMBINATION BY FLP RECOMBINASE 
In addition to Cre recombinase, other integrase enzymes have been used for site-specific 
UHFRPELQDWLRQ ZLWKLQ WKH PRXVH JHQRPH )/3 UHFRPELQDVH GHULYHG IURP WKH EDNHU¶V \HDVW
Saccharomyces cerevisiae binds to a thirty four bp sequence, the FLP recombination target 
(FRT) site, and catalyses in cis the excision of DNA lying between two FRT sites (Broach and 
Hicks, 1980, O'Gorman et al., 1991). However, FLP recombinase is not stable at mouse body 
temperature (37°C) and early work using the FLP-FRT recombination system was not 
successful, although the enzyme has subsequently been modified to optimise its activity at 37°C 
(Buchholz et al., 1998). These constraints, coupled with historical precedent and the now large 
number of Cre expressing mice lines under the control of diverse tissue specific promoters, 
means that the Cre-LoxP system is significantly more widely used than any other recombination 
system. 
 
2.2 GENE TARGETING IN POST-NATAL LIFE 
Targeted modification of the post-natal mouse genome overcomes the problem of developmental 
compensation or, in some cases, lethality associated with embryonic stem cell technology. Post-
natal gene targeting also allows for the spatial control of transgene expression and could 
therefore EHXVHGWRDOWHU75ȕH[SUHVVLRQVSHFLILFDOO\ZLWKLQWKH901 
75ȕH[SUHVVLRQLQWKH901Fould be knocked down in adult mice in which the THRB gene has 
been floxed 75ȕflox/flox) (see 2.6). In these mice, the direct administration of the Cre 
recombinase transgene into the VMN would result in excision of the floxed cassette and 
transcription of a non-IXQFWLRQDO IRUPRI75ȕ7KLV WDUJHWHGNQRFNGRZQRI75ȕ LQ WKH901
ZRXOG\LHOGLPSRUWDQWQRYHOLQIRUPDWLRQDERXWWKHSK\VLRORJLFDOUROHRI75ȕLQWKHPHGLDWLRQRI
energy homeostasis.  
Essential features of the vector to be used for delivery of the Cre recombinase transgene were: a 
sufficiently large transgene carrying capacity, the facility to deliver DNA into neurons, sustained 
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transgene expression, non-pathogenicity and non-immunogenicity. Several possible vectors for 
gene transfer were considered. 
 
2.2.1 ADMINISTRATION OF NAKED DNA  
Naked plasmid DNA can be administered in vivo and transgene expression in the target tissue 
has been demonstrated (Wolff et al., 1990). Naked DNA has the advantage of the large size of 
the transgene which can be administered, up to 10 kilobases (kb), and the ease of its preparation 
compared with other techniques. In addition, plasmid DNA has very low immunogenicity and if 
necessary can be repeatedly administered. However, the uptake of naked DNA into cells and its 
nuclear retention is inefficient and gene expression, if it occurs, is usually short lived (Acsadi et 
al., 1991, Buttrick et al., 1992). Furthermore, the number of cells transfected is small as 
evidenced by the histology of reporter gene expression (Acsadi et al., 1991, Lin et al., 1990). 
 
2.2.2 USE OF NON-VIRAL DNA CARRIERS 
Packaging of plasmids containing a transgene into a non-viral carrier significantly augments 
DNA delivery and expression as compared with the administration of naked DNA. This former 
approach has several advantages. Most of the non-viral vectors that have been used have a large 
DNA carrying capacity and in comparison to viral vectors they are cheaper and easier to prepare, 
with no risk of pathogenicity. Most are cationic polymers which hold negatively charged DNA in 
a positively charged lattice structure and when administered in vitro and in vivo enter the target 
cell by fusion with or diffusion across the plasma membrane. 
Examples of non-viral vectors which have been used include liposomes, gelatine and 
polyethylenimine. However, the efficiency of gene transfer and expression is often low and can 
be short lived. Furthermore, carrier-associated toxicity in the target tissue has also been reported 
(Fraley et al., 1979, Roques et al., 2007, Tokunaga et al., 2004). 
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2.2.3 USE OF VIRAL VECTORS FOR GENE TRANSFER 
The viral genome can be manipulated to incorporate the transgene of interest and viral vectors 
have been shown to be highly efficient for DNA transfer into mammalian cells. These constructs 
exploit some or all of the viral characteristics of gaining entry into specific cell types, integration 
of the DNA carried by the virus into the host DNA, expression of the introduced transgene and 
WKHXVHRIWKHKRVW¶VFHOOXODUV\QWKHWLFPDFKLQHU\IRUWKHV\QWKHVLVRIWKHSURWHLn encoded by the 
transgene. Viruses from several different families have been trialled as vectors, most commonly 
adenoviruses, herpes viruses, retroviruses/lentiviruses and parvoviruses. 
 
2.2.3.1 ADENOVIRUSES 
Adenoviruses are large double stranded DNA viruses with a genome of thirty to forty kb. 
Recombinant adenoviruses rendered replication deficient have been available for gene transfer 
for over thirty years (Graham et al., 1977). These viruses have a large insert capacity of seven to 
thirty kb and, in addition, they have a high nuclear transfer efficiency, broad tissue tropism and 
low immunogenicity. However, the carried transgene is not incorporated into the host DNA and 
expression of the transgene may be transient (Engelhardt et al., 1993). Furthermore, recombinant 
adenoviruses elicit a marked host cytotoxic T cell response often resulting in the clearance of the 
vector transduced cells, DOWKRXJKQHZHUKLJKFDSDFLW\µJXWOHVV¶ adenoviruses in which all genes 
encoding viral proteins have been deleted are less immunogenic (Morsy et al., 1998, Schiedner et 
al., 1998, Yang et al., 1994). 
 
2.2.3.2 HERPES VIRUSES 
Herpes viruses are large neurotrophic double stranded DNA viruses. Herpes simplex virus-1 
(HSV-1) is the herpes virus that is most commonly used as a DNA transfer vector because of its 
large transgene carrying capacity. Following cellular infection, HSV1 causes latent infection 
resulting in transcriptional activity without virion production (Becker et al., 1968). HSV-1 does 
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not integrate into host DNA but remains episomal which is thought to reduce the risk of 
insertional mutagenesis. A drawback WR LWVXVH LV WKHYLUXV¶FDSDFLW\ WR WUDYHODORQJD[RQVDQG
transgene expression may therefore occur beyond the site of administration (Cook and Stevens, 
1973). Furthermore, although HSV vectors are deprived of the wild type genes which cause cell 
lysis, the virus may still stimulate a marked host inflammatory response (McMenamin et al., 
1998).  
 
2.2.3.3 RETROVIRUSES/LENTIVIRUSES 
Retroviruses do not infect post-mitotic cells and therefore cannot be used to alter gene expression 
in the CNS, although lentiviruses, which are a subgroup of retroviruses, can infect non-dividing 
cells (Miyoshi et al., 1997). Lentiviruses are single stranded RNA viruses. They encode the 
enzyme reverse transcriptase which enables the conversion of the viral genome into double 
stranded DNA, thereby allowing integration into the mammalian host genome. However, this 
viral vector is usually derived from human immunodeficiency virus-1 (HIV-1) which has led to 
concerns about the possibility of HIV wild type contamination. 
 
2.2.3.4 PARVOVIRUSES 
Parvoviruses are small single stranded DNA viruses. The most commonly used parvovirus for 
gene transfer is adeno-associated virus (AAV). 
 
2.2.3.4.1 ADENO-ASSOCIATED VIRUS  
AAV can transduce post-mitotic tissues which, following a single injection into the area of 
interest, leads to sustained transgene expression (Klein et al., 2002). To date, eleven AAV 
serotypes have been identified, each of which has tropism for specific cell types.                   
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AAV serotype 2 (AAV-2) has a tropism for neurons and has been shown to transduce adult 
neurons in vivo for over one year (Klein et al., 2002). 
 
2.2.3.4.2 ADENO-ASSOCIATED VIRUS STRUCTURE 
AAV is a small single stranded DNA virus, surrounded by a non-enveloped proteinaceous 
capsid. The AAV-2 genome is 4675 nucleotides long and contains two open reading frames, the 
¶rep JHQHDQGWKH¶cap gene (Srivastava et al., 1983) (FIGURE 2.2). The rep gene codes for 
the rep proteins, the structural regulatory proteins needed for virus replication. In addition, in the 
absence of helper virus (see 2.2.3.4.2.1), rep proteins suppress AAV gene expression (Trempe 
and Carter, 1988). The cap gene encodes the three proteins of the capsid, Vp1, Vp2 and Vp3, 
which form the external protein coat of the virus particle (Kronenberg et al., 2001). The AAV 
genome is flanked by inverted terminal repeats (ITRs) which are the only cis-acting elements 
necessary for genome replication. Each ITR consists of 145 nucleotides, the first 125 of which 
form a palindromic sequence which is critical for incorporation of the virus into the host genome 
(Srivastava et al., 1983). 
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FI GURE 2.2  SCHEMATIC REPRESENTATION OF THE ADENO-ASSOCIATED VIRUS-2 GENOME 
The open boxes represent the inverted terminal repeats (ITRs). The black boxes represent the 
promoters p5, p19 and p40. The rep gene is transcribed from the p5 and p19 promoters. The cap 
gene is transcribed from the p40 promoter.  
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2.2.3.4.2.1 ADENO-ASSOCIATED VIRUS LIFE CYCLE 
AAV belongs to the genus dependovirus, a group of viruses which cannot replicate 
autonomously (Atchison et al., 1965). AAV requires co-infection with a helper virus such as 
adenovirus or HSV that provide the necessary helper functions in trans which allow for AAV 
replication (Buller et al., 1981). This adds a safety feature that prevents the generation of 
replication competent pseudo wild-type AAV via homologous recombination and also mitigates 
the possibility of a host immune reaction. 
The primary cellular receptor for AAV is heparan sulphate proteoglycan and cells cannot be 
transfected with AAV if they do not express this receptor (Summerford and Samulski, 1998). In 
addition, AAV serotype 2 (AAV-2) requires the host cell to express a co-receptor, either 
fibroblast growth factor receptor 1 or alphaVbeta5 integrin to permit viral entry into the cell 
(Qing et al., 1999, Summerford et al., 1999). Neuronal expression of these receptors results in 
AAV-2 neural tropism. Upon entering the host cell, AAV particles travel in endosomes and once 
inside the nucleus AAV integrates at the AAVS1 locus on chromosome 19 (Kotin et al., 1990). 
The palindromic sequence of the ITR allows the single stranded ITR to fold back on itself 
creating a µhairpin loop¶ which acts as an origin of replication for the synthesis of a second 
complementary strand of DNA. Therefore, the ITRs allow single stranded AAV DNA to be 
converted into double stranded DNA, permitting integration of the virus into the host genome. 
The conversion of viral DNA from single into double stranded is the rate limiting step for AAV 
mediated gene transfer and is reflected in the delayed onset of transgene expression which ranges 
from seven to twenty one days (Ferrari et al., 1996). In the presence of a helper virus, gene 
expression and viral replication occurs establishing lytic infection, whereas in the absence of a 
helper virus, following integration into the genome, the virus enters a latent phase (Laughlin et 
al., 1986). 
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2.2.3.4.2.2 RECOMBINANT ADENO-ASSOCIATED VIRUS 
Recombinant AAV (rAAV) is a genetically modified AAV in which all viral genes have been 
deleted so that the only part of the wild type genome that remains is the ITRs, while the 
remainder is replaced with the transgene of interest of up to five kb (Dong et al., 1996, Grieger 
and Samulski, 2005). In addition, the AAV vector plasmid, pTR-CGW, also contains genes 
which are essential for transgene expression (FIGURE 2.3). The removal of all viral genes from 
an essentially non-pathogenic virus results in a very safe vector for gene delivery.  
Recombinant AAV serotype 2 (rAAV-2) is widely used for gene transfer into the CNS because 
of its tropism for neurons and lack of tropism for glia (Daly, 2004). In addition, its integration 
into the host genome and its low immunogenicity allow for sustained gene expression within the 
target tissue (Bartlett et al., 1998). Recombinant AAV has been successfully used to introduce 
transgenes which effect energy homeostasis into specific areas of the hypothalamus (Dube et al., 
2002, Gardiner et al., 2005, Smith et al., 2008). In addition, sustained expression, activity and 
lack of toxicity in the mouse CNS of rAAV carrying the Cre recombinase transgene have been 
demonstrated (Ahmed et al., 2004, Kaspar et al., 2002). 
Recombinant AAV can be used to deliver the reporter gene green fluorescent protein (GFP) into 
the CNS. GFP was originally isolated from the jellyfish Aequorea victoria and has become a 
commonly used reporter gene because ex vivo, the protein will fluoresce within cells without the 
addition of further substrates (Chalfie et al., 1994). GFP has been expressed in the CNS using a 
number of different gene transfer vectors, including rAAV (rAAV-GFP) and is widely used as a 
control transgene in studies using rAAV (Chamberlin et al., 1998). Importantly, rAAV-GFP has 
been shown not to affect food intake or body weight when expressed within the rodent 
hypothalamus (Gardiner et al., 2005).  
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FI GURE 2.3  SCHEMATIC REPRESENTATION OF THE STRUCTURE OF PTR-CGW VECTOR 
PLASMID 
7KH WUDQVJHQHF'1$FDVVHWWH LV IODQNHGE\ WKH¶DQG¶ LQYHUWHG WHUPLQDO UHSHDWV ,757KH
plasmid also contains genes necessary for transgene expression and rAAV construction; The 
early cytomegalovirus promoter (CMV prom) is a constitutively active promoter which is active 
in a wide variety of mammalian cells and is essential for driving transgene expression. The 
woodchuck post-transcriptional regulatory element (WPRE) has been shown to improve the in 
vivo transcription of mRNA whilst the polyadenylation signal (PolyA) stabilises the mRNA 
transcripts. The ampicillin resistance gene (AmpR) is needed to select for transformed bacteria 
containing the vector plasmid (see 2.5.2.2). 
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2.3 CHOICE OF GENE VECTOR FOR TARGETED THYROID HORMONE RECEPTOR BETA KNOCK 
DOWN IN THE VENTROMEDIAL NUCLEUS OF ADULT MICE 
In this work, for the reasons described, the direct injection of rAAV-Cre into the VMN of adult 
PDOH 75ȕflox/flox mice was selected to produce the targetHG NQRFN GRZQ RI 75ȕ LQ WKH901
whilst rAAV-GFP was chosen for control injections. 
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2.4 CHAPTER TWO AIMS 
The aims of the work described in this chapter were: 
1. To sub-clone the Cre recombinase transgene into an AAV vector plasmid. 
2. To produce rAAV carrying the Cre recombinase transgene. 
3. 7RVXFFHVVIXOO\EUHHG75ȕflox/flox mice. 
4. To determine the VMN coordinates for stereotaxic surgery in the adult mouse. 
5. To accurately target bilateral micro-injections to the adult mouse VMN. 
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CHAPTER TWO METHODS  
 
2.5 CONSTRUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS PLASMIDS 
The first stage in the preparation of rAAV is to sub-clone the cDNA of interest, in this case Cre 
recombinase, into an AAV vector plasmid (pTR-CGW) (FIGURE 2.3). The transformed plasmid 
is then used for the production of rAAV which overexpresses Cre recombinase. 
 
2.5.1 SUB-CLONING OF CRE RECOMBINASE CDNA INTO PTR-CGW 
Restriction endonucleases are enzymes that are naturally produced by bacteria to degrade 
specific nucleotide sequences of exogenous DNA. Each restriction endonuclease recognises a 
specific restriction site, a palindromic sequence of four or six nucleotide bases and cleaves the 
DNA at this point. Therefore, a given fragment of DNA can be cut at particular points in its 
sequence. This results in the production of restriction fragments which can be used for a range of 
applications including DNA modification and cloning.  
The plasmid, p-bluescript 500 (pBS500), contains the gene for Cre recombinase. pBS500 also 
codes for GFP although this moiety has not been codon optimised for mammalian expression 
(Gagneten et al., 1997). In the restriction endonuclease digestion reactions described below, 
pBS500 was cleaved with restriction endonucleases, resulting in the excision of Cre-GFP cDNA.  
pTR-CGW was also cut with restriction endonucleases. This results in the opening up of the 
circular plasmid structure and the exposure of 3' and 5'-overhangs of one to four nucleotides, the 
so-FDOOHGµVWLFN\HQGV¶ZKLFKDUHFRPSOLPHQWDU\WRWKHFXWµVWLFN\HQGV¶RIWKHH[FLVHGCre-GFP 
cDNA. A virus derived enzyme can then be used to catalyse the ligation of the transgene into the 
YHFWRUSODVPLGWKURXJKWKHIRUPDWLRQRISKRVSKRGLHVWHUERQGVEHWZHHQDIUHH¶SKRVSKDWe and a 
IUHH¶K\GUR[\OJURXS 
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2.5.1.1 RESTRICTION ENDONUCLEASE DIGESTION OF P-BLUESCRIPT 500 PLASMID AND 
RECOMBINANT ADENO-ASSOCIATED VIRUS PLASMID PTR-CGW 
Materials 
pBS500 plasmid (0.75mg/ml) 
pTR-CGW plasmid (4.5mg/ml) (a kind gift from Professor Joost Verhaagen, The 
Netherlands Institute for Brain Research, Amsterdam, The Netherlands) 
Restriction endonucleases XhoI (20,000U/ml), SpeI (10,000U/ml), XbaI (20,000U/ml) 
(New England Biolabs, Hertfordshire, UK) 
10x Restriction buffer as supplied (New England Biolabs, Hertfordshire, UK) 
100x Purified bovine serum albumin (BSA) (New England Biolabs, Hertfordshire, UK) 
Shrimp alkaline phosphatase (4U/µl) (GE Healthcare, Buckinghamshire, UK) 
Phenol: chloroform: iso-amyl alcohol (pH 8.0) (VWR International, Leicestershire, UK) 
(APPENDIX I) 
99.7-100% Ethanol (VWR International, Leicestershire, UK) 
2M Sodium acetate (NaAc) (pH 5.2) (APPENDIX I) 
Method 
In separate reactions, 22.5µg pBS500 and 13.5µg pTR-CGW were diluted in autoclaved glass 
distilled water (GDW). Restriction buffer, purified BSA and equal volumes of each restriction 
endonuclease (XhoI and XbaI in the pBS500 restriction endonuclease digestion and XhoI and 
SpeI in the pTR-CGW restriction endonuclease digestion) were added to give a final 
concentration of 1x. The total volume of enzyme added was kept below ten percent of the final 
volume. The reaction was incubated for at least one hour at 37°C. In the digestion of pTR-CGW, 
8U SAP ZHUHDGGHGWKLUW\PLQXWHVEHIRUHWKHHQGRIWKHLQFXEDWLRQ6$3UHPRYHV¶SKRVSKDWH
groups preventing self-ligation of the plasmid. The reactions were extracted with an equal 
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volume of phenol/chloroform and the phases separated by centrifugation for three minutes at 
13,000xg. The DNA was ethanol precipitated with 0.1 volumes 2M NaAc and 2.5 volumes 99.7-
100% ethanol and was incubated at -20°C for at least one hour. The DNA was recovered by 
centrifugation for seven minutes at 13,000xg. 
 
2.5.1.2 PURIFICATION OF RESTRICTION FRAGMENTS 
Following restriction endonuclease digestion, the DNA fragments were purified in order to 
remove any contaminating fragments. This was done in order to remove unwanted DNA from 
the preceding reaction, in particular closed circular plasmid DNA which can produce a high rate 
of background transformations. Therefore, prior to ligation of the restriction fragments, the DNA 
was size fractionated on an agarose gel and the bands of interest electroeluted in order to extract 
the required restriction fragments.  
 
2.5.1.2.1 VISUALISATION OF RESTRICTION FRAGMENTS 
Materials 
Agarose type II-A medium EEO (Sigma-Aldrich, Dorset, UK) 
50x Tris-acetate-EDTA (TAE) buffer (APPENDIX I) 
Ethidium bromide solution (10mg/ml) (VWR International, Leicestershire, UK) 
DNA marker 1kb plus ladder (1µg/µl) (Invitrogen, Paisley, UK) 
DNA loading Buffer (APPENDIX I) 
Method 
A 1% (w/v) agarose gel was prepared by dissolving agarose in 1x TAE using a microwave oven. 
The gel was cooled to 45°C and ethidium bromide added to a final concentration of 0.5µg/ml. 
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Once set, the gel was placed into an electrophoresis tank containing 0.5x TAE with 0.5µg/ml 
ethidium bromide. 
The precipitate DNA was dissolved in 20µl GDW and 6µl of loading buffer added. One 
microlitre of DNA marker was added to 9µl GDW and 3µl loading buffer added. Samples were 
loaded onto the gel and electrophoresed at 10V/cm. The DNA was visualised by illumination 
with ultraviolet (UV) light. 
 
2.5.1.2.2 ELECTROELUTION OF DNA FRAGMENTS 
Materials 
Dialysis membrane (GE Healthcare, Buckinghamshire, UK) 
50x TAE (APPENDIX I) 
 DNA loading buffer (APPENDIX I) 
 DNA marker 1kb plus ladder (1µg/µl)  
Method 
Under UV illumination, the band of interest was cut out from the gel using a scalpel and placed 
into dialysis tubing sealed at one end with a clip. Four hundred microlitres of 0.5x TAE were 
added to the gel slice, air excluded from the end of the tubing and the unsealed end closed with a 
clip. The DNA was eluted from the gel by electrophoresis at 20V/cm for twenty minutes. TAE 
was removed from the tubing, phenol/chloroform extracted and ethanol precipitated as described 
in 2.5.1.1. The precipitated DNA was dissolved in 10µl GDW and quantified visually by running 
1µl on a 1% (w/v) agarose gel as described in 2.5.1.2.1.  
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2.5.1.3 LIGATION OF CRE-GFP CDNA INTO PTR-CGW 
Materials 
Cre-GFP restriction fragment (10ng/µl) 
Linearised pTR-CGW (20ng/µl) 
T4 DNA ligase (6U/µl) (New England Biolabs, Hertfordshire, UK) 
 10x Ligase buffer (as supplied) (New England Biolabs, Hertfordshire, UK) 
Method 
DNA ligation was used to insert the digested Cre-GFP cDNA into pTR-CGW plasmid. Twenty 
nanograms of plasmid were dissolved in GDW and a four-fold molar excess of Cre-GFP cDNA 
added. Reaction buffer was added to a final concentration of 1x and 6U T4 DNA ligase added to 
give a final volume of 10µl. The reaction was incubated at 16°C overnight.  
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2.5.2 PREPARATION AND PURIFICATION OF PLASMID CONSTRUCTS 
Bacterial replication is exponential. By introducing the transformed plasmid into bacterial cells, 
this property of bacterial replication can be exploited in order to produce a large number of 
copies of the plasmid. The bacterial cell membrane is impermeable to the entry of exogenous 
DNA, however this can be overcome by passing an electrical current through a suspension of 
bacterial cells rendering them competent, or permeable to the entry of the plasmid, a process 
known as electroporation.  
pTR-CGW contains an ampicillin resistance gene (AmpR). Incubation of transfected bacteria 
permits the expression of AmpR before exposure to antibiotic. This allows for selection of 
bacterial colonies which contain the transformed plasmid.  
One drawback of this method is that following plasmid transfection, the bacteria can excise the 
plasmid ITRs which renders rAAV incapable of incorporating the carried transgene into the host 
genome. In order to prevent this, E. Coli JC8111 was used. This strain was chosen as most of its 
recombination system has been knocked out making ITR excision less likely.  
 
2.5.2.1 PRODUCTION OF COMPETENT BACTERIA 
Materials 
E. Coli JC8111 bacteria (ATCC, Middlesex, UK) 
2x Yeast-tryptone (YT) culture medium (pH 7.0) (APPENDIX I) 
10% Glycerol solution (APPENDIX I) 
Method 
Competent bacteria were produced by Dr James Gardiner (Senior Lecturer, Division of Diabetes, 
Endocrinology and Metabolism, Imperial College London, UK). Two hundred microlitres E. 
Coli JC8111 bacteria were added to 5ml 2x YT culture medium and incubated overnight at 37°C 
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with vigorous shaking. Two millilitres of the overnight culture were added to 500ml fresh 2x YT 
culture medium and incubated at 37°C with vigorous shaking until the bacteria were in log phase 
growth (OD550=0.5-0.6). Cells were incubated on ice prior to transfer into chilled centrifuge 
tubes and centrifuged for ten minutes at 4500xg (5000rpm in HS-4 rotor in RC-5B Superspeed 
Centrifuge, Du Pont, Fisher Scientific, Loughborough, UK) and 4°C. Cells were washed with 
250ml ice cold sterilised GDW and centrifuged as described above. Cells were washed with 
20ml ice cold filtered sterilised 10% glycerol solution and centrifuged as described above. Cells 
were re-suspended in ice cold filtered sterilised 10% glycerol solution using an equal volume to 
that of the cell pellet. One hundred microlitre aliquots were prepared, frozen in a dry ice/ethanol 
water bath and stored at -70°C. 
  
95 
 
2.5.2.2 TRANSFORMATION OF COMPETENT BACTERIA BY ELECTROPORATION 
Materials 
Ligation reaction products 
5M Glycogen (5mg/ml) (Applied Biosystems, Warrington, UK) 
Competent E. Coli JC8111 bacteria  
Luria-Bertani (LB) culture medium (pH 7.5) (APPENDIX I) 
Method 
Prior to transformation, all salts must be removed from the reaction mixture to prevent arcing 
during electroporation. One microlitre of glycogen was added to the ligation reaction to act as a 
carrier and the DNA was ethanol precipitated for at least one hour as described in 2.5.1.1. DNA 
was recovered by centrifugation for seven minutes at 13,000xg and the ligation reaction products 
dissolved in 10µl GDW.  
Under aseptic conditions, an aliquot of frozen competent E. Coli JC8111 bacteria was thawed on 
ice. Five microlitres of the ligation reaction were added to the bacterial suspension and the 
mixture transferred to an electrocuvette with an intra-electrode distance of 1mm (VWR 
International, Leicestershire, UK). A voltage of 1.2kv was passed across the cuvette. Eight 
hundred microlitres of warmed LB culture medium were then added and the reaction incubated 
at 37°C for one hour with vigorous shaking. Agar plates (APPENDIX I) (supplemented with 
100µg/ml ampicillin) were warmed and 150µl of transformed bacteria added to the plate. 
Bacteria were spread over the surface of the agar, the plate inverted and incubated at 37°C 
overnight. 
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2.5.2.3 SMALL SCALE PLASMID PREPARATION 
To identify a clone for large scale plasmid preparation, plasmids were isolated from several 
bacterial colonies on an agar plate to allow simultaneous analysis of the clones. Plasmid isolation 
from bacteria requires disruption of the cell wall to release the plasmid. At the same time 
contaminants (proteins, bacterial genomic DNA and RNA) must be removed. Treatment with 
alkaline sodium dodecyl sulphate (SDS) disrupts the cell wall and bacterial debris is then 
precipitated using potassium acetate (KAc). This step also removes most of the genomic DNA. 
RNA is removed at a later stage by treatment with RNase A. Once the plasmid is isolated, the 
transgene insert can be cut out of the plasmid by restriction endonuclease digestion and size 
fractionated by gel electrophoresis (Sambrook and Russell, 2001). 
Materials 
LB culture medium (pH 7.5) (APPENDIX I) 
Ampicillin (100mg/ml) (APPENDIX I) 
Glucose-Tris-EDTA (GTE) buffer (APPENDIX I) 
0.2M Sodium hydroxide (NaOH)/1% SDS (0.2M NaOH/1% SDS) (w/v) (APPENDIX I) 
5M KAc (APPENDIX I) 
Phenol: chloroform: iso-amyl alcohol (pH 8.0) (APPENDIX I) 
Propan-2-ol (VWR International, Leicestershire, UK) 
Method 
A single bacterial colony was placed in 2ml LB culture medium supplemented with 0.05mg/ml 
ampicillin. This was incubated overnight at 37°C with vigorous shaking. From this, 1.5ml were 
removed and centrifuged at 13,000xg for three minutes. The remainder was stored at 4°C for 
future use. Supernatant was removed and the bacterial pellet dissolved in 100µl GTE. Two 
hundred microlitres of 0.2M NaOH/1% SDS were added to the bacteria and the mixture left on 
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ice for five minutes. One hundred and fifty microlitres of 5M KAc were then added and the 
mixture left on ice for a further five minutes. The mixture was centrifuged at 13,000xg for five 
minutes and 350µl supernatant were removed to a fresh tube. An equal volume of phenol 
chloroform was added and the DNA extracted following centrifugation for two minutes at 
13,000xg. The upper aqueous phase, containing the genetic material, was then carefully removed 
using a sterile Pasteur pipette. DNA was precipitated out of the solution by the addition of 0.6 
volumes propan-2-ol and incubated at room temperature for ten minutes, followed by 
centrifugation at 13,000xg for seven minutes to pellet the DNA. Following removal of the 
supernatant, DNA was dissolved in 100µl GDW. An ethanol precipitation was carried out to 
further purify the recovered DNA as described in 2.5.1.1. Restriction endonuclease digestion was 
carried out as described in 2.5.1.1 to verify which clones contained the transformed plasmid. 
Purified DNA was re-suspended in 10µl GDW. pTR-CGW-Cre-GFP was digested by XhoI and 
BsrGI to check insert size and was also digested by XmaI to check for the presence of the ITRs. 
Restriction fragments were size fractionated by gel electrophoresis as described in 2.5.1.2.1. 
Clones containing the correct insert and with retained ITRs were selected for large scale 
purification. 
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2.5.2.4 LARGE SCALE PLASMID PREPARATION  
This process follows the same principles as small scale plasmid preparation, but in addition uses 
a caesium chloride gradient to further purify the plasmid (Sambrook and Russell, 2001). 
Materials 
LB culture medium (pH 7.5) (APPENDIX I) 
Ampicillin (100mg/ml) (APPENDIX I) 
GTE (APPENDIX I) 
Lysozyme (Sigma-Aldrich, Dorset, UK) 
0.2M NaOH/1% SDS (w/v) (APPENDIX I) 
5M KAc (APPENDIX I) 
Propan-2-ol  
100x Tris-EDTA (TE) buffer (pH 7.5) (APPENDIX I) 
Phenol: chloroform: iso-amyl alcohol (pH 8.0) (APPENDIX I) 
Method 
A small quantity of bacteria containing pTR-CGW with the correct size insert was inoculated 
into 500ml LB culture medium supplemented with 0.05mg/ml ampicillin and incubated at 37°C 
overnight with vigorous shaking. Bacteria were recovered by centrifugation for eight minutes at 
3000xg (4000rpm in HS-4 rotor in RC-5B Superspeed Centrifuge, Du Pont, Fisher Scientific, 
Loughborough, UK) and 4°C. The pellet was re-suspended in 25ml GTE supplemented with 
2mg/ml lysozyme and the sample incubated at room temperature for five minutes. Fifty 
millilitres of 0.2M NaOH/1% SDS were added, the sample mixed by inversion and incubated on 
ice for five minutes. Then 38ml 5M KAc were added, the sample mixed by inversion and 
incubated on ice for ten minutes. Bacterial debris was removed by centrifugation for fifteen 
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minutes at 9000xg (7000rpm in HS-4 rotor in RC-5B Superspeed Centrifuge, Du Pont) and 4°C. 
The supernatant was transferred to a clean tube and 0.6 volumes propan-2-ol added. The sample 
was incubated on ice for fifteen minutes and the DNA recovered by centrifugation for fifteen 
minutes at 9000xg (7000rpm in HS-4 rotor in RC-5B Superspeed Centrifuge, Du Pont) and 4°C. 
The pellet was dissolved in 10ml GDW to which 100µl 100x TE buffer were added. RNase A 
was added at a concentration of 0.1mg/ml and the reaction incubated at 37°C for thirty minutes. 
The reaction was extracted with an equal volume of phenol/chloroform and the phases separated 
by centrifugation for twenty minutes at 10,000xg (8000rpm in HB-4 rotor in RC-5B Superspeed 
Centrifuge, Du Pont) and 4°C. Aqueous phase was removed and the DNA was recovered by 
addition of 0.1 volumes 2M NaAc and one volume propan-2-ol and incubation at -20°C for at 
least one hour. 
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2.5.2.5 CAESIUM CHLORIDE GRADIENT PURIFICATION 
Large scale plasmid purification was carried out using a caesium chloride gradient. The principle 
of this technique is that ethidium bromide will bind to all DNA in the sample including both 
plasmid DNA and bacterial genomic DNA, which results in a decrease in the density of nucleic 
acids. Ethidium bromide binds to DNA by intercalation, which causes unwinding of the helix. In 
closed circular DNA this increases supercoiling of the plasmid which limits ethidium bromide 
binding. This results in a higher buoyant density of closed plasmid DNA in comparison to linear 
or nicked plasmids. The difference in buoyant density allows separation of the plasmid on a 
caesium chloride density gradient. The plasmid DNA can then be visualised within the caesium 
chloride density gradient and extracted.  
Materials 
Tris-EDTA-sodium chloride (TES) buffer (APPENDIX I) 
Caesium-chloride (Sigma-Aldrich, Dorset, UK) 
Ethidium bromide solution (10mg/ml)  
Caesium chloride saturated propan-2-ol, (APPENDIX I) 
99.7-100% Ethanol 
Method 
DNA obtained from large scale plasmid purification was recovered by centrifugation for twenty 
minutes at 24,000xg (12,000rpm in an HB-4 rotor in RC-5B Superspeed Centrifuge, Du Pont) 
and 4°C. DNA was then dissolved in 8.25ml TES buffer. Eight point four grams of caesium 
chloride were dissolved in the DNA solution, 150µl of ethidium bromide added and the solution 
mixed. The sample was divided into two polyallomer tubes (Sorvall, Fisher Scientific, 
Loughborough, UK), balanced, and overlaid with mineral oil. The tubes were sealed and 
centrifuged for sixteen hours at 500,000xg (69,000rpm in a T-170 rotor in a Sorvall 100SE 
Centrifuge, Fisher Scientific, Loughborough, UK) and 20°C. 
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After centrifugation, DNA bands were visualised by UV illumination and the band containing 
closed pTR-CGW DNA removed using a 20G needle and a 2ml syringe. Ethidium bromide was 
removed from the plasmid by repeated extraction with an equal volume of caesium chloride 
saturated propan-2-ol, until both phases were colourless. The DNA was precipitated by addition 
of two volumes of GDW and six volumes of room temperature 99.7-100% ethanol. DNA was 
recovered by centrifugation for fifteen minutes at 24,000xg (12,000rpm in an HB-4 rotor in RC-
5B Superspeed Centrifuge, Du Pont) and 20°C. The DNA pellet was dissolved in 0.4ml GDW, 
ethanol precipitated and recovered by centrifugation for seven minutes at 13,000xg. The DNA 
was then dissolved in 1ml GDW. 
The concentration of pTR-CGW was quantified by spectrophotometry. Ten microlitres of DNA 
were diluted 1:100 and placed into a quartz cuvette. Absorbance was read at 260nm and 280nm 
using a UV 1101 spectrophotometer (Biochrom, Cambridge, UK). The reading at 280nm gives 
an indication of the purity of the sample as phenol absorbs more strongly than DNA at 280nm. 
The concentration of DNA was calculated using the following formula:  
Concentration (µg/ml) = (A260 x dilution factor) x 50 
The sample was digested using specific endonucleases, XhoI and BsrGI to check insert size and 
XmaI to check for ITR integrity as described in 2.5.1.1 and 2.5.2.3, then size fractionated by gel 
electrophoresis as described in 2.5.1.2.1. 
Insert sequences were confirmed by automated DNA sequencing (DNA Sequencing Service, 
Medical Research Council Genomics Core Laboratory, Imperial College London, UK) using 
specific oligonucleotide primers (APPENDIX III). 
102 
 
2.5.3 IN VITRO PREPARATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS IN HUMAN 
EMBRYONIC KIDNEY 293T CELLS AND PURIFICATION THROUGH AN ION EXCHANGE 
COLUMN 
Recombinant AAV particles were prepared by Dr James Gardiner (Senior Lecturer, Division of 
Diabetes, Endocrinology and Metabolism, Imperial College London, UK) using the two plasmid 
transfection system (FIGURE 2.4) (Grimm et al., 1998). Briefly, host cells, in this case human 
embryonic kidney (HEK) 293T cells, are permissive to AAV infection and can be made 
competent to take up the rAAV plasmid by exposure to calcium phosphate. Since the vector 
plasmid does not contain the genes needed for the production of new virion particles, the 
cultured cells are co-transfected with a pDG helper plasmid (FIGURE 2.5). This results in the 
production of rAAV particles. To release the particles, cells are lysed by freeze-thawing and the 
rAAV yield is purified through an ion exchange column. 
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FI GURE 2.4 SCHEMATIC REPRESENTATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS 
PRODUCTION USING THE TWO PLASMID SYSTEM OF GRIMM ET AL (GRIMM ET AL., 1998) 
pTR-CGW vector plasmid carrying the inserted cDNA cassette and a helper plasmid (pDG) 
which encodes all the genes required for viral amplification and packaging are transfected into 
transformable human embryonic kidney (HEK) 293T cells, following exposure of the host cells to 
calcium phosphate (Ca3(PO4)2). This method uses the cellular synthetic machinery of the 
immortalised HEK293T cell line to produce rAAV particles. There is no homology between the 
two plasmids and therefore they cannot recombine to form wild-type virus. Following viral 
replication and packaging, the HEK cells are lysed and the viral yield isolated and purified. 
Abbreviations: 293T, human embryonic kidney 293T cells; Ca3(PO4)2, calcium phosphate; ITR, 
inverted terminal repeat; rAAV, recombinant adeno-associated virus. 
  
104 
 
LTR MMTV-Rep-Cap
VA E2A E4 RTR
 
 
 
 
FI GURE 2.5 SCHEMATIC REPRESENTATION OF THE STRUCTURE OF THE HELPER/PACKAGING 
PDG PLASMID 
The pDG plasmid contains AAV and adenovirus genes required for amplification and packaging 
of rAAV particles. Rep and cap protein expression is driven by the long terminal repeat (LTR)-
mouse mammary tumour virus (MMTV) promoter. VA, E2A and E4 are adenovirus helper genes 
required for replication. RTR denotes right terminal repeat.  
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2.5.4 CELL MAINTENANCE 
Materials 
'XOEHFFR¶VPRGLILHGHDJOHPHGLXm (DMEM) (Invitrogen, Paisley, UK) 
Fetal bovine serum (FBS) (Invitrogen, Paisley, UK) 
100x Antibiotic (Invitrogen, Paisley, UK) 
10,000U/ml Penicillin 
10,000U/ml Streptomycin 
2.5% (w/v) Trypsin in Hanks balanced salt solution (MP Biomedicals, Orangeburg, NY, 
USA) 
Versene (APPENDIX I) 
Method 
Cells were cultured in 75cm2 flasks with 15ml DMEM and supplemented with 10% FBS and 5% 
penicillin and streptomycin. The cells were incubated at 37°C in a 5% CO2 atmosphere. Medium 
was changed every two to three days. Cells were passaged 1:10 when confluent, approximately 
every six days. To passage, cells were washed in 10ml versene. To detach cells from the flask, 
0.25% trypsin in versene was added and cells left for several minutes until all appeared to have 
detached from the flask. The suspension was then added to 10ml DMEM to inactivate the trypsin 
and spun for five minutes at 100xg. The resulting pellet of cells was dissolved in 10ml DMEM 
and 1ml was used to seed two 75cm2 flasks. 
  
106 
 
2.5.5 CALCIUM PHOSPHATE TRANSFECTION 
Materials 
DMEM  
FBS  
HEK 293T cells 
pTR-CGW plasmid containing Cre-GFP transgene (680mg/ml)  
pDG helper plasmid (2.1mg/ml) 
1x Hepes buffered saline (HeBS) (pH 7.05) (APPENDIX I) 
2M Calcium chloride (CaCl2) (APPENDIX I) 
Method 
Cells were plated into a ten chamber cell factory (L x W x H (mm): 335 x 205 x 190, culture 
area: 6320cm2). Cells were incubated in 2000ml DMEM with 10% FBS. After twenty four 
hours, when cells were fifty percent confluent, the culture medium was replaced (250ml culture 
medium were retained for transfection) and transfection performed two hours later.  
Transfection mix was prepared for the cell factory, consisting of 560µg pTR-CGW-Cre-GFP, 
1.68g pDG, 7.2ml 2M CaCl2 and 52ml GDW. Immediately before transfection 12ml 1x HeBS in 
48ml GDW were added and mixed gently. After standing at room temperature for one minute the 
mixture was slowly added to 250ml DMEM with 10% FBS which was then added to the cell 
factory. 
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2.5.6 RECOVERY AND PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS TITRE 
Materials 
0.01M (1x) Phosphate buffered saline (PBS) (pH 7.5) (APPENDIX I) 
Sepharose column (GE Healthcare, Buckinghamshire, UK) 
Iodixanol (Life Sciences Technology, Eggenstein, Germany) 
0.3x PBS/0.1M Sodium chloride (NaCl) (APPENDIX I) 
1x PBS/2mM Ethylenediaminetetra-acetic acid (EDTA) (pH 8.0) (APPENDIX I) 
2M Magnesium chloride (MgCl2) (APPENDIX I) 
Benzonase (Novagen, Nottingham, UK) 
Lysis buffer (pH 8.5) (APPENDIX I) 
Method 
Forty eight hours after transfection, cell medium was removed and cells were washed using 
500ml 1x PBS and then harvested using 500ml 1x PBS/2mM EDTA. Cells were collected by 
centrifugation at 5000xg for ten minutes, re-suspended in 150ml 1x PBS and then re-centrifuged 
at 5000xg for ten minutes. Cells were then re-suspended in a total of 60ml lysis buffer in falcon 
tubes. Cells were exposed to three freeze-thaw cycles comprising ten minutes in dry ice/ethanol 
followed by ten minutes in a 37°C water bath. Seven point three microlitres 2M MgCl2 and 1.2µl 
benzonase were then added to each falcon tube and incubated at 37°C for thirty minutes. The 
solutions were then centrifuged at 2000xg for ten minutes to pellet cell debris. The supernatant 
was equally loaded into four polyallomer tubes. A pre-formed iodixanol gradient composed of 
15%, 25%, 40% and 60% iodixanol was layered underneath. The tubes were then topped up with 
lysis buffer, heat sealed and centrifuged for one hour at 500,000xg (69,000rpm in a T-170 rotor 
in a Sorvall 100SE centrifuge, Fisher Scientific, Loughborough, UK) and 18°C. To remove the 
rAAV particles, the top of each tube was punctured with an 18G needle and rAAV collected by 
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puncturing the bottom of the tube and collecting 5ml of iodixanol gradient from the 60/40% 
interface. The fractions from the four tubes were pooled, added to 20ml 1x PBS and loaded onto 
a Sepharose column (pre-washed with 25ml 0.3x PBS/0.1M NaCl and 50ml 0.3x PBS). The 
column was washed with 50ml 0.3x PBS and the virus eluted with 15ml 350mM NaCl/0.3x PBS. 
The elutant was transferred to an Apollo Concentrator (Orbital Biosciences, Topsfield, MA, 
USA) containing 10ml 1x PBS and centrifuged at 4000xg for five minutes. The flow through 
was discarded with a further 5ml 1x PBS added below and 19.5ml 1x PBS added above the filter. 
The tube was again centrifuged at 4000xg for five minutes and the remaining 0.5ml rAAV 
remaining in the filter aliquoted into eppendorf tubes. Viral titre was quantified by dot-blot 
analysis (see 2.5.7). 
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2.5.7 DETERMINATION OF TOTAL VIRAL TITRE BY DOT-BLOT ANALYSIS 
The titre of rAAV affects the level of transgene expression and the total viral particle number 
must therefore be quantified by dot-blot analysis. Dot-blot analysis is based on similar principles 
to Southern and northern blots in which a probe can be used to quantify a specific DNA or RNA 
species in a sample. In dot-blot analysis, rather than being separated by size and transferred to a 
membrane, the sample being analysed is placed directly onto a membrane and the DNA or RNA 
species present in the sample can be detected and quantified using radio-labelled probes. 
Materials 
rAAV viral preparation 
Solution A (APPENDIX I) 
Solution B (APPENDIX I) 
Phenol: chloroform: iso-amyl alcohol (pH 8.0) (APPENDIX I) 
5M Glycogen (5mg/ml) 
99.7-100% Ethanol 
75% Ethanol in GDW (APPENDIX I) 
2M NaAc (pH 5.2) (APPENDIX I) 
Denaturing solution (APPENDIX I) 
Neutralising solution (pH 7.5) (APPENDIX I) 
pTR-CGW plasmid (4.5mg/ml) 
Hybridisation buffer (APPENDIX I) 
32P-labelled woodchuck post-transcriptional regulatory element (WPRE) cDNA probe 
(see 3.7.5) 
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Method 
Forty five microlitres of solution A were added to 5µl rAAV virus stock and incubated for thirty 
minutes at 37°C. Two hundred microlitres of solution B were added and the sample was 
incubated at 55°C for one hour. DNA was extracted by adding an equal volume of 
phenol/chloroform as described in 2.5.1.1. Ethanol precipitation of the DNA was performed by 
adding 0.1 volumes sodium acetate, 40µg glycogen and 2.5 volumes ice cold 99.7-100% ethanol 
as described in 2.5.2.2. After one hour at -20°C the solution was centrifuged at 8000xg and 4°C, 
the supernatant removed, the pellet washed in 75% ice cold ethanol and air-dried. The pellet was 
re-suspended in 10µl GDW and 1µl applied to a nylon membrane (Hybond-N) (GE healthcare, 
Buckinghamshire, UK). A series of dilutions of pTR-CGW (50 to 0.1ng) were also applied to the 
membrane to act as a standard curve. The membrane was washed for five minutes in denaturing 
solution, then washed twice for five minutes in neutralising solution. The membrane was then 
baked at 80°C for two hours.  
A cDNA fragment of WPRE was used as a probe for rAAV transgenes. The probe was radio-
labelled with 32P dCTP as described in 3.7.5. Half of the radio-labelled probe was boiled and 
added to 10ml hybridisation buffer. Hybridisation was carried out overnight at 60°C. The 
following day the membrane was washed as described in 3.7.6. The membrane was then placed 
on a phosphorimager screen overnight. Radio-labelled areas were visualised and quantified by 
image densitometry using ImageQuant software (Molecular Dynamics, Amersham, UK). 
Quantification was performed by comparing viral DNA to known amounts of pTR-CGW in the 
standard curve. 
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2.6 GENERATION OF TRANSGENIC MICE AND GENOTYPING 
Materials 
75ȕflox/flox ear clip biopsy samples 
REDExtract-N-Amp Tissue PCR Kit containing red Taq DNA polymerase (Sigma-
Aldrich, Dorset, UK) 
Extraction buffer as supplied (Sigma-Aldrich, Dorset, UK) 
Tissue preparation solution  
Neutralisation buffer  
10mM specific oligonucleotide primers (Oswel DNA Service, University of 
Southampton, Southampton, UK) (APPENDIX III). 
Method 
0DOHDQGIHPDOHKRPR]\JRXV75ȕflox/flox mice were a kind gift from Professor Jacques Samarut 
(ENS de Lyon, Lyon, France). On a C57BL/6 x 129/Sv background, tKH 75ȕflox allele was 
constructed by homologous recombination, introducing two LoxP sites into the THRB gene, ¶
DQG¶WRH[RQZKLFKFRntains part of the coding sequence for the DBD (Winter et al., 2009). 
Cre recombination in these mice introduces a frame shift, so that only truncated products are 
encoded by the deleted locus.  
Mouse breeding colonies were maintained by Miss Sofia Rashid (Research Technician, 
Molecular Endocrinology Group, Imperial College London). Male and female mice were bred 
XVLQJ D KRPR]\JRXV EUHHGLQJ VWUDWHJ\ KRPR]\JRXV75ȕflox/flox [ KRPR]\JRXV75ȕflox/flox). In 
order to maintain a stable inbred background, 75ȕflox/flox mice were backcrossed to the parental 
inbred strain every ten generations. Post-weaning, at three to four weeks of age, ear clip biopsies 
were collected and genotyped by polymerase chain reaction (PCR) using specific oligonucleotide 
primers (APPENDIX III).  
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DNA was extracted from 1mm ear clip biopsies and digested in 50µl of extraction buffer and 
12.5µl of tissue preparation solution. The solution was mixed by vortexing then incubated in a 
water bath at 37°C for fifteen minutes followed by immersion in a water bath at 95°C for three 
minutes. Fifty microlitres of neutralisation buffer were added and the mixture combined by 
vortexing. The sample was separated by centrifugation for two minutes at 13,000xg to allow 
removal of the supernatant containing the genomic DNA. 
In a total volume of 10µl, 5µl REDExtract-N-Amp Tissue PCR mix were added to a 200µl PCR 
well containing 2µl autoclaved GDW, 2µl genomic DNA and 0.5µl of each oligonucleotide 
primer 7KLV ZDV UHSHDWHG IRU D SRVLWLYH FRQWURO NQRZQ 75ȕflox/flox genomic DNA and for a 
negative control (GDW). The samples were placed in an automated PCR machine and the 
reaction was heated to 94°C for three minutes followed by cycling through the following 
temperatures: 94°C for thirty seconds, 59°C for thirty seconds and 72°C for thirty seconds, 
repeated for thirty five cycles, following which, the reaction was incubated at 10°C until removal 
from the machine. One microlitre of each sample was size fractionated on a 1% (w/v) agarose 
gel as described in 2.5.1.2.1. 
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2.7 CONFIRMATION OF VENTROMEDIAL NUCLEUS COORDINATES FOR STEREOTAXIC 
INJECTION 
Stereotaxic micro-injection into the mouse VMN is technically challenging, targeting a structure 
which is approximately 1.6mm3 (FIGURE 2.6). The THRB gene is floxed in every cell of the 
75ȕflox/flox mouse. Therefore, if rAAV-Cre is delivered inaccurately, Cre mediated recombination 
will occur in CNS areas other than, or as well as, the VMN. This will make the phenotype 
inconsistent and difficult to interpret. For this reason, direct stereotaxic micro-injection into the 
VMN of adult mice was trialled with injection of Indian ink. When WKHELODWHUDO µKLW UDWH¶KDG
reached eighty five percent, rAAV-GFP was injected, in order to confirm the stereotaxic 
coordinates and to verify injection accuracy and transgene expression following rAAV 
administration into the mouse VMN. 
 
2.7.1 ANIMAL MAINTENANCE 
Prior to stereotaxic surgery, mice were group housed in Allentown XJ individually ventilated 
cages (IVC) (Allentown, NJ, USA) at 21-23°C with a twelve hour light/dark cycle with ad 
libitum access to food (RM1 diet; Special Diets Services (SDS), Witham, Essex, UK) and water 
unless otherwise specified in the procedure protocol. In the rAAV studies, following surgery, 
mice were individually housed in IVC cages under the conditions described above. All animal 
studies were approved under the British Home Office Animals (Scientific Procedures) Act 
(1986) (Project Licence 70/6377). 
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FI GURE 2.6  SCHEMATIC REPRESENTATION OF THE STEREOTAXIC POSITION OF THE 
VENTROMEDIAL NUCLEUS IN THE MOUSE AT -1.34MM FROM BREGMA 
The position of the VMN within the mouse brain is indicated by the red arrow. The VMN sits 
above the arcuate nucleus (Arc) and adjacent to the third ventricle (3V). Three subdivisions of 
the VMN are depicted; dorsomedial (VMHDM), central (VMHC) and ventrolateral (VMHVL). 
Figure fURPµ7KH mouse brain in stereotaxic coordinates¶ (Franklin and Paxinos, 2007).  
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2.7.2 STEREOTAXIC BILATERAL MICRO-INJECTION OF INDIAN INK INTO THE VENTROMEDIAL 
NUCLEUS OF TRȕFLOX/FLOX AND TRȕFLOX/THRB MICE 
Materials 
Sodium pentobarbital (Euthatal) (200mg/mL) (Merial, Harlow, UK) 
Indian ink (Sigma-Aldrich, Dorset, UK) diluted 1:20 with water for injection (Braun 
Medical Ltd., Sheffield, UK) 
4% Formaldehyde solution (VWR, Leicestershire, UK) (APPENDIX I) 
20% Sucrose solution (APPENDIX I) 
Method 
Eight week old male and female homozygous 75ȕflox/flox and heterozygous 75ȕflox/THRB mice 
(n=64) weighing 25-30g were terminally anesthetised with 0.75ml intraperitoneal (ip) sodium 
pentobarbital (Euthatal) and held in a Kopf stereotaxic frame (Bilaney Consultants Ltd., 
Sevenoaks, Kent, UK). The surgical area was shaved, a 1cm rostro-caudal incision made in the 
skin over the vertex of the skull and the periosteum removed from the underlying bone to expose 
bregma. Using an electric drill (Clark Electromedical Instruments, Pangbourne, UK), which was 
mounted onto the stereotaxic frame, bilateral burr holes were drilled according to coordinates 
calculated using the µ7KHPRXVHErain in stereotaxic coordinates¶ (Franklin and Paxinos, 2007). 
The coordinates used over successive injections were 1.2mm to 1.6mm posterior to bregma, 
0.4mm to 0.5mm lateral to bregma and 5.7mm to 6.4mm below the skull surface. Each mouse 
received bilateral intra-VMN injections of 1µl Indian ink over five minutes using a stainless steel 
injector (Bilaney Consultants Ltd., Sevenoaks, Kent, UK) and an infusion pump (Harvard 
Apparatus, Edenbridge, UK). The cannula and injector were left in position for five minutes to 
limit back-diffusion and then slowly withdrawn. The animal was dismounted from the frame, the 
brain rapidly removed and fixed in ice cold 4% formaldehyde solution at 4°C overnight. The 
following day, brains were dehydrated in 20% sucrose solution for three days followed by 
storage at -70°C. 
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2.7.2.1 CRESYL VIOLET STAINING OF INK-INJECTED MOUSE BRAINS 
Materials 
0.1M PBS (APPENDIX I) 
1% Cresyl violet solution (APPENDIX I) 
5% Acetic acid in 95% ethanol (APPENDIX I) 
70% Ethanol in GDW (APPENDIX I) 
99.7-100% Ethanol 
Acetic acid (VWR, Leicestershire, UK) 
Xylene (VWR, Leicestershire, UK) 
DPX mounting medium (VWR, Leicestershire, UK) 
Method 
Brains were sliced into 40µm coronal sections on a freezing sled microtome (Thermo Shandon 
Ltd., Cheshire, UK), floated in 0.1M PBS and alternate sections mounted on poly-lysine coated 
slides (VWR, Leicestershire UK). Slides were fixed in 5% acetic acid in 95% ethanol for fifteen 
minutes followed by immersion in 1% cresyl violet solution for fifteen to thirty minutes. Slides 
were rinsed twice in GDW prior to acid-ethanol differentiation for up to one minute in a solution 
(total volume 400ml) containing 4ml acetic acid, 280ml 99.7-100% ethanol and 116ml GDW. 
Slides were then dehydrated for thirty seconds in 70% then 99.7-100% ethanol prior to two 
fifteen minute delipidation steps in xylene. Cover-slips were applied, secured by DPX mounting 
medium and left to dry overnight. Sections were viewed under a microscope for confirmation of 
the injection site. 
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2.7.3 STEREOTAXIC BILATERAL MICRO-INJECTION OF RAAV-GFP INTO THE VENTROMEDIAL 
NUCLEUS OF TRȕFLOX/FLOX MICE 
Recombinant AAV-GFP was bilaterally injected into the VMN of eight week old male 
75ȕflox/flox mice followed by verification of injection accuracy and transgene expression by 
deconvoluting fluorescence microscopy or in situ hybridisation. In addition, this was a rAAV-
GFP dose finding study. It was important to determine the volume of rAAV to be injected 
because rAAV gene transfer and expression are dose-dependent which means its use balances 
the infectious titre of the rAAV with the volume administered (Herzog et al., 1999). 
Materials 
Xylazine (Rompun) (23mg/ml) (Bayer, Newbury, UK)  
Ketamine (Ketaset) (100mg/ml) (Parke-Davis, Gwent, UK) 
Betadine (10% w/v povidine-iodine solution) (Seton Scholl Healthcare Ltd., Gloucester, 
UK)  
rAAV-GFP (titre: 8.57x1013 genome particles/ml) 
Amoxicillin powder for injection (500mg) (CP Pharmaceuticals, Wrexham, UK)  
Flucloxacillin powder for injection (500mg) (CP Pharmaceuticals, Wrexham, UK)  
Water for injection  
0.9% NaCl (Braun Medical Ltd., Sheffield, UK) 
Buprenorphine hydrochloride (Temgesic) (0.3mg/ml) (Schering-Plough Ltd., 
Hertfordshire, UK)  
Carprofen (Rimadyl) (50mg/ml) (Kemprotec Ltd., Middlesbrough, UK) 
Atipamezole hydrochloride (Antisedan) (5mg/ml) (Centaur Services, Somerset, UK) 
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Method 
Eight week old male 75ȕflox/flox mice were anesthetised with a mixture of ip xylazine and 
ketamine (APPENDIX II) and held in a Kopf stereotaxic frame. Under aseptic conditions, the 
surgical area was shaved then cleaned with betadine. A 1cm rostro-caudal incision was made in 
the skin over the vertex of the skull and the periosteum removed from the underlying bone to 
expose bregma. Using an electric drill, which was mounted onto the stereotaxic frame, bilateral 
burr holes were drilled according to coordinates calculated using the µ7KH PRXVH Erain in 
VWHUHRWD[LF FRRUGLQDWHV¶ and further determined by Indian ink injection as described in 2.7.2 
(Franklin and Paxinos, 2007). The VMN coordinates were 1.3mm posterior to bregma, 0.4mm 
lateral to bregma and 6mm below the skull surface. Each mouse received an intra-VMN injection 
of 1µl rAAV-GFP on one side and 0.5µl rAAV-GFP on the contralateral side (n=7). The 
injection was delivered over five minutes using a stainless steel injector and an infusion pump. 
The cannula and injector were left in position for five minutes to limit back-diffusion and then 
slowly withdrawn. The scalp incision was sutured with a 6.0 polypropylene suture (Surgipro II) 
(Ethicon, Gargrave, Yorkshire, UK). 
After surgery, mice were placed on a warming mat. Atipamezole hydrochloride (Antisedan) 
(APPENDIX II) was administered by subcutaneous (sc) injection to reverse the sedative effect of 
xylazine. Prophylactic flucloxacillin and amoxicillin were administered ip (APPENDIX II) and 
0.3ml 0.9% NaCl were given by ip injection for rehydration. Analgesia was administered by sc 
injection. Carprofen (Rimadyl) (APPENDIX II) was given at anaesthetic induction and 
buprenorphine hydrochloride (Temgesic) (APPENDIX II) was injected post-operatively. 
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2.7.3.1 COLLECTION OF TRȕFLOX/FLOX MOUSE BRAINS FOLLOWING RAAV-GFP INJECTION 
Twenty eight days after rAAV-GFP injection, brains were taken for assessment of injection 
accuracy and verification of transgene expression. 
For brains which were to be assessed by fluorescence microscopy (n=4), mice were terminally 
anesthetised with 0.75ml sodium pentobarbital (Euthatal) (200mg/ml), the thoracic cavity 
exposed and 0.1M ice cold PBS (APPENDIX I) was used for trans-cardial perfusion for five 
minutes followed by five minutes of perfusion with 4% formaldehyde/0.01M PBS (APPENDIX I). 
The brains were rapidly dissected, placed in ice cold 4% formaldehyde (APPENDIX I) and post-
fixed at 4°C for twenty four hours before being removed from the formaldehyde and dehydrated 
in 20% sucrose solution (APPENDIX I). After forty eight hours, brains were removed from the 
sucrose solution and stored at -70°C. 
For brains to be used for in situ hybridisation (n=3), mice were killed by carbon dioxide 
asphyxiation followed by cervical dislocation. Brains were then rapidly removed and mounted 
onto cork discs with tissuetek cryoembed (Bright Instrument Company, Huntingdon, 
Cambridgeshire, UK), immersed in ice cold isopentane (Sigma-Aldrich, Dorset, UK) and snap 
frozen in liquid nitrogen before storage at -70°C. 
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2.8 VERIFICATION OF INJECTION INTO THE VENTROMEDIAL NUCLEUS AND TRANSGENE 
EXPRESSION BY FLUORESCENCE MICROSCOPY 
Sections were viewed by direct fluorescence microscopy using a Zeiss deconvoluting 
microscope (Axiovert S100 TV, Carl Zeiss, Jena, Germany) using the fluoroscein isothiocyanate 
(FITC) filter. GFP expression was detected by apple green fluorescence and correct anatomical 
localisation was determined by comparison with µ7KHPRXVH Erain LQ VWHUHRWD[LF FRRUGLQDWHV¶
(Franklin and Paxinos, 2007). 
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2.9 IN SITU HYBRIDISATION FOR WOODCHUCK POST-TRANSCRIPTIONAL REGULATORY 
ELEMENT MRNA 
In situ hybridisation is a method used for the detection and quantification of mRNA whilst 
maintaining the structural integrity of the tissue. It relies on the hybridisation of a complimentary 
probe, usually radio-labelled to the target mRNA, in tissue mounted on poly-lysine coated slides.  
An in situ hybridisation reaction was performed to confirm the correct injection site of rAAV. 
&RURQDOVHFWLRQVRIȝPZHUHXVHGIRU35S-labeled antisense RNA probes raised for woodchuck 
post-transcriptional regulatory element (WPRE). The WPRE sequence is part of the expression 
cassette of all vectors used in this study to enhance expression but is not endogenously expressed 
by mammalian cells. Its detection therefore verifies successful rAAV neuronal infection and 
transgene expression. A 35S-labelled WPRE sense probe was used as a control to validate that 
there was no non-specific binding of the antisense probe. 
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2.9.1 PRODUCTION OF RADIO-LABELLED RNA PROBE FOR IN SITU HYBRIDISATION 
Materials 
Linearised template (for WPRE in situ p-bluescript-WPRE (200ng/µl) linearised by 
digestion with Bam HI for antisense probe or EcoRI for sense probe, prepared as 
described in 2.5.1.1) 
10mM DTT (APPENDIX I)  
RNase inhibitor (30U/µl) (Invitrogen, Paisley, UK) 
10x nucleotide mix: 10mM of each ATP, UTP, GTP (GE Healthcare, Buckinghamshire, 
UK) 
T7 RNA polymerase (20U/µl) (Promega, Southampton, UK) 
T3 RNA polymerase (20U/µl) (Promega, Southampton, UK) 
10x RNA polymerase buffer as supplied (Promega, Southampton, UK) 
DNase I (7.5 U/µl) (GE Healthcare, Buckinghamshire, UK) 
10x DNase buffer as supplied (GE Healthcare, Buckinghamshire, UK) 
5M Ammonium acetate (APPENDIX I)  
99.7-100% Ethanol  
(35S)&73Į67%TPPRO*%TPO*(+HDOWKFDUHBuckinghamshire, UK) 
Method 
Radioactively labelled RNA was produced using an in vitro transcription reaction. Two hundred 
nanograms of template were added to a reaction buffer containing 10mM DTT, 1x nucleotide 
mix, 1x polymerase buffer, 30U RNase inhibitor and 3.75MBq (35S)&73Į6LQDWRWDOYROXPHRI
9µl. To this 20U of RNA polymerase were added (T3 to the anti-sense reaction and T7 to the 
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sense reaction) and the reaction incubated for at least two hours at 37°C. After incubation, 6µl 
GDW, 1µl DNase I and 3µl DNase buffer were added. This was followed by incubation at 37°C 
for fifteen minutes. Ammonium acetate was added to a final concentration of 2M and 2.5 
volumes ice cold 99.7-100% ethanol were added and the mixture left at -20°C for at least one 
hour for the RNA to precipitate. RNA was recovered by centrifugation at 8000xg for seven 
minutes and the pellet was re-suspended in 100µl GDW. To measure the activity of the radio-
labelled probe, 1µl was counted on a microbeta counter (Wallac, Waltham, MA, USA). 
 
2.9.2 PREPARATION OF SLIDES 
Materials 
4% Formaldehyde (VWR International, Leicestershire, UK) in 0.01M PBS (APPENDIX I) 
0.01M PBS (pH 7.5) (APPENDIX I) 
Acetic anhydride (VWR International, Leicestershire, UK) 
0.1M Triethanolamine (TEA) buffer (pH 8.0) (APPENDIX I) 
20x Saline sodium citrate (SSC) buffer (pH 7.0) (APPENDIX I) 
3M NaCl (APPENDIX I) 
70% Ethanol in GDW (APPENDIX I) 
95% Ethanol in GDW (APPENDIX I) 
99.7-100% Ethanol  
Chloroform (VWR International, Leicestershire, UK) 
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Method 
Twelve micrometre sections of mouse brain were cut on a cryostat at -Û&%ULJKW,QVWUXPHQW
Company, Huntingdon, Cambridgeshire, UK). The sections were mounted onto poly-lysine 
coated slides and stored at -Û& XQWLO K\EULGLVDWLRQ In situ hybridisation was performed on 
every third slide. 
The selected slides were placed in a rack and fixed in 4% formaldehyde in 0.01M PBS on ice for 
twenty minutes. Slides were then washed twice in 0.01M PBS for five minutes. Slides were 
subsequently washed in 0.1M TEA for two minutes and acetylated in 0.25% (v/v) acetic 
anhydride in 0.1M TEA for ten minutes, followed by two rinses in 0.01M PBS for two minutes 
each time. Slides were dehydrated by sequential immersion in 70%, 95% and 99.7-100% ethanol 
before washing in GDW for three minutes. Finally slides were delipidated in chloroform for five 
minutes before dehydration in 70% and then 95% ethanol and finally being left to air dry. 
 
2.9.3 HYBRIDISATION OF RADIO-LABELLED PROBE TO SLIDES 
Materials 
35S labelled WPRE sense and anti-sense riboprobes 
Hybridisation buffer (APPENDIX I) 
1x RNase buffer (APPENDIX I) 
10mM DTT (APPENDIX I) 
20x SSC (pH 7.0) (APPENDIX I) 
70% Ethanol in GDW (APPENDIX I) 
99.7-100% Ethanol  
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Method 
Enough 35S labelled probe for one million counts per slide was added to the hybridisation buffer 
DQGȝOZere applied to each slide. A coverslip was placed on each slide and the slides were 
K\EULGLVHGRYHUQLJKWDWÛ&   
The slides were soaked in 4x SSC with gentle agitation to remove coverslips and then washed 
four times in 4x SSC for five minutes. Slides were RNase treated by incubation for thirty 
PLQXWHVDWÛ& LQ[RNase EXIIHUFRQWDLQLQJȝJPORNase A (APPENDIX I) followed by 
two five minute washes in 10mM DTT/2x SSC, followed by a ten minute wash in 10mM 
DTT/1x SSC and a ten minute wash in 10mM DTT/0.5x SSC, all at room temperature. Finally, 
slides wHUHZDVKHGLQP0'77[66&DWÛ&IRUWKLUW\PLQXWHVULQVHGEULHIO\LQP0
DTT/0.1x SSC at room temperature and then dehydrated for three minutes in 70% ethanol and 
three minutes in 99.7-100% ethanol and air dried. After washing and dehydration, the slides were 
exposed to Bio-Max film (Kodak, Hemel Hempstead, Hertfordshire, UK). After a three day 
exposure, the film was developed using developer and fixer (Jet X-Ray, London, UK). WPRE 
distribution was determined by observation of specific hybridisation. 
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CHAPTER TWO RESULTS 
 
2.10 SEQUENCING OF PTR-CGW PLASMID CONTAINING SUB-CLONED CRE-GFP TRANSGENE 
Automated DNA sequencing confirmed the presence of Cre-GFP in the pTR-CGW plasmid 
(APPENDIX IV).  
 
2.11 DETERMINATION OF TOTAL VIRAL TITRE BY DOT-BLOT ANALYSIS 
The rAAV-Cre titre was 7.63x1013 genome particles/ml. 
 
2.12 GENOTYPE OF MICE 
0DOH75ȕflox/flox mice were born at Mendelian frequency with normal appearance. Allele specific 
3&5FRQILUPHGWKHSUHVHQFHRI WKHES75ȕflox DOOHOHLQPDOHKRPR]\JRXV75ȕflox/flox mice 
(FIGURE 2.7). 
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FI GURE 2.7  REPRESENTATIVE AGAROSE GEL OF GENOTYPING DNA SAMPLES FROM MALE 
TRȕFLOX/FLOX MICE VISUALISED UNDER UV ILLUMINATION 
Lane 1=HyperLadder I (DNA molecular weight marker) (Bioline, London, UK); Lanes 2±
12 '1$IURP75ȕflox/flox mice with a band at 1111bp representing the 75ȕflox allele; Lanes 13 
and 15=positive controls (DNA from known 75ȕflox/flox mice); Lane 14=DNA from wild type 
mouse with a band at 931bp representing the wild type µQRQ-IOR[HG¶ 7+5% DOOHOH Lane 
16=negative control (autoclaved GDW); Lane 17=HyperLadder I (DNA molecular weight 
marker). 
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2.12.1 INDIAN INK INJECTION INTO THE VENTROMEDIAL NUCLEUS TO CONFIRM COORDINATES 
FOR STEREOTAXIC MICRO-INJECTION 
Mice were injected bilaterally with Indian ink into the VMN (n=64). Correct anatomical 
localisation was determined by comparison with µ7he mouse brain atlas in stereotaxic 
coordinates¶DQG stereotaxic coordinates were adjusted following ex vivo assessment of injection 
sites (Franklin and Paxinos, 2007). At the end of the study, VMN coordinates were determined 
as 1.3mm posterior to bregma, 0.4mm lateral to bregma and 6mm below the skull surface. In the 
final fourteen mice to be injected, eighty five percent of the injections correctly targeted the 
VMN (FIGURE 2.8 A). Injection VLWHV ZHUH FRPSDUHG WR µ7KH PRXVH EUDLQ LQ VWHUHRWD[LF
coordinateV¶FIGURE 2.8 B) (Franklin and Paxinos, 2007).  
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FI GURE 2.8  CONFIRMATION OF VENTROMEDIAL NUCLEUS STEREOTAXIC COORDINATES BY 
INDIAN INK INJECTION 
Indian ink was identified within the VMN (white arrows, panel A) following cresyl violet staining 
of brain sections,QMHFWLRQVLWHVZHUHFRPSDUHGWRµ7KHPRXVHEUDLQLQVWHUHRWD[LFcoordinates¶
(panel B) (Franklin and Paxinos, 2007).  
Abbreviations: 3V, third ventricle; Arc, arcuate nucleus; VMHC, ventromedial hypothalamus, 
central; VMHDM, ventromedial hypothalamus, dorsomedial; VMHVL, ventromedial 
hypothalamus, ventrolateral. 
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2.12.2 CONFIRMATION OF RAAV-GFP TRANSGENE EXPRESSION AND INJECTION ACCURACY BY 
FLUORESCENCE MICROSCOPY 
Recombinant AAV-GFP transgene expression and the accuracy of the intra-VMN targeting was 
confirmed by fluorescence microscopy (n=4) (FIGURE 2.9 A and B). GFP was only detected in 
the VMN into which 1µl rAAV-GFP had been injected as compared with the VMN on the 
contralateral side into which 0.5µl rAAV-GFP had been injected. Injection sites were compared 
WRµ7KHPRXVHEUDLQLQVWHUHRWD[LFFRRUGLQDWHV¶FIGURE 2.9 C) (Franklin and Paxinos, 2007).  
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FI GURE 2.9  REPRESENTATIVE CORONAL SECTION THROUGH THE MOUSE BRAIN AT -1.3MM 
FROM BREGMA SHOWING GREEN FLUORESCENT PROTEIN FLUORESCENCE WITHIN THE 
VENTROMEDIAL NUCLEUS 
Panel A shows GFP within the VMN at 2.5x magnification, viewed under a fluorescence 
microscope. Panel B depicts the same coronal brain section as panel A at 10x magnification 
represented as a montage of images showing GFP within the VMN. Injection sites were 
FRPSDUHG WR µ7KH PRXVH EUDLQ LQ VWHUHRWD[LF coordinates¶ SDQHO & (Franklin and Paxinos, 
2007).  
Abbreviations: 3V, third ventricle; Arc, arcuate nucleus; VMHC, ventromedial hypothalamus, 
central; VMHDM, ventromedial hypothalamus, dorsomedial; VMHVL, ventromedial 
hypothalamus, ventrolateral. 
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2.12.3 CONFIRMATION OF RAAV-GFP TRANSGENE EXPRESSION AND INJECTION ACCURACY BY 
IN SITU HYBRIDISATION USING A RADIO-LABELLED WOODCHUCK POST-
TRANSCRIPTIONAL REGULATORY ELEMENT PROBE 
The accuracy of intra-VMN injection and GFP transgene expression were confirmed by in situ 
hybridisation (n=3) using a 35S-labelled WPRE riboprobe (FIGURE 2.10). The radioactive signal 
was more intense in the VMN into which 1µl rAAV-GFP had been injected as compared with 
the VMN on the contralateral side into which 0.5µl rAAV-GFP had been injected (FIGURE 2.10 
A and B). No signal was detected in the slices hybridised with the WPRE sense riboprobe 
(FIGURE 2.10 C). +\EULGLVDWLRQ VLWHV ZHUH FRPSDUHG WR µ7KH PRXVH EUDLQ LQ VWHUHRWD[LF
FRRUGLQDWHV¶FIGURE 2.10 D) (Franklin and Paxinos, 2007).  
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FI GURE 2.10  IN SITU HYBRIDISATION IMAGES OF REPRESENTATIVE CORONAL SECTIONS 
THROUGH THE MOUSE BRAIN AT -1.3MM FROM BREGMA FOLLOWING INJECTION OF RAAV-GFP 
INTO THE VENTROMEDIAL NUCLEUS 
Panels A and B depict a brain section radio-labelled with 35S WPRE antisense riboprobe bound 
within the VMN. The left hand side of the image was the site of the 0.5µl rAAV-GFP injection. 
The right hand side of the image was the site of the 1µl rAAV-GFP injection. The image in panel 
B is of the same section as depicted in panel A, with the mediobasal hypothalamus enlarged. 
Panel C depicts a control brain section hybridised with 35S WPRE sense riboprobe in which no 
riboprobe binding has occurred. +\EULGLVDWLRQ VLWHV ZHUH FRPSDUHG WR µ7KH PRXVH EUDLQ LQ
VWHUHRWD[LFFRRUGLQDWHV¶SDQHO' (Franklin and Paxinos, 2007).  
Abbreviations: 3V third ventricle; Arc, arcuate nucleus; CCX, cerebral cortex; LF, longitudinal 
fissure; VMHC, ventromedial hypothalamus, central; VMHDM, ventromedial hypothalamus, 
dorsomedial; VMHVL, ventromedial hypothalamus, ventrolateral; VMN, ventromedial nucleus. 
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2.13 CHAPTER TWO DISCUSSION 
TKH UROH RI 75ȕ LQ WKH901 LQ WKHPHGLDWLRQ RI HQHUJ\ KRPHRVWDVLV can be investigated by 
manipulating the mouse genome. In order to accomplish this, several different transgenic 
approaches were considered. Ultimately, site-specific recombination within the THRB gene in 
adult mice, UHVXOWLQJ LQ75ȕNQRFNGRZQ in the VMN was selected. This approach allows for 
temporo-VSDWLDO FRQWURO RYHU 75ȕ NQRFN GRZQ, which mitigates the drawbacks of global 
transgenic models. 
Recombinant AAV-2 was selected as the most suitable vector for the delivery of the Cre 
recombinase transgene into the VMN. This is because of its tropism for neurons, lack of tropism 
for glia, ability to integrate into the host genome and efficiency of transgene expression. In 
addition, rAAV-2 is non-pathogenic, non-immunogenic and non-toxic. In the work described in 
this chapter, the Cre recombinase transgene was sub-cloned into the AAV plasmid, pTR-CGW, 
and rAAV carrying the Cre recombinase cDNA cassette was produced. In addition, the 
VXFFHVVIXO EUHHGLQJ RI75ȕflox/flox mice is described in this chapter. These two pieces of work 
form the basis for the site-speciILF NQRFN GRZQ RI 75ȕ LQ WKH 901 of adult mice which is 
described in chapter three.  
The accuracy of rAAV-Cre injection is critical to the correct interpretation of the phenotype of 
injected 75ȕflox/flox mice. This is because Cre mediated excision of the 75ȕflox allele will occur in 
any cell in which the Cre recombinase transgene is expressed. If this occurs in hypothalamic 
nuclei other than the VMN, WKHQ WKH HIIHFWV RI 75ȕ NQRFN GRZQ LQ WKH 901 FDQQRW EH
determined. It has been shown in this chapter, by injection of Indian ink and rAAV-GFP that it is 
possible to accurately target bilateral micro-injections to the VMN of adult mice. By performing 
bilateral stereotaxic Indian ink injections in sixty four mice and by adjusting the coordinates 
following ex vivo tissue analysis of the injection site, stereotaxic coordinates for intra-VMN 
micro-injection have been determined as 1.3mm posterior to bregma, 0.4mm lateral to bregma 
and 6mm below the skull surface. 
Recombinant AAV transgene expression depends upon the infectious titre and the number of 
viral particles delivered. It was important to determine the volume of rAAV to be delivered into 
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the mouse VMN that would result in high transgene expression without viral spread into      
extra-VMN sites. It was shown, both by fluorescence microscopy and by in situ hybridisation, 
that expression following injection of 1µl rAAV-GFP (titre: 8.57x1013 genome particles/ml) was 
subjectively stronger than following 0.5µl injected into the contralateral VMN. A volume of 1µl 
of rAAV was therefore used for the work described in chapters three and four.  
By synthesising rAAV-&UH VXFFHVVIXOO\EUHHGLQJ75ȕflox/flox mice, accurately targeting micro-
injections to the mouse VMN and determining the volume of rAAV to be administered, the work 
LQWKLVFKDSWHUVHWVWKHVWDJHIRUWKHWDUJHWHGNQRFNGRZQRI75ȕLQWKH901DQGDQDO\VLVRIWKH
resultant phenotype with respect to energy homeostasis. 
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CHAPTER THREE 
THE EFFECT OF THYROID HORMONE RECEPTOR 
BETA KNOCK DOWN IN THE VENTROMEDIAL 
NUCLEUS ON FOOD INTAKE, BODY WEIGHT AND 
ENERGY EXPENDITURE 
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3 CHAPTER THREE 
 
3.1 INTRODUCTION 
,WKDVEHHQGLVFXVVHGLQWKHSUHFHGLQJFKDSWHUVWKDWWKHUROHRI75ȕLQWKH901LQWKHmediation 
of energy homeostasis is unknown and may be physiologically important. In chapter two, 
75ȕflox/flox mice were successfully bred and rAAV-Cre was synthesised. These materials were 
XVHGLQWKHZRUNGHVFULEHGLQWKLVFKDSWHUIRU WKHWDUJHWHGNQRFNGRZQRI75ȕLQWKH901RI
adult male mice. 
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3.2 CHAPTER THREE AIMS 
The aims of the work described in this chapter were: 
1. To NQRFN GRZQ 75ȕ LQ WKH 901 RI DGXOW 75ȕflox/flox mice by intra-nuclear stereotaxic 
injection of rAAV-Cre. 
2. To measure the effect of intra-90175ȕNQRFNGRZQRQIRRGLQWDNHDQGERG\ZHLJKWRYHU
sixty three days. 
3. To determine the effect of intra-VMN 75ȕ NQRFN GRZQ RQ HQHUJ\ H[SHQGLWXUH E\
quantitation of uncoupling protein-1 mRNA in brown adipose tissue. 
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CHAPTER THREE METHODS  
 
3.3 STEREOTAXIC BILATERAL MICRO-INJECTION OF RAAV-CRE OR RAAV-GFP INTO THE 
VENTROMEDIAL NUCLEUS OF TRǺ)/2;/FLOX MICE 
 
3.3.1 ANIMAL MAINTENANCE 
Animals were maintained as described in 2.7.1. 
 
3.3.2 STEREOTAXIC SURGERY 
Stereotaxic surgery was performed as described in 2.7.3. Each mouse received bilateral intra-
VMN injections of 1µl rAAV-Cre (titre: 7.63x1013 genome particles/ml) (n=10-11) or 1µl 
rAAV-GFP (titre: 8.57x1013 genome particles/ml) (n=10). 
 
3.3.3 CUMULATIVE FOOD INTAKE AND BODY WEIGHT CHANGE 
Following surgery, mice were allowed to recover for seven days. After this time, food intake and 
body weight were measured three times per week at 09.00h. The study was terminated at day 
sixty three post-injection. 
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3.4 COLLECTION OF TISSUE SAMPLES 
In all studies, unless otherwise stated in the methods, mice were killed in the early light phase by 
carbon dioxide asphyxiation followed by cervical dislocation. 
For excision PCR analysis, brains were rapidly removed and dissected to isolate the 
hypothalamus, brainstem and cerebellum which were snap frozen in liquid nitrogen before 
storage at -70°C. 
For real time quantitative PCR (qPCR) analysis, brains were rapidly removed and dissected to 
isolate the hypothalamus which was snap frozen in liquid nitrogen before storage at -70°C. 
Brains to be used for in situ hybridisation were taken as described in 2.7.3.1. 
Blood was taken by cardiac puncture and was collected using a 22G needle and a 1ml syringe 
coated with heparin (CP Pharmaceuticals, Wrexham, UK) before decanting into a 1.5ml 
eppendorf contaLQLQJ ȝO DSURWLQLQ 7UDV\ORO (500,000KIU/ml) (Bayer, Newbury, UK). 
Samples were incubated on ice prior to centrifugation at 4°C to obtain plasma. Plasma samples 
were stored at -70°C. 
Inter-scapular brown adipose tissue was dissected, weighed, snap frozen in liquid nitrogen and 
stored at -70°C. 
An incision was made in the abdomen and the abdominal cavity exposed. The liver was 
dissected, removed, snap frozen in liquid nitrogen and stored at -70°C. Epididymal white adipose 
tissue (WAT) was dissected, weighed, snap frozen in liquid nitrogen and stored at -70°C.  
An incision was made in one hind limb and the quadriceps femoris muscle dissected, removed, 
snap frozen in liquid nitrogen and stored at -70°C. 
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3.5 VERIFICATION BY POLYMERASE CHAIN REACTION OF CRE RECOMBINASE MEDIATED 
EXCISION OF THE TRȕflox ALLELE 
Materials 
75ȕflox/flox CNS tissue samples  
REDExtract-N-Amp Tissue PCR Kit containing red Taq DNA polymerase  
Tissue DNA Extraction buffer as supplied 
Tissue preparation solution  
Neutralisation buffer  
10mM specific oligonucleotide primers (Oswel DNA Service, University of 
Southampton, Southampton, UK) (APPENDIX III) 
Method 
Cre mediated excision of the 75ȕflox allele was investigated by PCR of whole hypothalami. The 
brainstem and cerebellum from the same animal were used as control CNS tissues to demonstrate 
localisation of Cre mediated excision within the hypothalamus.  
The tissues were homogenised as described in 2.6 and DNA extracted. Excised THRB DNA was 
amplified by PCR. In a total volume of 10µl, 5µl REDExtract-N-Amp Tissue PCR mix were 
added to a 200µl PCR well containing 2µl autoclaved GDW, 1.5µl genomic DNA and 0.5µl of 
each oligonucleotide primer. This was repeated for two positive controls NQRZQ 75ȕflox/flox 
genomic DNA and a sample known to contain the exFLVHG75ȕflox allele. DNA from a wild type 
µQRQ-IOR[HG¶PRXVHand GDW were used as negative controls. 
The samples were placed in an automated PCR machine and the reaction was heated to 94°C for 
two minutes followed by cycling through the following temperatures: 94°C for thirty seconds, 
60°C for thirty seconds and 72°C for one minute repeated for thirty five cycles, then 72°C for 
three minutes, following which, the reaction was incubated at 4°C until removal from the 
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machine. One microlitre of each sample was size fractionated on a 1% (w/v) agarose gel as 
described in 2.5.1.2.1. 
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3.6 IN SITU HYBRIDISATION FOR WOODCHUCK POST-TRANSCRIPTIONAL REGULATORY 
ELEMENT MRNA 
An in situ hybridisation reaction (rAAV-Cre, n=7) was performed to confirm transgene 
expression and to determine the accuracy of rAAV-Cre injection into the VMN as described in 
2.9. 
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3.7 NORTHERN BLOT ANALYSIS OF UNCOUPLING PROTEIN-1 MRNA EXPRESSION IN BROWN 
ADIPOSE TISSUE 
Northern blotting was used to measure the quantity of UCP-1 mRNA in brown adipose tissue 
(BAT). Northern blotting is a technique used to identify and quantify RNA in tissues. It is an 
adaptation of Southern Blotting, a technique developed in the 1970s to quantify DNA (Southern, 
1975). The RNA is size fractioned on a denaturing agarose gel, transferred to a nylon membrane 
by capillary action and covalently linked to it by baking. The RNA is denatured to remove 
secondary structure ensuring the rate of migration of the RNA is proportional to its total length. 
 
3.7.1 TOTAL RNA EXTRACTION 
Materials 
Tri-reagent (Helena Biosciences, Sunderland, Tyne and Wear, UK) 
Bromo-chloro-propane (Sigma-Aldrich, Poole, UK) 
Propan-2-ol  
75% Ethanol in GDW (APPENDIX I) 
Method 
Total RNA was extracted using the Tri-reagent methoGDFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO
BAT was ground under liquid nitrogen with a pestle and mortar before homogenisation in 1ml 
Tri-reagent and subsequent transfer to 1.5ml eppendorfs to incubate at room temperature for five 
minutes. One hundred microlitres bromo-chloro-propane were then added, mixed vigorously for 
fifteen seconds, and then incubated for a further five minutes at room temperature. The emulsion 
ZDV WKHQ FHQWULIXJHG DW Û& IRU ILIWHHQ PLQXWHV at 12,000xg with the brake off. The upper 
aTXHRXV SKDVH ZDV WUDQVIHUUHG WR D FOHDQ HSSHQGRUI SUHFLSLWDWHG ZLWK D KDOI YROXPH ȝO
room temperature propan-2-ol for five minutes and then centrifuged at 12,000xg for ten minutes 
DW Û& 7KLV UHVXOWHG LQ D SHOOHW, which was washed with one volume (1ml) 75% ethanol, 
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centrifuged at 12,000xJ IRU D IXUWKHU WHQ PLQXWHV DW Û& WKH SHOOHW ZDV WKHQ DLU GULHG DQG
GLVVROYHGLQȝODXWRFODYHG*': 
RNA concentration was determined by spectrophotometry. RNA was diluted 1:100 in GDW and 
1ml placed in a quartz cuvette. The absorbance was read at 260nm and 280nm using a UV 1101 
spectrophotometer (Biochrom, Cambridge, UK). The 280nm reading gives an indication of the 
purity of the sample. The concentration of RNA was calculated using the following formula: 
&RQFHQWUDWLRQȝJPO $260 x dilution factor) x 40 
Following quantification, the RNA samples were ethanol precipitated with 0.1 volumes 2M 
NaAc (pH 5.2) and 2.5 volumes ice cold 99.7-100% ethanol as described in 2.5.1.1. The samples 
were precipitated at -20°C for a minimum of one hour and centrifuged at 12,000xg for twenty 
minutes, the supernatant was discarded and the pellet vacuum dried for five minutes. The pellets 
were re-suspended in the appropriate volume of GDW to give a final concentration of 5mg/ml. 
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3.7.2 INTEGRITY ANALYSIS OF TOTAL RNA 
Materials 
Agarose type II-A medium EEO  
Formaldehyde  
20x 3-(N-Morpholino) propanesulphonic acid (MOPS) buffer (pH 7.0) (APPENDIX I) 
Ethidium bromide  
RNA denaturing buffer (DENAT) (APPENDIX I) 
RNA loading Buffer (APPENDIX I) 
100x TE (pH 7.5) (APPENDIX I) 
Method 
The RNA secondary structure was denatured before confirming the integrity of the samples 
using a formaldehyde gel. One microlitre of RNA VROXWLRQ ZDV DGGHG WR ȝO '(1$7 7KH
VDPSOHV ZHUH GHQDWXUHG DW & IRU ILYH PLQXWHV DQG ȝO RNA loading buffer added. The 
samples were loaded onto the gel and run in 1x MOPS buffer with 7.5 % formaldehyde (v/v) at 
10V/cm. The gel was stained in 1x TE with 0.1 mg/ml ethidium bromide on a shaking platform 
for thirty minutes and de-stained overnight in 1x TE to allow visualisation of the 18S and 28S 
ribosomal bands under UV light. The presence of intact ribosomal bands indicated that the RNA 
was not degraded. 
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3.7.3 TRANSFER OF RNA TO NYLON FILTERS (LEHRACH ET AL., 1977)  
Materials 
Agarose type II-A medium EEO 
Formaldehyde  
20x MOPS (pH 7.0) (APPENDIX I) 
RNA denaturing buffer (DENAT) (APPENDIX I) 
RNA loading Buffer (APPENDIX I) 
Hybond-N membrane (GE Healthcare, Buckinghamshire, UK) 
20x SSC (pH 7.0) (APPENDIX I) 
Method 
An agarose gel was made by dissolving 1g agarose in GDW, 20x MOPS was added to a final 
concentration of 1x and formaldehyde added to 3% (v/v). Once set, the gel was transferred to an 
electrophoresis tank containing 1x MOPS, and 3% formaldehyde (v/v). Before loading, 50µg of 
total RNA were GHQDWXUHGE\DGGLWLRQRIȝODENAT DQGLQFXEDWLRQDWÛ&IRUILYHPLQXWHV
After denaturation, ȝOORDGLQJEXIIHUZere added and the samples loaded onto the gel. The gel 
was electrophoresed at a constant voltage of 10V/cm. After electrophoresis, the RNA in the gel 
was transferred to a Hybond-N membrane by capillary action by inverting the gel and placing it 
into a stack constructed as illustrated in FIGURE 3.1. After transfer, the filter was baked at 80°C 
for one to two hours. 
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Weight 
(approx. 200g)
Glass plate
Paper towels
3mm Filter paper
20x SSC
Capillary wickSupport
Saran wrap
Inverted gel
Hybond N
 
 
 
 
 
 
 
 
 
 
 
 
FI GURE 3.1  DIAGRAMMATIC REPRESENTATION OF THE APPARATUS USED FOR CAPILLARY 
TRANSFER OF RNA FROM A GEL ONTO A HYBOND-N MEMBRANE PRIOR TO NORTHERN BLOT 
ANALYSIS   
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3.7.4 HYBRIDISATION OF 32P LABELLED PROBE TO THE FILTER 
Probes for northern blot analysis were prepared using a primer set specific for the mouse UCP-1 
gene (APPENDIX III). Fragments were labelled using random primer labelling. Pre-hybridisation 
was carried out before binding of the radio-labelled probe to the membrane; this blocks 
irreversible non-specific probe binding. Following hybridisation, a number of increasingly 
stringent washes were performed to remove non-specifically bound probe. 
 
3.7.5 RANDOM PRIMER LABELLING OF DNA FRAGMENTS 
Materials 
DNA fragment (UCP-1 probe) 
5x ABC Buffer (APPENDIX I) 
BSA, fraction V (10mg/ml) (Sigma-Aldrich, Dorset, UK) 
(Į-32P)-dCTP: 10Ci/ml, 3000Ci/mmol (GE Healthcare, Buckinghamshire, UK) 
DNA polymerase I, Klenow fragment (8ȝO) (GE Healthcare, Buckinghamshire, UK) 
Sephadex G50 (APPENDIX I) 
1x TE (pH 7.5) (APPENDIX I) 
Method 
7ZHQW\ QDQRJUDPV RI'1$ LQ D WRWDO YROXPHRI ȝO RI*':Zere boiled for five minutes. 
$IWHU ERLOLQJ WKH VROXWLRQZDVPDGHXS WR D WRWDO YROXPHRI ȝO FRQWDLQLQJ [$%&EXIIHU
2mg/PO%6$ȝ&LG&73DQG8.OHQRZ7KHUHDFWLRQZDVLQFXEDWHGDW&IRUDWOHDVWRQH
hour. Incorporation of radio-labelled nucleotide into the DNA probe was measured using a mini 
Sephadex G50 column. The column was prepared by plugging a glass Pasteur pipette with glass 
wool, and adding Sephadex G50 7KH ODEHOOLQJ UHDFWLRQ YROXPH ZDV PDGH XS WR ȝO ZLWK      
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[7(DQGORDGHGRQWRWKHFROXPQ7KHFROXPQZDVWKHQHOXWHGZLWK[7(DQGȝOIUDFWLRQV
collected. The fractions were counted and the percentage incorporation calculated. The hottest 
two fractions were pooled and half added to the hybridisation mix. 
 
3.7.6 HYBRIDISATION OF NORTHERN FILTERS 
Materials 
32P Labelled probe  
Hybridisation buffer (APPENDIX I) 
Amasino wash buffer (APPENDIX I) 
Universal wash buffer (APPENDIX I) 
Method 
The baked filter was placed in a heat sealed polythene bag and pre-hybridised in 20ml 
hybridisation buffer at 60°C for at least two hours. Before hybridisation of the nylon filter, the 
radio-labelled probe was denatured for five minutes in a boiling water bath. The pre-
hybridisation solution was removed and replaced with 20ml fresh hybridisation buffer. Two 
hundred microlitres of the probe were added, the bag sealed and the filter incubated overnight at 
60°C. The following day, the filter was washed to remove any non-specifically bound probe. 
Three twenty minute washes at 60°C were carried out in amasino wash buffer followed by a 
further three twenty minute washes at 60°C in universal wash buffer. The filter was then sealed 
in a clean plastic bag and exposed to a storage phosphorimager screen for two days (Molecular 
Dynamics, Amersham, UK). Radio-labelled RNA was visualised and quantified using Storm 
Imaging System and ImageQuant software (Molecular Dynamics, Amersham, UK). 
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3.7.7 FILTER STRIPPING 
Following hybridisation with a radio-labelled probe, northern filters can be stripped of 
radioactivity and re-used with minimal loss of RNA. Most northern filters can be stripped and re-
probed five or six times depending on the abundance of the transcript of interest. 
Materials 
100 x TE (pH 7.5) (APPENDIX I) 
20% (w/v) SDS (APPENDIX I) 
Method 
The filter was stripped by incubation in 200 ml of 1xTE/0.5% SDS for thirty minutes in an 80°C 
water bath. The filter was then exposed overnight to a phosphorimager plate to ensure that all 
radioactive probe had been removed. 
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3.7.8 OLIGO DEOXYTHYMIDYLIC ACID CORRECTION 
A radio-labelled oligo deoxythymidylic acid (oligo dT) probe was prepared which hybridises 
with the polyA tail of mRNA species. This corrects for variation in gel loading and RNA transfer 
when performing northern blot analysis and allows total mRNA on the filter to be quantified.  
Materials 
Oligo dT template (200ng/ȝO) (GE Healthcare, Buckinghamshire, UK) 
Terminal deoxytransferase (8ȝO) (Promega, Southampton, UK) 
5x Reaction buffer (as supplied) (Promega, Southampton, UK) 
(Į-32P)-dATP: 10ci/ml, 3000 Ci/mmol (GE Healthcare, Buckinghamshire, UK) 
Sephadex G50 (APPENDIX I) 
1x TE (pH 7.5) (APPENDIX I) 
Pre-hybridisation buffer (APPENDIX I) 
Hybridisation buffer (APPENDIX I) 
20x Sodium chloride, sodium hydrogen phosphate, EDTA (SSPE) buffer (pH 7.7) 
(APPENDIX I) 
20% (w/v) SDS (APPENDIX I) 
Method 
Twenty nanograms of oligo dT template were added to 1x reaction buffer with 20U of terminal 
deoxyWUDQVIHUDVHLQDILQDOYROXPHRIȝOZLWK*':7KHUHDFWLRQZDVLQFXEDWHGDW& for 
one hour. A mini sephadex G50 column was used to measure incorporation of the labelled 
nucleotide, as described in section 3.7.5.  
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The filter was pre-hybridised in 20ml pre-hybridisation buffer for at least two hours at room 
temperature in a sealed polythene bag on a shaking platform. Hybridisation solution was 
prepared by adding one tenth of the labelled probe to 10ml of hybridisation buffer. The pre-
hybridisation solution was removed and replaced with the hybridisation solution. Hybridisation 
was carried out overnight at room temperature. Non-specifically bound probe was removed by a 
series of increasingly stringent washes. The hybridisation solution was removed and the filter 
was washed twice in 5x SSPE with 0.2% SDS for five minutes, then twice in 2x SSPE with 0.2% 
SDS for thirty minutes. All wash steps were performed at room temperature. Following this, the 
filter was exposed to a phosphorimager screen and radio-labelled bands visualised and quantified 
using Storm imaging system and ImageQuant software. 
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3.8 STATISTICAL ANALYSES 
Data are presented as arithmetic mean +/- standard error of the mean (SEM). Differences in body 
weight and cumulative food intake were assessed using a generalised estimating equation (GEE) 
for repeated measures. Group differences in starting body weight and in UCP-1 mRNA 
expression in BAT were analysed using unpaired t-tests. Differences between groups were 
considered statistically significant at the 95% confidence level (p<0.05). Data analysis was 
performed using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA) 
and Stata 9 software (Stata, StataCorp LP, TX, USA). 
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CHAPTER THREE RESULTS  
 
3.9 CONFIRMATION BY POLYMERASE CHAIN REACTION OF EXCISION OF THE TRȕflox ALLELE 
IN THE HYPOTHALAMUS 
([FLVLRQRI WKH75ȕflox DOOHOHE\&UHUHFRPELQDVH LQ WKHK\SRWKDODPXVRI75ȕflox/flox mice was 
confirmed by PCR of whole hypothalami. As expected, in rAAV-Cre injected mice, PCR 
LGHQWLILHGDEDQGZLWKLQWKHK\SRWKDODPXVDWESFRUUHVSRQGLQJWRWKHH[FLVHG75ȕflox allele 
as well as a band at 1111bp corresponding to the non-H[FLVHG75ȕflox allele (FIGURE 3.2).  
In rAAV-GFP injected hypothalami, an 1111bp band corresponding to the non-H[FLVHG75ȕflox 
allele was detected with no band visible at 601bp (FIGURE 3.2). 
Samples were compared to genomic DNA from a wild type mouse in which the expected band at 
931bp corresponding to the non-floxed THRB allele was observed (FIGURE 3.2) and with 
JHQRPLF'1$IURPDNQRZQ75ȕflox/flox mouse (FIGURE 3.2 and FIGURE 3.3). Samples were also 
compared to a sample known to contain the excised 75ȕflox allele (FIGURE 3.3). 
In the negative control samples (GDW) there were no bands visible (FIGURE 3.2 and FIGURE 
3.3). 
In the brainstem and cerebellar samples, which were used as CNS control tissues, a band at 
1111bp corresponding to the non-H[FLVHG75ȕflox allele was identified. There was no band visible 
at 601bp, confirming that Cre recombinase mediated excision had not occurred in these tissues 
(FIGURE 3.3). 
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FI GURE 3.2  REPRESENTATIVE AGAROSE GEL VISUALISED UNDER UV ILLUMINATION 
SHOWING HYPOTHALAMIC DNA SAMPLES FROM MALE TRȕFLOX/FLOX MICE FOLLOWING 
INJECTION OF 1µL RAAV-CRE OR 1µL RAAV-GFP INTO THE VENTROMEDIAL NUCLEUS 
Lane 1=HyperLadder I (DNA molecular weight marker); Lanes 2-5=hypothalamic DNA from 
IRXU75ȕflox/flox mice injected with rAAV-Cre showing a band at 601bp representing the excised 
75ȕflox allele and a band at 1111ES UHSUHVHQWLQJ WKH 75ȕflox allele; Lanes 6-8=hypothalamic 
'1$IURPWKUHH75ȕflox/flox mice injected with rAAV-GFP showing a band at 1111bp representing 
WKH 75ȕflox allele; The absence of a band at 601bp in lanes 6- GHPRQVWUDWHV WKDW WKH 75ȕflox 
allele has not been excised in the hypothalami of rAAV-GFP injected mice. Lane 9=positive 
FRQWURO'1$IURPNQRZQ75ȕflox/flox mouse; Lane 10=DNA from wild type mouse with a band at 
ES UHSUHVHQWLQJ WKH ZLOG W\SH µQon-IOR[HG¶ 7+5% DOOHOH /DQH  Qegative control 
(autoclaved GDW); Lane 12=HyperLadder I (DNA molecular weight marker). 
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FI GURE 3.3  REPRESENTATIVE AGAROSE GEL VISUALISED UNDER UV ILLUMINATION 
SHOWING HYPOTHALAMIC, CEREBELLAR AND BRAINSTEM DNA SAMPLES FROM MALE 
TRȕFLOX/FLOX MICE FOLLOWING INJECTION OF 1µL RAAV-CRE OR 1µL RAAV-GFP INTO THE 
VENTROMEDIAL NUCLEUS  
Lane 1=HyperLadder I (DNA molecular weight marker); DNA from the hypothalamus (lane 2), 
cerebellum (lane 3) and brainstem (lane 4) of a 75ȕflox/flox mouse injected with rAAV-GFP 
showing a band at 1111ES UHSUHVHQWLQJ WKH75ȕflox allele; Lane 5=hypothalamic DNA from a 
rAAV-Cre injected mouse VKRZLQJDEDQGDWESUHSUHVHQWLQJWKHH[FLVHG75ȕflox allele and a 
band at 1111ESUHSUHVHQWLQJWKH75ȕflox allele; DNA from the cerebellum (lane 6) and brainstem 
(lane 7) of the rAAV-Cre 75ȕflox/flox mouse represented in lane 5, showing a band at 1111bp 
UHSUHVHQWLQJ WKH75ȕflox allele. The absence of a band at 601bp in lanes 6 and 7 demonstrates 
that the 75ȕflox allele has not been excised in these tissues; DNA from the hypothalamus (lane 8), 
cerebellum (lane 9) and brainstem (lane 10) of a 75ȕflox/flox mouse injected with rAAV-GFP 
showing a band at 1111ESUHSUHVHQWLQJWKH75ȕflox allele; Lane 11=hypothalamic DNA from a 
rAAV-Cre injected mouse VKRZLQJDEDQGDWESUHSUHVHQWLQJWKHH[FLVHG75ȕflox allele and a 
band at 1111ES UHSUHVHQWLQJ WKH 75ȕflox allele; DNA from the cerebellum (lane 12) and 
brainstem (lane 13) of the rAAV-Cre injected 75ȕflox/flox mouse represented in lane 11, showing a 
band at 1111ESUHSUHVHQWLQJWKH75ȕflox allele. The absence of a band at 601bp in lanes 12 and 
13 demonstrates that the 75ȕflox allele has not been excised in these tissues; Lanes 14-
16=positive controls, DNA from three NQRZQ 75ȕflox/flox mice showing a band at 1111bp 
UHSUHVHQWLQJ WKH 75ȕflox allele; Lane 17=pRVLWLYH FRQWURO NQRZQ H[FLVHG 75ȕflox allele 
represented by a band at 601bp; Lane 18=negative control (autoclaved GDW); Lane 
19=HyperLadder I (DNA molecular weight marker). 
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3.10 CONFIRMATION OF CRE RECOMBINASE TRANSGENE EXPRESSION AND INJECTION 
ACCURACY BY IN SITU HYBRIDISATION USING A RADIO-LABELLED WOODCHUCK POST-
TRANSCRIPTIONAL REGULATORY ELEMENT PROBE 
The accuracy of bilateral intra-VMN injection and Cre recombinase transgene expression were 
confirmed by in situ hybridisation (n=7) using a 35S-labelled WPRE anti-sense riboprobe. 
Hybridisation was observed in the VMN (FIGURE 3.4 A and B). No expression was observed in 
other areas of the hypothalamus or the brain including the PVN. No signal was detected in the 
slices hybridised with the 35S-labelled WPRE sense riboprobe (FIGURE 3.4 C). Hybridisation 
VLWHVZHUHFRPSDUHGWRµ7KHPRXVHEUDLQLQVWHUHRWD[LFFRRUGLQDWHV¶FIGURE 3.4 D) (Franklin 
and Paxinos, 2007).  
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FI GURE 3.4  IN SITU HYBRIDISATION IMAGES OF REPRESENTATIVE CORONAL SECTIONS 
THROUGH THE MOUSE BRAIN AT -1.3MM FROM BREGMA FOLLOWING INJECTION OF RAAV-CRE 
INTO THE VENTROMEDIAL NUCLEUS 
Panel A depicts a brain section radio-labelled with 35S WPRE antisense riboprobe bound within 
the VMN. The image in panel B is of the same section as depicted in panel A, with the 
mediobasal hypothalamus enlarged. Panel C depicts a control brain section hybridised with 35S 
WPRE sense riboprobe in which no riboprobe binding has occurred. Hybridisation sites were 
FRPSDUHG WR µ7KH PRXVH EUDLQ LQ VWHUHRWD[LF FRRUGLQDWHV¶ SDQHO ' (Franklin and Paxinos, 
2007).  
Abbreviations: 3V third ventricle; Arc, arcuate nucleus; CCX, cerebral cortex; LF, longitudinal 
fissure; VMHC, ventromedial hypothalamus, central; VMHDM, ventromedial hypothalamus, 
dorsomedial; VMHVL, ventromedial hypothalamus, ventrolateral; VMN, ventromedial nucleus. 
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3.11 THE EFFECT OF THYROID HORMONE 5(&(3725 Ǻ(7$ .12&. DOWN IN THE 
VENTROMEDIAL NUCLEUS ON FOOD INTAKE OVER SIXTY THREE DAYS 
Following rAAV injection, mice were fed on a normal chow diet. By day sixty three post-
injection, rAAV-Cre animals had consumed significantly more food than controls (cumulative 
food intake (g) 209.3 +/- 7.5 (rAAV-GFP) vs. 246.4 +/- 12.5 (rAAV-Cre), p<0.008, n=10-11) 
(FIGURE 3.5). 
A repeat study, in a separate group of animals, confirmed this finding (cumulative food intake 
(g) 212.3 +/- 8.3 (rAAV-GFP) vs. 244.5 +/- 9.2 (rAAV-Cre), p<0.01, n=10). 
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FI GURE 3.5  CUMULATIVE FOOD INTAKE (DAY 21-63) IN TRȕFLOX/FLOX MICE AFTER INJECTION 
OF 1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Trend analysis revealed that rAAV-Cre animals (black circles) ate significantly more than rAAV-
GFP controls (blue triangles) over the sixty three day period. Values are shown as mean +/- 
SEM. **p<0.008 vs. rAAV-GFP, n=10-11. 
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3.12 THE EFFECT OF THYROID HORMONE 5(&(3725 Ǻ(7$ .12&. DOWN IN THE 
VENTROMEDIAL NUCLEUS ON BODY WEIGHT OVER SIXTY THREE DAYS 
There was no difference in body weight between the two groups at the start of the study (pre-
injection body weight (g) 26.9 +/- 0.7 (rAAV-GFP) vs. 24.6 +/- 0.6 (rAAV-Cre), p=0.60, n=10-
11). By day sixty three post-injection, rAAV-Cre animals appeared fatter (FIGURE 3.6) and had 
gained significantly more weight than controls (cumulative body weight gain (g) 3.1 +/- 0.5 
(rAAV-GFP) vs. 11.2 +/- 2.1 (rAAV-Cre), p<0.005, n=10-11) (FIGURE 3.7). 
A repeat study, in a separate group of animals, confirmed these findings (cumulative body 
weight gain (g) 2.9 +/- 0.4 (rAAV-GFP) vs. 7.4 +/- 1.3 (rAAV-Cre), p<0.005, n=10). 
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FI GURE 3.6  OBESE PHENOTYPE OF MALE TRȕFLOX/FLOX MOUSE AT DAY SIXTY THREE POST-
INJECTION OF 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS (MOUSE ON THE LEFT OF 
THE PHOTOGRAPH) COMPARED WITH A CONTROL ANIMAL INJECTED WITH 1µL RAAV-GFP INTO 
THE VENTROMEDIAL NUCLEUS (MOUSE ON THE RIGHT OF THE PHOTOGRAPH) 
  
rAAV-Cre rAAV-GFP
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FI GURE 3.7  CUMULATIVE BODY WEIGHT GAIN (DAY 21-63) IN TRȕFLOX/FLOX MICE AFTER 
INJECTION OF 1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Trend analysis revealed that rAAV-Cre mice (black circles) gained significantly more weight 
than rAAV-GFP controls (blue triangles) over the sixty three day period. Values are shown as 
mean +/- SEM. ***p<0.005 vs. rAAV-GFP, n=10-11. 
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3.13 MEAN WEIGHT OF THE EPIDIDYMAL FAT PAD SIXTY THREE DAYS AFTER INJECTION OF 
RAAV-CRE OR RAAV-GFP INTO THE VENTROMEDIAL NUCLEUS 
The weight of the epididymal fat pad, which is a well-recognised indicator of whole body white 
adipose tissue (WAT) mass, was significantly greater in the rAAV-Cre group than in the rAAV-
GFP control group (epididymal fat pad weight (g) 0.28 +/- 0.1 (rAAV-GFP) vs. 0.76 +/- 0.1 
(rAAV-Cre), p<0.005, n=10-11) (FIGURE 3.8). 
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FI GURE 3.8  MEAN EPIDIDYMAL FAT PAD WEIGHT OF TRȕFLOX/FLOX MICE SIXTY THREE DAYS 
AFTER INJECTION OF 1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Recombinant AAV-Cre mice (black bar) had a significantly higher epididymal fat pad weight 
than rAAV-GFP control animals (blue bar). Values are shown as mean +/- SEM. ***p<0.005 
vs. rAAV-GFP, n=10-11. 
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3.14 QUANTITATION OF UNCOUPLING PROTEIN-1 MRNA IN BROWN ADIPOSE TISSUE BY 
NORTHERN BLOT ANALYSIS 
To determine whether 75ȕ NQRFN GRZQ LQ WKH 901 affects peripheral energy expenditure, 
UCP-1 mRNA expression in BAT, which had been taken at day sixty three post-injection, was 
measured as a surrogate marker of energy expenditure. There was no difference in UCP-1 
mRNA levels between rAAV-Cre injected animals and controls (UCP-1 mRNA (AU) 3.56 +/- 
0.29 (rAAV-GFP) vs. 3.16 +/- 0.4 (rAAV-Cre), p=0.42, n=7-11) (FIGURE 3.9). 
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FI GURE 3.9  MEAN UNCOUPLING PROTEIN-1 MRNA LEVELS IN INTER-SCAPULAR BROWN 
ADIPOSE TISSUE TAKEN FROM MALE TRȕFLOX/FLOX MICE SIXTY THREE DAYS AFTER INJECTION OF 
1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
There was no difference in expression of UCP-1 mRNA between rAAV-Cre injected mice (black 
bar) and the rAAV-GFP injected group (blue bar). Values are shown as mean +/- SEM, n=7-11. 
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3.15 CHAPTER THREE DISCUSSION 
The work described in this chapter demonstrates the in vivo excision by rAAV-&UHRIWKH75ȕflox 
allele within the hypothalamus. In addition, it has been shown both by PCR and by in situ 
hybridisation that rAAV-Cre injection into the VMN is localised within the VMN and does not 
spread to other hypothalamic areas or to extra-hypothalamic sites within the CNS.  
&RQGLWLRQDO75ȕNQRFNGRZQ LQ WKH901UHVXOWHG LQD VLJQLILFDQW LQFUHDVH LQERG\ZHLJKW in 
adult male mice over the sixty three day study period. Over the course of the study, mice had a 
mean increase in body weight of sixty four percent compared to the control group. This is a 
substantial increase in body weight and is comparable to the severe obesity of the POMC 
knockout mouse (Yaswen et al., 1999).  
At first, the marked obesity and hyperphagia that occur IROORZLQJ75ȕNQRFNGRZQLQWKH901
may appear to be an unexpected finding. In chapter one it was stated that peripheral and central 
administration of T3 to rodents results in hyperphagia and furthermore, in humans, the majority 
of patients with thyrotoxicosis experience weight loss and will subsequently gain weight on 
restoration of the euthyroid state (Alton and O'Malley, 1985). 
However, two important differences come into play with respect to these studies and the results 
reported in this chapter. Firstly, in the majority of studies on rodents and in hyperthyroid 
humans, the plasma level of thyroid hormones is supra-physiological and therefore the study 
becomes one of pharmacology or of pathophysiology. Secondly, there is a marked difference 
between changing the level of ligand as opposed to reducing expression of the receptor. This is 
partly because TRs exert an effect on transcription both in the absence of T3 and when ligand is 
bound (see 1.4.2). At a negative TRE, gene transcription will occur in the absence of TR bound 
T3 and is silenced on ligand binding. Conversely, at a positively regulated TRE, T3 binding to a 
TR results in the activation of gene transcription. This prevents the extrapolation of the 
relationship between T3 and body weight to that between TRs and body weight. 
Although the effect of T3 on body weight has been extensively studied by other investigators, the 
relationship between TRs and body weight has not been widely examined. In one study, TR 
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function in the VMN was attenuated in thyrotoxic rats by intra-nuclear injection of AAV 
encoding a dominant negative form of TR (Lopez et al., 2010). These animals showed blunting 
of the weight loss associated with hyperthyroidism over the course of the six day study period. 
However, several caveats exist to the interpretation of this finding. The first, is that it is widely 
accepted that reliable AAV transgene expression does not occur until at least seven days post-
injection and in the majority of studies which use AAV, the phenotype is not observed until 
fourteen to twenty one days post-injection (see 2.2.3.4.2.1). In addition, it is unusual to study 
differences in food intake and body weight in the days immediately following surgery, since 
these almost always fall in the immediate post-operative period. It is for these reasons that the 
measurement of food intake and body weight in this work is reported from day twenty one post-
injection, which allowed for post-surgical recovery as well as transgene expression. In addition, 
/RSH] HW DO NQRFNHG GRZQ ERWK 75Į DQG 75ȕ DQG LPSRUWDQWO\ WKLV ZRUN ZDV SHUIRUPHG LQ
thyrotoxic animals making it, by definition, a non-physiological study. 
The human disorder, resistance to thyroid hormone (RTH) serves as a model of TR dysfunction 
that is a more appropriate comparison with the work described in this chapter. RTH is associated 
with diverse heterozygous THRB gene mutations that impair hormone binding and or TR 
transcriptional activity (Adams et al., 1994, Parrilla et al., 1991, Weiss et al., 1993). Recently, it 
has been reported that subjects with RTH have a raised BMI and a significantly greater fat to 
lean body mass in comparison to control subjects (Mitchell et al., 2010). This is despite the 
raised energy expenditure associated with RTH which is due to elevated levels of circulating 
thyroid hormones (Mitchell et al., 2010).  
The work presented in this chapter demonstrates WKHHVVHQWLDOIXQFWLRQRI75ȕLQWKHUHJXODWLRQ
of food intake, since mice ZLWK75ȕNQRFNGRZQ LQ WKH901DWH VLJQLILFDQWO\PRUHRYHU WKH
course of the study compared with control animals. Although rAAV-Cre mice weighed 
significantly more than the controls, this should not account for the higher food intake in this 
group. This may be surmised because the higher body weight in the rAAV-Cre mice is likely to 
be due to the demonstrated increase in WAT mass, which although metabolically active does not 
utilise as much energy as lean tissues (Frayn et al., 2003, Zurlo et al., 1990).  
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The relationship between thyroid hormones and food intake in rodents and in humans is well 
described. It is known that central and peripheral T3 administration to rodents increases food 
intake and this occurs at both physiological and supra-physiological levels of plasma T3 (Ishii et 
al., 2003, Kong et al., 2004, Luo and MacLean, 2003). Furthermore, in humans, one of the 
characteristics of thyrotoxicosis is hyperphagia (Pijl et al., 2001). However, as has been 
discussed, it is not possible to infer, from the actions of the ligand, the role of hypothalamic TRs 
in the mediation of food intake. In a more pertinent model, subjects with RTH exhibit significant 
hyperphagia as compared with controls and when fed to energy balance, report increased hunger 
and decreased satiety (Mitchell et al., 2010). 
In mammals, body weight is determined by the relative ratio of energy taken in and energy 
utilised by the organism. In order to investigate the relative contribution of energy expenditure to 
the increase in body weight seen in this model, expression of UCP-1 mRNA in inter-scapular 
BAT was quantified by northern blot analysis. UCP-1 expression in BAT is a well-established 
marker of peripheral energy expenditure with levels rising in proportion to ATP utilisation in the 
tissue. In this study, there was no difference in the expression of UCP-1 mRNA between the two 
groups. This may imply that there is no difference in energy expenditure between the two 
groups, however it is essential to bear in mind that UCP-1 expression is not the sole marker of 
peripheral energy expenditure DQG LWPD\ZHOO EH WKHFDVH WKDW75ȕNQRFNGRZQ LQ WKH901
does affect energy expenditure in the absence of a change in UCP-1 expression. 
In previous work, important sympathetic connections between the VMN and BAT have been 
demonstrated (see 1.5.2). Increased sympathetic outflow from the VMN to BAT results in 
enhanced thermogenesis within the tissue, whereas lesions of the VMN have the opposite effect. 
The molecular events within the VMN which culminate in changes in sympathetic outflow to 
BAT are QRWFOHDUO\GHILQHG7KHZRUNGHVFULEHG LQ WKLVFKDSWHUGHPRQVWUDWHV WKDW75ȕ LQ WKH
VMN is not implicated in these effects. More importantly, the results of the northern blot 
analysis suggest that a change in energy expenditure does not contribute to the obesity of intra-
90175ȕNQRFNGRZQPLFH 
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In summary, important preliminary findings with respect to the phenotype of intra-90175ȕ
knock down have been reported in this chapter. The mice described are obese and hyperphagic 
and it may be that the increase in body weight is independent of a change in energy expenditure, 
although this finding has yet to be confirmed by other measures of energy utilisation (see 5.2). 
The food intake and body weight findings have been verified in a repeat study, in a separate 
group of animals, which has produced an identical phenotype. These important phenotypic 
observations have been further examined by the work described in chapter four.  
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4 CHAPTER FOUR 
 
4.1 INTRODUCTION 
,QFKDSWHUWKUHHWKHSKHQRW\SHRIDGXOWPLFHZLWK75ȕNQRFNGRZQLQWKH901ZDVGHVFULEHG
These mice were shown to be obese and hyperphagic, with normal energy expenditure. These 
GDWD VXJJHVW WKDW 75ȕ DFWLRQZLWKLQ WKH901 LV D FULWLFDO UHJXODWRU RI ERG\ZHLJKW DQG IRRG
intake and the phenotype of these mice therefore warrants further investigation. 
It was shown in chapter three, that mice with intra-90175ȕNQRFk down have a significantly 
higher food intake than control mice, although the contribution of food intake to the obesity of 
the experimental group was not fully determined. The role of food intake in the development of 
the obese phenotype will therefore be examined. 
,QDGGLWLRQWKHVSHFLILFLW\RIWKHSKHQRW\SHWR75ȕNQRFNGRZQVROHO\LQWKH901QHHGVWREH
FODULILHG LQ SDUWLFXODU LW LV QRW NQRZQZKHWKHU REHVLW\ZLOO DOVR DULVH IURP75ȕ NQRFN GRZQ
within other areas of the hypothalamus and or CNS. This will be studied following the 
administration of rAAV-Cre into the cerebroYHQWULFXODUV\VWHPRI75ȕflox/flox mice.  
The physiological importance of receptor knock down is loss of receptor function within a tissue. 
It has previously been shown in rats that both peripheral injection and direct administration of T3 
into the VMN elicits an orexigenic response (Kong et al., 2004, Luo and MacLean, 2003) (see 
1.6 and 1.6.1.1). Therefore, tKHIXQFWLRQDOFRQVHTXHQFHRI75ȕNQRFNGRZQLQWKe VMN would 
be predicted to abolish the orexigenic effect of T3 and this concept will be investigated. 
Since thyroid hormones are known to influence food intake and body weight in rodents and in 
humans (see 1.6) it is essential to verify that circulating levels of thyroid hormones are 
XQDIIHFWHGE\ WKH H[SHULPHQWDO WUHDWPHQW7KLVZRXOGRFFXU LI75ȕZHUH WREHNQRFNHGGRZQ
within the PVN, which would result in a phenotype resembling RTH (see 3.15). Although it has 
been shown by in situ hybridisation (see 3.10) that transgene expression is confined to the VMN, 
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plasma mouse TSH, T4 and T3 must be measured in order to confirm the integrity of the HPT 
axis in this mouse model.  
It is well-established that animals that are stressed, unwell or which have an altered neurological 
state may manifest these disturbances as changes in feeding behaviour and body weight. 
Although these perturbations usually result in reduced food intake and a fall in body weight, it is 
nevertheless important to assess the behaviour of the knock down mice in order to exclude any 
contribution of abnormal behaviour to the phenotype. This is particularly apposite to this work, 
as it is known that disruption of the HPT axis may result in atypical behaviours (Bunevicius and 
Prange, 2010). 
0LFHZLWK75ȕNQRFNGRZQ LQ WKH901ZHLJKPRUH DQG DSSHDU IDWWHU WKDQ FRQWUROPLFH ,Q
addition, these mice have a higher epididymal fat pad weight which is a well-recognised marker 
of WAT content. In order to further develop these findings, the tissue distribution of WAT 
within intra-90175ȕ knock down mice will be determined. This is important because the site 
of WAT accumulation, be it visceral, subcutaneous or both has metabolic consequences (Fox et 
al., 2007).  
Lastly, although a robust and novel phenotype has been demonstrated, the mechanism by which 
75ȕ knock down in WKH901UHVXOWVLQK\SHUSKDJLDDQGREHVLW\KDVQRWEHHQFODULILHG75ȕLVD
nuclear transcription factor and as such, receptor knock down may alter the synthesis of 
neuropeptides known to be important in the regulation of food intake and body weight. This can 
be investigated by ex vivo analysis of changes in hypothalamic mRNA expression of peptides 
known to affect food intake and body weight. 
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4.2 CHAPTER FOUR AIMS 
The aims of the work described in this chapter (to be carried out on intra-90175ȕ knock down 
mice) were:  
1. To determine the contribution of increased food intake to the obese phenotype. 
2. To determine the specificity to the phenotype of receptor knock down within the VMN as 
opposed to other hypothalamic and or CNS areas. 
3. To investigate the effect of peripheral T3 administration on food intake. 
4. To assess mouse behaviour, in particular looking for behavioural irregularities caused by 
75ȕ knock down.  
5. To analyse the tissue distribution of WAT. 
6. To investigate the impact on circulating insulin and leptin. 
7. To assess the integrity of the HPT axis by measurement of plasma TSH, T3 and T4. 
8. 7RLQYHVWLJDWHWKHPHFKDQLVPE\ZKLFK75ȕNQRFNGRZQLQWKH901UHVXOWVLQK\SHUSKDJLD
and obesity. 
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CHAPTER FOUR METHODS 
 
4.3 EFFECT OF PAIR-FEEDING ON BODY WEIGHT CHANGE IN MICE WITH THYROID HORMONE 
RECEPTOR BETA KNOCK DOWN IN THE VENTROMEDIAL NUCLEUS 
The purpose of this study was to investigate the contribution of food intake to the increased body 
weight of mice with 75ȕNQRFNGRZQin the VMN. 
Eight ZHHN ROG PDOH 75ȕflox/flox mice were given ad libitum access to food and water until 
nineteen days post-rAAV injection, DW ZKLFK WLPH HDFK DQLPDO ZLWK 75ȕ NQRFN GRZQ LQ WKH
VMN (rAAV-Cre-pair, n=9) was pair-fed to the daily food intake of a weight-matched rAAV-
GFP injected litter mate (rAAV-GFP, n=9) as previously described (Small et al., 2001). Food 
intake and body weight were measured three times per week at 09.00h. After each measurement 
the pair-fed animals immediately received their food. Sixty three days post-rAAV injection, ad 
libitum access to food for the pair-fed animals was re-instated for a further twenty eight days.  
 
4.3.1 MEASUREMENT OF PLASMA CORTICOSTERONE IN PAIR-FED MICE 
Since intra-VMN 75ȕNQRFNGRZQPLFHDUHK\SHUSKDJLF WKH UHFHLSWRID UHGXFHGTXDQWLW\RI
food during pair-feeding may produce a stress response in these animals. This could have 
implications for food intake and body weight.  
In order to investigate this, blood was collected at the start of the early light phase for 
measurement of circulating corticosterone. The first samples were collected once pair-feeding 
had been established. Blood was taken by warming the mouse in a specialised thermal chamber 
at 30°C for three minutes, followed by a brief period of restraint in order to carry out tail-vein 
sampling from rAAV-Cre-pair injected mice (n=8) and from the control group (rAAV-GFP, 
n=9). In order to acclimatise the animals to the procedure, all mice underwent two sham 
procedures at four and two days prior to tail-vein sampling. During the ad libitum feeding phase, 
at the termination of the study, mice were killed by carbon dioxide asphyxiation and blood 
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samples were immediately collected by cardiac puncture (rAAV-GFP, n=7; rAAV-Cre-pair, 
n=9) (see 3.4).  
Plasma corticosterone was measured by radioimmunoassay (RIA). The measurement of 
hormones by RIA relies on competition between radio-labelled and non-radio-labelled antigen 
for a fixed number of antibody binding sites. As increasing amounts of unlabelled antigen, either 
from samples or standards are added to a constant quantity of labelled antigen and a constant and 
limited amount of antibody, there is a decrease in the labelled antigen bound to antibody at 
equilibrium. The antibody-bound antigen is then separated from the free antigen either by 
addition of dextran-coated charcoal (which binds free antigen in the charcoal pellet) or by 
complexing the primary antibody with a secondary antibody (free antigen remains in the 
supernatant). Following separation, the activity in the bound and free components is measured in 
DȖFRXQWHUDQGWKHGDWDXVHGWRFRQVWUXFWDVWDQGDUGFXrve. 
Corticosterone levels in plasma were determined by a commercial RIA kit (MP Biomedicals, 
Orangeburg, NY, USA). Calibrators, buffer and reference preparations were supplied in liquid 
form ready to use. The assay was formed in phosphosaline gelatine buffer (pH 7.0) containing 
UDEELWȖ-globulins in a total volume of 500µl. Samples were diluted 1:200 in buffer and diluted 
samples, calibrators and reference preparations were added at a volume of 100µl to numbered 
tubes. Labelled 125I-corticosterone (200µl, 50,000cpm) was then added to all tubes followed by 
200µl of specific corticosterone antibody. All tubes were vortexed and incubated at room 
temperature for two hours. The free and bound fractions were then separated by addition of 
500µl of precipitant solution (goat anti-rabbit in Tris buffer) followed by centrifugation at 
1000xg at 4ºC for twenty minutes. The pellet and supernatant were counted for sixty seconds in a 
Ȗ-counter. The concentration of corticosterone in the samples was then calculated using a non-
linear plot and results calculated in terms of the standard preparations.  
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4.4 STEREOTAXIC BILATERAL MICRO-INJECTION OF RAAV-CRE OR RAAV-GFP INTO THE 
LATERAL VENTRICLE OF TRȕFLOX/FLOX MICE 
This study was performed in order to determine whether the observed weight gain and 
K\SHUSKDJLDZHUHVSHFLILFDOO\GXHWR75ȕNQRFNGRZQLQWKH9015HFRPELQDQt AAV injected 
into the cerebroventricular system will deposit randomly within periventricular areas of the CNS, 
including extra-VMN hypothalamic areas. This will result in Cre-mediated excision of the 
75ȕflox allele in these areas. 
One microlitre of rAAV-Cre (rAAV-Cre-LV, n=11) or rAAV-GFP (rAAV-GFP-LV, n=11) was 
LQMHFWHGELODWHUDOO\LQWRWKHODWHUDOYHQWULFOH/9RIHLJKWZHHNROGPDOH75ȕflox/flox mice. Prior to 
rAAV injection, LV stereotaxic coordinates were trialled with Indian ink injection (n=5) as 
described in 2.7.2 and ex vivo, injection sites were compared to µ7KHPRXVHErain in stereotaxic 
FRRUGLQDWHV¶ (Franklin and Paxinos, 2007). The LV stereotaxic coordinates which were used for 
rAAV injections were 0.5mm posterior to bregma, 1.1mm lateral to bregma and 2.4mm below 
the skull surface. Stereotaxic surgery was performed as described 2.7.3. 
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4.5 EFFECT OF ACUTE PERIPHERAL ADMINISTRATION OF TRI-IODOTHYRONINE ON FOOD 
INTAKE IN TRȕFLOX/FLOX MICE AT LEAST TWENTY EIGHT DAYS AFTER INJECTION OF 1µL 
RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Acute peripheral injection of T3 increases food intake in rats, an effect which may be mediated 
in the VMN (Kong et al., 2004). T3 was administered by peripheral injection in order to 
LQYHVWLJDWHIXQFWLRQDO75ȕNQRFNGRZQLQWKH901 
Materials 
T3 powder for injection (Sigma-Aldrich, Dorset, UK) 
0.1µM NaOH (APPENDIX I) 
0.9% NaCl  
Method 
For sc injections, T3 was prepared as T3 dissolved in 0.1µM NaOH diluted 1:10 in saline 
(volume 0.1ml). Controls received vehicle (0.1µM NaOH diluted 1:10 in saline) alone. Before 
the study, mice received two sham vehicle injections. At least twenty eight days after rAAV 
injection, in a randomised three way crossover, ad libitum IHGPDOH75ȕflox/flox mice (rAAV-Cre, 
n=7; rAAV-GFP, n=5) received either low dose T3 (4.5nmol/kg), high dose T3 (75nmol/kg) or 
vehicle as previously described (Kong et al., 2004). All injections were given at the start of the 
early light phase. Body weight was measured at zero and twenty four hours post-injection. Food 
was weighed at one, two, four, eight and twenty four hours post-injection. A seventy two hour 
washout period was instituted between injections.  
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4.6 QUANTITATION OF WHITE ADIPOSE TISSUE MASS AND WHITE ADIPOSE TISSUE 
DISTRIBUTION BY MAGNETIC RESONANCE IMAGING  
Magnetic resonance imaging (MRI) was performed in order to quantify WAT mass and to 
GHWHUPLQH WKHGLVWULEXWLRQRI:$7LQREHVHPLFHZLWK75ȕNQRFNGRZQ LQ WKH9017KLV LV
important since visceral adipose tissue may confer an increased metabolic risk as compared with 
subcutaneous adipose tissue (Fox et al., 2007). 
Method 
MRI was performed in collaboration with Professor Jimmy Bell (Metabolic and Molecular 
Imaging Group, Imperial College London). Sixty three days after intra-VMN rAAV injection, 
PDOH 75ȕflox/flox mice (rAAV-Cre, n=3; rAAV-GFP, n=3) were scanned using a 4.7T Varian 
system MRI scanner (Varian Medical Systems Ltd., West Sussex, UK) under isoflurane 
anaesthesia (1.5% isoflurane-oxygen mixture for induction, reduced to 1% for maintenance) 
(VWR International, Leicestershire, UK). Whole-body images (between 50 and 60 slices; 2mm 
thick) were obtained for each mouse using a spin-echo sequence (TR4500/TE20). At the 
completion of the study, mice were killed by deep isoflurane anaesthesia followed by cervical 
dislocation. Semiautomatic image segmentation software (SliceOmatic version 4.2; TomoVision, 
Quebec, Canada) was used by Professor Jimmy Bell to separate and quantify tissue volumes for 
analysis of total, subcutaneous and internal adiposity. Liver and skeletal muscle adiposity were 
quantified the author using ImageJ spectroscopy software (National Institutes of Health (NIH), 
Bethesda, MD, USA). 
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4.7 EFFECT OF THYROID HORMONE RECEPTOR BETA KNOCK DOWN IN THE VENTROMEDIAL 
NUCLEUS ON BEHAVIOUR 
In order to exclude the possible effect of behavioural abnormalities contributing to the 
phenotype, a mouse behavioural analysis was performed. At least twenty eight days after rAAV 
LQMHFWLRQ EHKDYLRXUDO SDWWHUQV RI PDOH 75ȕflox/flox mice (rAAV-Cre, n=7; rAAV-GFP, n=10) 
were monitored continuously for sixty minutes at 08.30h, 12.30h, 16.30h, 19.30h, 00.00h and 
04.00h, by observers blinded to the experimental treatment. At every time point, each animal was 
observed for three five second periods every five minutes and the behaviour noted. Behaviour 
was classified into eight categories: feeding, drinking, grooming, burrowing, rearing, 
locomotion, head down, and still/sleeping as previously described (Abbott et al., 2001, Fray et 
al., 1980). Abnormal behaviour was defined by a significant increase in head down, burrowing or 
rearing as previously described (Abbott et al., 2001). 
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4.8 QUANTITATION OF HYPOTHALAMIC MRNA BY REAL TIME QUANTITATIVE POLYMERASE 
CHAIN REACTION 
Real time quantitative PCR (qPCR) was used to analyse the expression of a range of mRNA 
sequences in dissected hypothalami using TaqMan gene expression assays. Total RNA was 
extracted from tissue samples. From this RNA, cDNA was amplified by reverse transcription and 
used for qPCR analysis. All materials for qPCR were supplied by Applied Biosystems, 
Warrington, UK, unless otherwise stated. 
 
4.8.1 TOTAL RNA EXTRACTION 
RNA was extracted from hypothalamic tissue as described in 3.7.1. 
 
4.8.2 RNA PURIFICATION 
Sample RNA must be devoid of any genomic DNA in order to accurately analyse mRNA levels 
by TaqMan probe assay. This was achieved by treating the RNA samples with DNase solution. 
Materials 
Chloroform (VWR International, Leicestershire, UK) 
Purelink RNA Mini Kit (Invitrogen, Paisley, UK) 
Purelink DNase set (Invitrogen, Paisley, UK) 
Method 
Following nucleoprotein digestion with Tri-reagent, nucleic acids were extracted by adding 
200µl of chloroform per 1ml of Tri-reagent used. RNA samples were processed for DNA 
removal using the Purelink RNA Mini Kit according to the PDQXIDFWXUHU¶V protocol (FIGURE 
4.1). 
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The RNA was then dissolved in autoclaved GDW before its yield was determined by 
spectrophotometry as described in 3.7.1. 
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Dissociation of nucleoprotein 
complexes in Tri-reagent
Isolation of nucleic acids by 
chloroform extraction
Add sample to spin cartridge 
and centrifuge to allow RNA to 
bind membrane
Removal of DNA contaminants 
by incubation at room 
temperature with 80µl Purelink
DNAsesolution for fifteen 
minutes.
 
 
 
 
 
 
 
 
 
 
 
FI GURE 4.1  EXTRACTION AND PURIFICATION OF TOTAL HYPOTHALAMIC RNA USING 
PURELINK RNA MINI KIT 
Figure adapted from Purelink RNA Mini Kit user manual available at 
http://tools.invitrogen.com/content/sfs/manuals/purelink_rna_mini_kit_man.pdf 
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4.8.3 REVERSE TRANSCRIPTION OF HYPOTHALAMIC MRNA 
Messenger RNA was converted into its complementary cDNA sequence by reverse transcription 
(RT) in order to allow its amplification by PCR. The High Capacity cDNA Reverse 
Transcription Kit uses the random primer scheme for initiating cDNA synthesis. 
Materials 
Extracted mouse hypothalamic RNA 
High Capacity cDNA Reverse Transcription Kit  
2x RT master mix (per 20µl reaction) 
2µl 10x RT buffer 
0.8µl 25x dNTP mix (100mM)  
2µl 10x RT random primers 
50U Multiscribe reverse transcriptase 
Method 
Complementary DNA was synthesised from RNA using a High Capacity cDNA Reverse 
7UDQVFULSWLRQ.LWDFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO%ULHIO\ILve hundred nanograms of 
each RNA sample were added in triplicate to reaction wells in a ninety six well reaction plate 
containing 10µl 2x RT master mix and pipetted up and down twice to ensure thorough mixing. 
The ninety six well plate was foil-sealed before incubation in a thermal cycler (Techne Genius, 
Techne Inc., Burlington, NJ, USA) under the following conditions: 25°C for ten minutes, 37°C 
for 120 minutes, 85°C for five minutes and 4°C until the plate was removed and stored at -20°C. 
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4.8.4 QUANTITATIVE POLYMERASE CHAIN REACTION ASSAYS FROM HYPOTHALAMIC CDNA 
Each qPCR TaqMan assay allows accurate quantification of gene expression by incorporating a 
reporter-tagged probe, which is complementary to part of the targeted cDNA sequence, into the 
amplification process. During PCR, the TaqMan MGB probe anneals specifically to a 
complementary sequence between the forward and reverse primer sites. When the probe is intact, 
the proximity of the reporter dye to the quencher dye results in suppression of reporter 
fluorescence, primarily by Förster-type energy transfer. DNA polymerase will only cleave 
probes that are hybridised to the target. Cleavage separates the reporter dye from the quencher 
dye to allow fluorescence of the reporter. 
Materials 
TaqMan Universal PCR Master Mix  
20x TaqMan Gene Expression Assay  
cDNA synthesised from mouse hypothalamic RNA (100ng/µl) 
Endogenous control cDNA template (2.5µg/ml) 
Method 
Within a 384 well assay plate, the following constituents were mixed in each well for each qPCR 
reaction: 10µl TaqMan Universal PCR Master Mix, 1µl 20x TaqMan Gene Expression Assay, 
1µl cDNA and GDW added to a total volume of 20µl. For total RNA quantification, a gene 
expression assay targeting the 18S ribosomal subunit and 2µl of cDNA template were used. Each 
reaction was mixed before the plate was sealed and loaded into a qPCR machine (7900HT Fast 
Real-Time PCR System, Applied Biosystems, Warrington, UK) and PCR performed under the 
following conditions: 50°C for two minutes, 95°C for ten minutes. Thermal cycling then 
proceeded to incubation at 95°C for fifteen seconds, followed by incubation at 60°C for one 
minute and this was repeated for forty cycles. The amplification data for the target gene was 
normalised to the expression of the 18S endogenous control and expressed relative to an internal 
calibrator (control group sample) using the 2-ǻǻCT method. The 2-ǻǻCT method calculates the fold 
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change in gene expression normalised to an endogenous reference gene (18S) and relative to an 
untreated control.   
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4.9 MEASUREMENT OF CIRCULATING HORMONES 
 
4.9.1 MEASUREMENT OF CIRCULATING HORMONES BY ENZYME LINKED IMMUNOSORBENT 
ASSAY  
Enzyme linked immunosorbent assay (ELISA) is a technique used for the non-radioactive 
quantification of biologically active substances in plasma and in other medium. The assay 
described below is based on the capture of a hormone from the plasma sample by a monoclonal 
antibody which is immobilised on a microplate. This is followed by the binding of a second 
monoclonal antibody specific for the bound hormone. A detection conjugate is then added which 
binds to the bound monoclonal antibody. The detection conjugate undergoes a colour change in 
the presence of an enzyme substrate which can be quantified by spectrophotometry. Since the 
colour change is directly proportional to the concentration of hormone in the sample, the latter 
can be derived by interpolation from a standard curve generated in the same assay with reference 
standards of known concentrations of hormone.  
 
4.9.1.1 MEASUREMENT OF PLASMA LEPTIN BY ENZYME LINKED IMMUNOSORBENT ASSAY  
Materials 
 Mouse leptin ELISA Kit (Crystal Chem, IL, USA) 
 75ȕflox/flox mouse plasma 
Method 
Plasma leptin levels was measured by ELISA (Crystal Chem, IL, USA) (rAAV-Cre, n=10; 
rAAV-GFP, n=10) DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV %ULHIO\ WKH DQWLERG\ FRDWHG
microplate was washed twice with 300ml wash buffer. Forty five microlitres of sample diluent 
were DGGHG WR HDFK ZHOO DORQJ ZLWK ȝO JXLQHD SLJ DQWL-OHSWLQ VHUXP 6DPSOHV ȝO DQG
standards (0, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4 and 12.8ng/ml) were added and the microplate covered 
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and incubated overnight at 4ºC. The contents of each well were aspirated and the wells washed 
ILYHWLPHVZLWKȝOZDVKEXIIHU2QHKXQGUHGPLFUROLWUHVRIDQWL-guinea pig immunoglobulin 
G (IgG) enzyme conjugate were added to each well and the microplate covered and incubated for 
three hours at 4º&&RQWHQWVZHUHUHPRYHGDQGHDFKZHOOZDVZDVKHGVHYHQWLPHVLQȝOZDVK
buffer. One hundred microlitres of enzyme-substrate solution were added to each well and 
DOORZHG WR UHDFW IRU WKLUW\ PLQXWHV DW URRP WHPSHUDWXUH LQ WKH GDUN )LQDOO\ ȝO Hnzyme 
reaction stop solution were added to each well and the absorbance was measured using a plate 
reader (Labsystems Multiskan RC Plate Reader, Fisher Scientific, Loughborough, UK). 
Absorbance was measured at 360nm and 450nm, and the final value calculated by subtracting 
the A360 value from the A450 value. Concentrations of standards were plotted on a semi-log scale 
and the sample concentrations interpolated from this graph. 
 
4.9.1.2 MEASUREMENT OF PLASMA INSULIN BY ENZYME LINKED IMMUNOSORBENT ASSAY 
Materials 
Mouse insulin ELISA Kit (Crystal Chem, IL, USA) 
75ȕflox/flox mouse plasma 
Method 
Plasma insulin levels was measured by ELISA (Crystal Chem, IL, USA) (rAAV-Cre, n=10; 
rAAV-GFP, n=10) DFFRUGLQJ WR WKHPDQXIDFWXUHU¶V LQVWUXFWLRQV$OOEXIIHUVZHUHVXSSOLHGDQG
the insulin standard was prepared as instructed. Ninety five microlitres of sample diluent were 
added followed by 5µl of sample or standard. These were done in duplicate to increase accuracy. 
The microplate was then covered and incubated for two hours at 4ºC. The wells were aspirated 
and washed five times with the provided wash buffer before the addition of anti-mouse insulin 
enzyme conjugate and the microplate incubated at room temperature for thirty minutes. 
Following this incubation, wells were washed a further seven times before addition of                
3, ¶ 5, ¶-tetramethylbenzidine (TMB) and incubation for forty minutes at room temperature in 
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the dark. Finally, the enzyme reaction was stopped by the addition of 100µl 1M sulphuric acid 
and absorbance was measured as described in 4.9.1.1. 
 
4.9.2 MEASUREMENT OF PLASMA MOUSE THYROID STIMULATING HORMONE, TOTAL TRI-
IODOTHYRONINE AND TOTAL THYROXINE BY RADIOIMMUNOASSAY  
Plasma mTSH, total T3 and total T4 were measured by Professor Roy Weiss (University of 
Chicago, IL, USA). Plasma mTSH was determined by a sensitive, heterologous, disequilibrium, 
double-antibody precipitation RIA and total T3 and total T4 were measured by coated tube RIA 
adapted for mouse serum as previously described (Dumitrescu et al., 2006, Pohlenz et al., 1999). 
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4.10 STATISTICAL ANALYSES 
Data are presented as arithmetic mean +/- standard error of the mean (SEM). Differences in body 
weight and cumulative food intake were assessed using a generalised estimating equation (GEE) 
for repeated measures. Group differences in starting body weight, food intake and body weight 
following T3 administration, MRI results, ELISA results, RIA results and qPCR results were 
analysed using unpaired t-tests. Values from the behavioural study were analysed using a 
Kruskal-Wallis one way analysis of variance (ANOVA) and are presented as median 
(interquartile range). Differences between groups were considered statistically significant at the 
95% confidence level (p<0.05). Data analysis was performed using GraphPad Prism 5 software 
(GraphPad Software Inc., San Diego, CA, USA) and Stata 9 software (Stata, StataCorp LP, TX, 
USA). 
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CHAPTER FOUR RESULTS 
 
4.11 EFFECT OF PAIR-FEEDING ON BODY WEIGHT CHANGE IN MICE WITH THYROID HORMONE 
RECEPTOR BETA KNOCK DOWN IN THE VENTROMEDIAL NUCLEUS 
In order to determine whether the observed weight gain in intra-VMN 75ȕNQRFNGRZQPLFHLV
due to increased food intake, HLJKWZHHNROGPDOH75ȕflox/flox mice injected with rAAV-Cre into 
the VMN were pair-fed for forty four days to the food intake of weight-matched eight week old 
PDOH75ȕflox/flox litter mates injected with rAAV-GFP into the VMN.  
There were no differences in body weight between the two groups at the start of the study (pre-
injection body weight (g) 27.3 +/- 0.4 (rAAV-GFP) vs. 27.5 +/- 0.3 (rAAV-Cre-pair), p=0.71, 
n=9). Pair-feeding commenced on day nineteen post-rAAV injection and ceased on day sixty 
three post-rAAV injection. 
At day sixty three post-injection, there was no significant difference in cumulative body weight 
gain (FIGURE 4.2 A) or food intake (FIGURE 4.2 B) between the rAAV-Cre-pair animals and the 
rAAV-GFP animals (cumulative body weight gain (g) 3.4 +/- 0.4 (rAAV-GFP) vs. 3.0 +/- 1.1 
(rAAV-Cre-pair), p=0.51, n=9) (cumulative food intake (g) 256.9 +/- 6.1 (rAAV-GFP) vs. 244.0 
+/- 6.3 (rAAV-Cre-pair), p=0.14, n=9). 
At day sixty three post-rAAV injection, pair-fed intra-VMN 75ȕNQRFNGRZQPLFHZHUHJLYHQ
ad libitum access to food until day ninety post-rAAV injection. Between day sixty three and day 
ninety post-injection, rAAV-Cre-pair fed animals gained significantly more weight (FIGURE 4.2 
A) and ate significantly more (FIGURE 4.2 C) than controls (cumulative body weight gain (g) 1.6 
+/- 0.4 (rAAV-GFP) vs. 8.7 +/- 1.8 (rAAV-Cre-pair), p<0.005, n=9), (cumulative food intake (g) 
150.9 +/- 5.9 (rAAV-GFP) vs. 168.9 +/- 5.3 (rAAV-Cre-pair), p<0.05 n=9).  
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FI GURE 4.2  CUMULATIVE BODY WEIGHT GAIN (DAY 14-90) (A) AND FOOD INTAKE (DAY 14-
63) (B) (DAY 63-90) (C) AFTER INJECTION OF 1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE 
VENTROMEDIAL NUCLEUS 
Up to day nineteen post-rAAV injection, all animals had ad libitum access to food. From day 
nineteen post-rAAV injection (solid arrow A and B) each rAAV-Cre-pair animal (open circles) 
was pair-fed to the food intake of a weight-matched rAAV-GFP litter mate (blue triangles) until 
day sixty three at which point ad libitum access to food for the pair-fed animals was re-instated 
for a further twenty eight days (dashed arrow A and C). Trend analysis revealed no difference in 
weight gain or food intake between rAAV-Cre-pair animals and rAAV-GFP controls over the 
forty four day period of pair-feeding. At the re-instatement of free feeding to the rAAV-Cre-pair 
animals (dashed arrow A and C) between day sixty three and day ninety post-rAAV injection, 
rAAV-Cre-pair animals ate significantly more and gained significantly more weight than rAAV-
GFP controls over the twenty seven day study period. Values are shown as mean +/- SEM. 
*p<0.05 vs. rAAV-GFP, ***p<0.005 vs. rAAV-GFP, n=9. 
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4.11.1 EFFECT OF PAIR-FEEDING ON PLASMA CORTICOSTERONE 
Plasma corticosterone was measured by RIA to assess whether pair-feeding produced a stress 
response in rAAV-Cre-pair mice. This is important as stress can affect food intake and body 
weight. Samples were taken at the start of the early light phase during the pair-feeding phase of 
the study and at the end of the study when ad libitum feeding had been re-instated. There was no 
difference in plasma corticosterone between the two groups during pair-feeding (plasma 
corticosterone (ng/ml) 21.7 +/- 8.2 (rAAV-GFP) vs. 21.3 +/- 9.4 (rAAV-Cre-pair), p=0.98, n=8-
9) (FIGURE 4.3 A) or following the re-instatement of ad libitum access to food (plasma 
corticosterone (ng/ml) 14.1 +/- 5.1 (rAAV-GFP) vs. 14.4 +/- 4.5 (rAAV-Cre-pair), p=0.97, n=7-
9) (FIGURE 4.3 B). 
  
196 
 
rAAV-GFP rAAV-Cre
0
5
10
15
20
25
Pl
as
m
a 
co
rti
co
st
er
on
e 
(n
g/
m
l)B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FI GURE 4.3  MOUSE PLASMA CORTICOSTERONE AFTER INJECTION OF 1µL RAAV-GFP OR 1µL 
RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS DURING PAIR-FEEDING (A) AND FOLLOWING 
THE RESTORATION OF AD LIBITUM ACCESS TO FOOD (B)  
There was no difference in plasma corticosterone between the rAAV-Cre-pair group (black bars) 
and the rAAV-GFP group (blue bars) during pair-feeding (A) or following the re-instatement of 
ad libitum access to food (B). Values are shown as mean +/- SEM, n=7-9. 
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4.11.2 EFFECT ON FOOD INTAKE AND BODY WEIGHT OF STEREOTAXIC BILATERAL MICRO-
INJECTION OF RAAV-CRE OR RAAV-GFP INTO THE LATERAL VENTRICLE OF 
TRȕFLOX/FLOX MICE 
In order to determine whether the observed weight gain and hyperphagia were specifically due to 
75ȕNQRFNGRZQLQWKH901U$$9-Cre (rAAV-Cre-LV) or rAAV-GFP (rAAV-GFP-LV) was 
injected bilaterally into the LV RI HLJKW ZHHN ROG PDOH 75ȕflox/flox mice. There were no 
differences in body weight between the two groups at the start of the study (pre-injection body 
weight (g) 25.4 +/- 0.6 (rAAV-GFP-LV) vs. 26.7+/-0.6 (rAAV-Cre-LV), p=0.15, n=11). 
Following rAAV injection, mice were fed on a normal chow diet. At day sixty three post-
injection, there was no significant difference in cumulative food intake between the rAAV-Cre-
LV and the rAAV-GFP-LV groups (cumulative food intake (g) 213.0 +/- 5.1 (rAAV-GFP-LV) 
vs. 216.7 +/- 11.7 (rAAV-Cre-LV), p=0.41, n=11) (FIGURE 4.4 A). At day sixty three post-
injection, there was no significant difference in cumulative body weight gain between the rAAV-
Cre-LV and the rAAV-GFP-LV groups (cumulative body weight gain (g) 2.8 +/- 0.4 (rAAV-
GFP-LV) vs. 3.5 +/- 0.3 (rAAV-Cre-LV), p=0.4, n=11) (FIGURE 4.4 B).  
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FI GURE 4.4  CUMULATIVE FOOD INTAKE (A) AND BODY WEIGHT GAIN (B) (DAY 21-63) 
AFTER INJECTION OF 1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE LATERAL VENTRICLE 
Trend analysis revealed no difference in food intake (A) or weight gain (B) between rAAV-Cre-
LV animals (black squares) and rAAV-GFP-LV controls (blue squares) over the course of the 
study period. Values are shown as mean +/- SEM, n=11. 
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4.11.3 EFFECT OF ACUTE PERIPHERAL ADMINISTRATION OF TRI-IODOTHYRONINE ON FOOD 
INTAKE IN TRȕFLOX/FLOX MICE AT LEAST TWENTY EIGHT DAYS AFTER INJECTION OF 1µL 
RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
,Q RUGHU WR LQYHVWLJDWH WKH IXQFWLRQDO HIIHFW RI 75ȕ NQRFN GRZQ LQ the VMN, T3 was 
administered by sc injection and food intake and body weight were measured over twenty four 
hours.  
In rAAV-GFP animals, food intake significantly increased one hour post-injection of low dose 
T3 (4.5nmol/kg) (food intake 0-1h (g) 0.2 +/- 0.04 (control) vs. 0.4 +/- 0.08 (T3), p<0.05, n=5) 
(FIGURE 4.5 A) and at twenty four hours post-injection of high dose T3 (75nmol/kg) (food intake 
0-24h (g) 4.8 +/- 0.3 (control) vs. 6.2 +/- 0.5 (T3), p<0.05, n=5) (FIGURE 4.5 C). In rAAV-Cre 
injected animals there was no change in food intake at one hour post-injection following low 
dose T3 (food intake 0-1h (g) 0.2 +/- 0.06 (control) vs. 0.16 +/- 0.04 (T3), p=0.62, n=7) (FIGURE 
4.5 B) nor high dose T3 at twenty four hours post-injection (food intake 0-24h (g) 5.79 +/- 0.52 
(control) vs. 6.20 +/- 0.28 (T3), p=0.50, n=7) (FIGURE 4.5 D). 
There was no difference in body weight change at twenty four hours post-injection in either 
group following the injection of low dose T3 (body weight change (g) 0.24 +/- 0.19 (vehicle) vs. 
0.14 +/- 0.06 (rAAV-GFP), p=0.86, n=5), (body weight change (g) 0.09 +/- 0.69 (vehicle) vs. 
0.19 +/- 0.21 (rAAV-Cre), p=0.71, n=7) or high dose T3 (body weight change (g) 0.24 +/- 0.19 
(vehicle) vs. -0.06 +/- 0.13 (rAAV-GFP), p=0.30, n=5) (body weight change (g) -0.09 +/- 0.69 
(vehicle) vs. 0.16 +/- 0.23 (rAAV-Cre), p=0.74, n=7). 
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FIGURE 4.5  EFFECT OF PERIPHERAL ADMINISTRATION OF TRI-IODOTHYRONINE ON FOOD 
INTAKE IN TRȕFLOX/FLOX MICE AT LEAST TWENTY EIGHT DAYS AFTER INJECTION OF 1µL RAAV-
GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Peripheral administration of T3 increased food intake in intra-VMN rAAV-GFP injected 
75ȕflox/flox mice (blue bars) but did not affect feeding in PLFHZLWK75ȕNQRFNGRZQLQWKH901
(rAAV-Cre) (grey/black bars). Animals received a single peripheral injection of T3 at the doses 
indicated (nmol/kg) or vehicle (V). Food intake was 0-1h (A and B) and 0-24 h (C and D) post-
T3 injection. Values are shown as mean +/- SEM. *p<0.05 vs. vehicle, n=5-7. 
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4.12 EFFECT OF THYROID HORMONE RECEPTOR BETA KNOCK DOWN IN THE VENTROMEDIAL 
NUCLEUS ON BEHAVIOUR 
During the dark phase, there was a significant reduction in observed episodes of locomotor 
activity in the intra-VMN 75ȕNQRFNGRZQ JURXS FRPSDUHGZLWK FRQWUROV (21episodes (7-22 
episodes) (rAAV-GFP) vs. 11 episodes (7-13 episodes) (rAAV-Cre), p<0.008, n=7-10) (TABLE 
2). Neither treatment was associated with an increase in abnormal behaviours. 
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 Dark phase Light phase 
rAAV-GFP rAAV-Cre rAAV-GFP rAAV-Cre 
Feeding 19 (16-23) 21 (9-25) 14 (13-17) 9 (9-14) 
Drinking 2 (0-3) 0 (0-0) 0 (0-1) 0 (0-0) 
Grooming 24 (22-26) 17 (11-24) 15(10-19) 13 (4-16) 
Burrowing 1 (0-2) 1 (0-3) 3 (0-4) 6 (1-8) 
Rearing 2 (0-3) 0 (0-1) 0 (0-0) 0 (0-0) 
Locomotion 21 (17-22) 11 (7-13)**  9 (7-10) 6 (3-8) 
Sleep 24 (19-24) 36 (32-41) 60 (42-65) 60 (48-68) 
Head 
down/still 
17 (11-21) 21 (13-32) 10 (3-15) 15 (13-18) 
TABLE 2  MOUSE BEHAVIOUR AT LEAST TWENTY EIGHT DAYS AFTER INJECTION OF 1µL 
RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Behavioural patterns were monitored continuously for sixty minutes at three time points during 
the dark phase and at three time points during the light phase by observers blinded to the 
experimental treatment. Data are presented as median number of episodes of each behaviour 
(interquartile range). **p<0.008 vs. rAAV-GFP, n=7-10. 
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4.12.1 QUANTITATION OF WHITE ADIPOSE TISSUE MASS AND WHITE ADIPOSE TISSUE 
DISTRIBUTION BY MAGNETIC RESONANCE IMAGING  
The quantity and distribution of mouse WAT was assessed by MRI. Total body fat mass was 
significantly higher in rAAV-Cre animals compared to rAAV-GFP control mice (total body fat 
mass (g) 3.8 +/- 0.4 (rAAV-GFP) vs. 13.9 +/- 8.0 (rAAV-Cre), p<0.05, n=3) (FIGURE 4.6 A). 
Subcutaneous fat was significantly higher in rAAV-Cre animals compared to rAAV-GFP control 
mice (subcutaneous fat (g) 2.1 +/- 1.0 (rAAV-GFP) vs. 8.0 +/- 2.1 (rAAV-Cre), p<0.05, n=3) 
(FIGURE 4.6 B and FIGURE 4.7 A and B). Internal fat was significantly higher in rAAV-Cre 
animals compared to rAAV-GFP control mice (internal fat (g) 1.6 +/- 0.2 (rAAV-GFP) vs. 5.9 
+/-1.5 (rAAV-Cre), p<0.05, n=3) (FIGURE 4.6 C). There was no difference in hepatic or skeletal 
muscle fat content between the two groups as measured by MRI spectroscopy (total hepatic fat 
content (integral units) 0.02 +/- 0.01 (rAAV-GFP) vs. 0.07 +/- 0.04 (rAAV-Cre), p=0.22, n=3) 
(FIGURE 4.6 D and FIGURE 4.7 C and D) (total skeletal muscle fat content (integral units) 0.001 
+/- 0.00 (rAAV-GFP) vs. 0.02 +/- 0.001 (rAAV-Cre), p=0.17, n=3) (FIGURE 4.6 E and FIGURE 
4.7 E and F).  
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FI GURE 4.6  TOTAL WHITE ADIPOSE TISSUE MASS AND WHITE ADIPOSE TISSUE DISTRIBUTION 
QUANTIFIED BY MAGNETIC RESONANCE IMAGING SCANNING SIXTY THREE DAYS AFTER 
INJECTION OF 1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Recombinant AAV-Cre animals (black bars) had significantly higher total body adiposity (panel 
A), as well as subcutaneous (B) and internal fat content (C) compared with rAAV-GFP control 
animals (blue bars). There was no difference in hepatic (D) or skeletal muscle (E) fat deposition. 
Values are presented as mean +/- SEM. *p<0.05 vs. rAAV-GFP, n=3. 
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FI GURE 4.7  REPRESENTATIVE CORONAL MAGNETIC RESONANCE IMAGING SECTIONS 
THROUGH THE THORAX (A AND B), ABDOMEN (C AND D) AND FORELIMBS (E AND F) SIXTY 
THREE DAYS AFTER INJECTION OF 1µL RAAV-GFP OR 1µL RAAV-CRE INTO THE 
VENTROMEDIAL NUCLEUS 
Abundant subcutaneous fat deposition was observed in the rAAV-Cre animals (n=3) (panel B) 
compared with the lean rAAV-GFP controls (panel A). There was no difference between the two 
groups in intra-hepatic (panel C and panel D) or skeletal muscle (panel E and panel F) fat 
content.  
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4.13 MEASUREMENT OF CIRCULATING HORMONES 
 
4.13.1 QUANTITATION OF PLASMA LEPTIN BY ENZYME LINKED IMMUNOSORBENT ASSAY  
Plasma leptin was significantly higher in the rAAV-Cre group compared with rAAV-GFP 
animals (plasma leptin (ng/ml) 8.9 +/- 4.0 (rAAV-GFP) vs. 55.83 +/- 16.5 (rAAV-Cre), p<0.008, 
n=10-11) (FIGURE 4.8). 
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FI GURE 4.8  PLASMA LEPTIN LEVELS SIXTY THREE DAYS AFTER INJECTION OF 1µL RAAV-
GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS  
Recombinant AAV-Cre injected mice (black bar) had a significantly higher plasma leptin level 
compared with rAAV-GFP control animals (blue bar). Values are shown as mean +/- SEM. 
**p<0.008 vs. rAAV-GFP, n=10-11. 
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4.13.2 QUANTITATION OF PLASMA INSULIN BY ENZYME LINKED IMMUNOSORBENT ASSAY  
Plasma insulin was significantly higher in the rAAV-Cre group compared with rAAV-GFP 
animals (plasma insulin (ng/ml) 1.43 +/- 0.30 (rAAV-GFP) vs. 13.49 +/- 4.78 (rAAV-Cre), 
p<0.05, n=10) (FIGURE 4.9). 
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FI GURE 4.9  PLASMA INSULIN LEVELS SIXTY THREE DAYS AFTER INJECTION OF 1µL RAAV-
GFP OR 1µL RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
Recombinant AAV-Cre injected mice (black bar) had a significantly higher plasma insulin level 
compared with rAAV-GFP control animals (blue bar). Values are shown as mean +/- SEM. 
*p<0.05 vs. rAAV-GFP, n=10. 
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4.13.3 QUANTITATION OF CIRCULATING MOUSE THYROID STIMULATING HORMONE, TOTAL 
THYROXINE AND TOTAL TRI-IODOTHYRONINE BY RADIOIMMUNOASSAY 
There was no difference in plasma mTSH (plasma mTSH (mU/l) 118 +/- 21 (rAAV-GFP) vs. 
121 +/- 19 (rAAV-Cre), p=0.92, n=7) (FIGURE 4.10 A), plasma total T4 (plasma total T4 (µg/dl) 
3 +/- 0 (rAAV-GFP) vs. 4 +/- 0 (rAAV-Cre), p=0.59, n=7) (FIGURE 4.10 B) or plasma total T3 
(plasma total T3 (ng/dl) 110 +/- 7 (rAAV-GFP) vs. 118 +/- 4 (rAAV-Cre), p=0.33 n=7) (FIGURE 
4.10 C). 
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FI GURE 4.10  PLASMA MOUSE THYROID STIMULATING HORMONE (A), TOTAL THYROXINE (B) 
AND TOTAL TRI-IODOTHYRONINE (C) SIXTY THREE DAYS INJECTION OF 1µL RAAV-GFP OR 1µL 
RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
There was no difference in plasma mTSH (A), total T4 (B) or total T3 (C) between rAAV-Cre 
injected mice (black bars) and rAAV-GFP control animals (blue bars). Values are shown as 
mean +/- SEM, n=7. 
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4.14 QUANTITATION OF HYPOTHALAMIC NEUROPEPTIDE EXPRESSION 
To determine whether 75ȕ NQRFN GRZQ LQ WKH 901 affects the expression of hypothalamic 
peptides known to influence food intake and body weight, RNA extracted from hypothalami 
taken at day sixty three post-injection, was quantitated by qPCR.  
There was no significant difference in the expression of hypothalamic NPY, AgRP, POMC or 
BDNF mRNA between rAAV-Cre injected animals and controls; (NPY mRNA (AU) 1.32 +/- 
0.5 (rAAV-GFP) vs. 0.83 +/- 0.21 (rAAV-Cre), p=0.42, n=8-10); (AgRP mRNA (AU) 1.27 +/- 
0.43 (rAAV-GFP) vs. 2.31 +/- 1.17 (rAAV-Cre), p=0.37, n=8-10); (POMC mRNA (AU) 2.89 
+/- 1.11 (rAAV-GFP) vs. 1.80 +/- 0.38 (rAAV-Cre), p=0.40, n=8-9); (BDNF mRNA (AU) 1.24 
+/- 0.37 (rAAV-GFP) vs. 0.97 +/- 0.24 (rAAV-Cre), p=0.58, n=7-9) (FIGURE 4.11). 
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FI GURE 4.11  HYPOTHALAMIC MRNA EXPRESSION SIXTY THREE DAYS AFTER INJECTION OF 
1µL RAAV-GFP OR RAAV-CRE INTO THE VENTROMEDIAL NUCLEUS 
There was no difference in hypothalamic expression of NPY, AgRP, POMC or BDNF mRNA 
between rAAV-Cre injected mice (black bars) and rAAV-GFP control animals (blue bars). 
Values are shown as mean +/- SEM, n=7-10. 
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4.15 CHAPTER FOUR DISCUSSION 
The obesity of intra-90175ȕNQRFNGRZQPLFH Ls due to increased food intake. This can be 
VXUPLVHGIRUWZRUHDVRQV)LUVWO\LQFKDSWHUWKUHHLWZDVVKRZQWKDW75ȕNQRFNGRZQPLFHGR
not have altered energy expenditure as compared with control animals. Secondly, in this chapter, 
the pair-feeding study demonstrated that when pair-fed to the food intake of rAAV-GFP mice for 
forty four days, intra-90175ȕknock down mice do not become obese and instead remain at 
the same body weight as the control group. It therefore follows, that when unrestricted access to 
food is restored, intra-VMN 75ȕNQRFNGRZQPLFHVKRXOGJDLQZHLJKW$WGD\VL[W\WKUHHRIWKH
study, when free feeding was re-started, the increase in body weight in the knock down group 
was rapid and marked. By the end of the study, the increase in body weight of the rAAV-Cre-
pair group was approaching that of the rAAV-Cre animals described in chapter three, which had 
been given ad libitum DFFHVVWRIRRGWKURXJKRXWWKHVWXG\7KHLQFUHDVHLQERG\ZHLJKWLQ75ȕ
knock down mice was accompanied by a significantly higher food intake than that of the control 
group, confirming the importance of food intake to the obese phenotype.  
Pair-feeding studies have two notable limitations. The first is that the food intake of the 
experimental mouse is mirroring the consumption of its control pair that occurred between the 
two preceding time points. The food intake of the mouse pair is not therefore in parallel. The 
second drawback is the potential for the development of stress in the food-restricted group, 
which can affect food intake and body weight. This is particularly apposite to this work because 
of the previously demonstrated hyperphagia of the rAAV-Cre mice. This was investigated by 
measuring plasma corticosterone in the early light phase during pair-feeding and following the 
re-instatement of free feeding. Mouse plasma corticosterone levels show the opposite diurnal 
rhythm to that of humans, being highest at the onset of the dark phase, the time of activity in 
rodents, and falling to a nadir in the early light phase which is the natural rest period. 
Reassuringly, plasma corticosterone was not elevated in rAAV-Cre mice either during or after 
pair-feeding, although it should be noted that prolonged stress can result in a dampening of the 
stress response (Lightman, 2008). However, the rise in food intake and body weight in rAAV-
Cre-pair mice on the restoration of ad libitum feeding implies a trumping of the phenotype over 
any stress related attenuation of food intake or body weight.  
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The caveat to the interpretation of the corticosterone analysis is that the plasma samples were 
obtained by differing methods depending on whether they were taken during the pair-feeding or 
during the ad libitum feeding phase of the study. The blood that was taken during pair-feeding 
was obtained by warming the mouse in a specialised thermal chamber, followed by a brief period 
of restraint in order to carry out tail-vein sampling. During the ad libitum feeding phase, at the 
termination of the study, mice were killed by carbon dioxide asphyxiation and blood samples 
were immediately collected by cardiac puncture. It is apparent that both methods of sample 
acquisition may in themselves have produced a stress response resulting in a rise in the plasma 
corticosterone, although this may have been somewhat ameliorated by acclimatising the mice to 
tail-vein sampling prior to sample procurement during pair-feeding. In the samples taken at the 
termination of the study, carbon dioxide asphyxiation, whilst resulting in a rapid death, would 
doubtless be highly stressful for the mouse, although interestingly the absolute values of plasma 
corticosterone obtained following this procedure were in fact lower than those obtained from 
tail-vein sampling.  
The hyperphagia and obesity which reVXOW IURP75ȕNQRFNGRZQDSSHDU to be specific to the 
VMN. The injection of rAAV-&UHLQWRWKH/9RI75ȕflox/flox mice will result in Cre recombinase 
H[SUHVVLRQLQSHULYHQWULFXODUEUDLQDUHDVDQGH[FLVLRQRIWKH75ȕflox allele within these regions. 
Injection into the LV did not result in an observable phenotype in rAAV-Cre-LV mice, which 
FRQILUPVWKHLPSRUWDQFHRI75ȕ, specifically within the VMN, in the mediation of food intake 
and body weight.  
In the lateral ventricle study, an injection volume of one microlitre rAAV was used for each 
injection, which is the same as the volume used for the intra-nuclear injections. It should be 
noted that one microlitre rAAV may not have contained a sufficiently high viral titre to allow for 
CrH PHGLDWHG H[FLVLRQ RI WKH 75ȕflox allele in other brain areas because of the flow and the 
dilutional effect of the cerebrospinal fluid. It is therefore possible that a higher injection volume 
PD\ KDYH SURGXFHG 75ȕ NQRFN GRZQ LQ DQ H[WUD-VMN region resulting in an observable 
SKHQRW\SH7KHUHIRUHZKLOVWWKLVVWXG\SURYLGHVVXSSRUWIRUWKHLPSRUWDQFHRI75ȕNQRFNGRZQ
LQWKH901WRWKHSKHQRW\SHLWGRHVQRWIXOO\UXOHRXWWKHSRVVLELOLW\RI75ȕDFWLRQLQRWKHUEUDLQ
areas in the mediation of food intake and body weight. In addition, the site of rAAV deposition 
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following injection into the lateral ventricle remains to be established. This will be investigated 
in future work by in situ hybridisation for WPRE mRNA in order to confirm both transgene 
expression and the site of rAAV deposition, as well as to establish the absence of deposition 
within the VMN (see 5.2).  
In study 4.5, the control group showed the expected increase in food intake at one hour post-
injection of low dose T3 and at twenty four hours following administration of high dose T3. The 
delayed response to high dose T3 occurs because the very high level of circulating T3 that occurs 
in the immediate post-injection period causes malaise in the animal and T3-stimulated food 
intake does not therefore occur until plasma levels have declined. Intra-90175ȕNQRFNGRZQ
mice failed to respond to the orexigenic effect of T3 at any time point and at either of the 
administered doses. The results of this study therefore support IXQFWLRQDO75ȕknock down in the 
VMN and serve to underscore the physiological relevance of the phenotype. Of note, the study 
design means that each mouse acted as its own control. This means that the treatments were 
administered on different days and therefore the results may be subject to interference from 
variability in daily baseline food intake. Nevertheless, the robust response in the control group 
and the abolition of the orexigenic effect of T3 in the experimental group adds veracity to the 
stated phenotype.  
Plasma analysis confirmed that rAAV-Cre and rAAV-GFP mice are euthyroid. Not only does 
this discount the possibility of an aberration of the HPT-axis accounting for the change in food 
LQWDNHDQGERG\ZHLJKWEXWDOVRQHJDWHV WKHSURVSHFWRI75ȕNQRFNGRZQLQ WKH391ZKLFK
would produce a phenotype of RTH (see 3.15), and consequently raised circulating thyroid 
hormones with a non-suppressed TSH. 
7KHEHKDYLRXUDOVWXG\FRQILUPHGWKDW75ȕNQRFNGRZQLQthe VMN does not result in abnormal 
behaviours as defined by a significant increase in head down, burrowing or rearing as previously 
described (Abbott et al., 2001). It was important to ascertain this in order to confirm that the 
phenotype is not the manifestation of induced neurological or cognitive dysfunction. 
Interestingly, the rAAV-Cre group were found to have a significant reduction in locomotor 
activity during the dark phase. Whilst this could be a contributing factor to the obesity of these 
217 
 
mice, it should be noted that the behavioural study was performed when the knock down group 
had already become fat, and it is therefore not possible to deduce whether reduced activity 
contributes to the obesity or vice versa. In future work this will be investigated by performing a 
behavioural analysis at twenty one days post-rAAV injection, when the transgene has been 
expressed but before the phenotype has developed (see 5.2).  
Measurement of plasma leptin levels and assessment of total body fat on MRI confirmed the 
increased adiposity of intra-901 75ȕ NQRFN GRZQ PLFH 05, DOVR VKRZHG WKDW :$7 LV
deposited in this group in both a subcutaneous and an internal distribution pattern. This is an 
important parameter to measure because of the increased metabolic risk associated with internal 
fat deposition (Fox et al., 2007). Despite the increase in internal fat content in the rAAV-Cre 
group, there was no increase in the deposition of fat in the liver or skeletal muscle of these mice. 
This latter finding may have arisen as a consequence of the small number of mice in each group 
thus resulting in a type II statistical error. The apparent lack of hepatic and skeletal muscle fat 
deposition in the knock down group therefore warrants further investigation, particularly since 
adiposity within these tissues is a significant contributor to the insulin resistance of obesity.  
Liver and skeletal muscle samples have been collected (see 3.4) and these will undergo 
histological analysis following oil red O staining for WAT. In addition, although plasma insulin 
was significantly raised in the obese knock down mice, glucose homeostasis in this group 
requires further investigation because the plasma samples from which insulin was measured were 
not fasting samples. Furthermore, the samples were taken by cardiac puncture following killing 
of the mouse. Since insulin is a well-UHFRJQLVHGµVWUHVV¶KRUPRQHOHvels may have been elevated 
because of the killing process, although if this were the case, this would be expected to have 
occurred in both groups. The issue will be resolved by future work in which formal, in vivo 
assessments of glucose homeostasis will be performed by glucose tolerance and insulin tolerance 
tests (see 5.2).  
$WSUHVHQW WKHPHFKDQLVPE\ZKLFK75ȕNQRFNGRZQLQWKH901UHVXOWV LQK\SHUSKDJLDDQG
obesity has not been defined. Quantitative PCR did not show a difference between the groups in 
the mRNA expression of four well-characterised hypothalamic mediators of food intake and 
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ERG\ZHLJKW ,Q WKLVVWXG\ WKHUHVXOWVRI WKHT3&5ZHUHµQRUPDOLVHG¶ WR Whe expression of the 
ULERVRPDO6VXEXQLW*HQHµQRUPDOLVDWLRQ¶PHDQVWKDWWKHUHVXOWVDUHH[SUHVVHGLQUHODWLRQWRD
reference gene product in order to correct for any differences in RNA extraction, volume of 
starting material, or other factors. The 18S subunit is a commonly used RNA species for gene 
µQRUPDOLVDWLRQ¶ VLQFH LW LV XELTXLWRXVO\ H[SUHVVHG DQG OHYHOV DUH DVVXPHG WR EH XQDOWHUHG E\
H[SHULPHQWDOWUHDWPHQWV,WLVLPSRUWDQWWRVWUHVVWKDWLWLVXQNQRZQDVWRZKHWKHU75ȕPRGXODWHV
18S expression anGIRUWKLVUHDVRQLQIXWXUHT3&5DQDO\VHVDVHFRQGµKRXVHNHHSLQJ¶JHQHZLOO
DOVREHXVHG LQRUGHU WRPLWLJDWH WKLVSRWHQWLDOSUREOHP2IQRWH WKH H[SUHVVLRQRI WKHȕ-actin 
JHQHZKLFKLVZLGHO\XVHGIRUJHQHµQRUPDOLVDWLRQ¶KDVUHFHQWO\EHHQVKRZQWREe influenced 
by systemic thyroid hormone status (Holford et al., 2008)$OWKRXJK WKH HIIHFWV RI75ȕRQȕ-
actin expression remain undefined it will nevertheless avoided as a reference gene in future 
qPCR studies, which will be performed to look at changes in the expression of other 
neuropeptides that are implicated in hypothalamic appetite pathways (see 5.2). 
In addition, in order to further investigate the mechanism by which intra-90175ȕNQRFNGRZQ
results in hyperphagia and obesity, static incubation of hypothalamic explants will be carried out 
in order to measure the ex vivo release of hypothalamic peptides (see 5.2). 
In summary, important findings have been presented in this chapter, which further define the 
phenotype of intra-901 75ȕ NQRFN GRZQ ,PSRUWDQWO\ WKH REHVLW\ DSSHDUV WR EH D
µK\SHUSKDJLFREHVLW\¶DOWKRXJKIXUWKHUZRUNLVQHHGHGWRGHILQLWLYHO\FODULI\WKHUROHRIHQHUJ\
expenditure and locomotor activity in this mouse model (see 5.2). In addition, the work 
described in this chapter confirms the specificity of the VMN to the phenotype. The wider 
implications of these findings and the future work that will be performed to further investigate 
WKHUROHRI75ȕLQWKH901LQWKHPHGLDWLRQRIIRRGLQWDNHDQGERG\ZHLJKWZLOOEHGLVFXVVHGLQ
chapter five.  
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5 CHAPTER FIVE 
 
5.1 GENERAL DISCUSSION 
Obesity represents one of the major public health challenges of our time. In 2007, the UK 
JRYHUQPHQWFRPPLVVLRQHGµ7DFNOLQJREHVLWLHV)XWXUHFKRLFHV¶ Foresight Report predicted that 
if no action was taken, sixty per cent of men, fifty percent of women and twenty five percent of 
children would be obese by the year 2050 (Foresight, 2007). These projections are important 
because obesity is associated with significant excess morbidity and mortality, both of which are 
greatly attenuated when even modest amounts of weight are lost.  
A robust and highly conserved physiological system is in place which maintains the consistency 
of body weight in mammals. Many of the complex neuronal and endocrine pathways that 
regulate body weight converge within the hypothalamus, which is a key CNS centre in the 
control of energy homeostasis. Targeted genetic disruption of these hypothalamic pathways can 
induce changes in feeding behaviour and body weight and these findings have provided 
significant insights into the pathophysiology of obesity, the archetypal outcome of an imbalance 
between food intake and energy expenditure.  
Several lines of evidence suggest the importance of thyroid hormones and the VMN in the 
regulation of food LQWDNHERG\ZHLJKWDQGHQHUJ\H[SHQGLWXUH75ȕLVKLJKO\H[SUHVVHGLQWKH
VMN, although its role in energy homeostasis has not previously been characterised. For these 
reasons, at the outset of this work, I hypothesised that 75ȕ LQ WKH 901 SOD\V D VLJQLILcant 
physiological role in the regulation of energy homeostasis.  
A combination of rAAV-mediated gene transfer into the VMN of adult mice and site-specific 
recombination by the Cre-LoxP system was used in this work. The advantages of these 
approaches are that they can be used in adult animals and that they allow for temporo-spatial 
control over transgene expression. These important features circumvent the problems associated 
with global transgenic models, in particular developmental abnormalities and compensations. In 
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addition, targeted knock down RI75ȕZLWKLQ WKH901 LQ DGXOW HXWK\URLGPLFHSHUPLWWHG WKH
study of the physiological, rather than the pharmacological or pathophysiological role of the 
receptor.  
75ȕ NQRFN GRZQ ZLWKLQ WKH 901 UHVXOWV LQ D SKHQRWype of hyperphagia and obesity. This 
phenotype is novel, highly significant and reproducible.  
7KHWHQHWRI WKHVHFRQFOXVLRQVLV WKDW75ȕNQRFNGRZQKDVRFFXUUHGLQWKH9017KLVFDQEH
surmised from several of the presented findings. Firstly, accurate nuclear targeting has been 
demonstrated by Indian ink injection, in situ hybridisation and fluorescence microscopy, with the 
latter two techniques also confirming transgene expression. Secondly, confirmation of Cre 
UHFRPELQDVH H[FLVLRQ RI WKH 75ȕflox allele solely within the hypothalamus, with no excision 
occurring within control CNS tissues has been shown by PCR. Lastly, rAAV-Cre mice failed to 
respond to the orexigenic stimulus of sc T3 which provides circumstantial evidence of functional 
75ȕNQRFNGRZQLQWKH901,WZRXOGEHSRVVLEOHWRGHULYHIXUWKHUFRQILUPDWLRQRI75ȕNQRFN
down by in situ hybridisation of rAAV-Cre brains with a radio-labelled 75ȕ SUREH, 
FRPSOHPHQWDU\WRH[FLVHG75ȕflox mRNA and this is discussed in 5.2.  
It has been known for over half a century that lesioning the VMN in rats results in marked 
hyperphagia and severe obesity (Hetherington and Ranson, 1940). It is therefore important to clarify 
that the increased food intake and body weight described in this work arise due to intra-90175ȕ
knock down and that they do not occur because of surgical damage to the nucleus. This former point 
can be concluded because identical stereotaxic surgery was performed in both rAAV-Cre and 
rAAV-GFP control mice. If the observed phenotype were due to surgical damage of the VMN, it 
should follow that both rAAV-Cre and rAAV-GFP mice would develop hyperphagia and obesity. 
Instead, the control mice remained lean, with an unchanged in food intake. In addition, whilst the 
features of VMN-lesioned rats appear to be similar to those presented in this work, certain important 
difference exist between the two models. Firstly, VMN-lesioned rats become hyperphagic 
immediately after surgery. Indeed, the onset is so rapid, that it occurs in some animals even before 
full recovery from anaesthesia (Brooks et al., 1946). This speed of onset was not seen in intra-VMN 
75ȕNQRFNGRZQPLFHLQZKLFKWKHKyperphagic/obese phenotype manifested itself in parallel to 
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the expected chronology of rAAV delivered transgene expression. Secondly, rats with VMN lesions 
show a disruption to the normal circadian pattern of rodent food intake, such that a significant 
proportion of feeding occurs during the light phase which is the usual rest period (Kakolewski et al., 
1971). In the behavioural analysis, which was conducted in this work at six different time points 
over a twenty four hour period, there was no change in the normal diurnal feeding pattern.  
Despite these differences between rats with VMN lesions and mice with intra-90175ȕNQRFN
GRZQ LW LV LPSRUWDQW WRFODULI\ZKHWKHU&UH UHFRPELQDVH LWVHOI FDXVHV D µFKHPLFDO OHVLRQ¶RI WKH
VMN, an effect which is not controlled for by the injection of rAAV-GFP in the control group. Cre 
recombinase has been widely used within the hypothalamus in order to define the central pathways 
regulating food intake and body weight and there has been no suggestion from these studies that Cre 
recombinase has a toxic effect on neurons (examples include (Balthasar et al., 2004, Dhillon et al., 
2006, Vong et al., 2011). Nevertheless, this issue can be easily addressed in future work by the 
injection of rAAV-Cre into the VMN of wild type mice in which the THRB gene does not contain 
LoxP sites. Recombinant AAV-GFP will be used for the control injections. It would be predicted 
WKDWLIWKHREVHUYHGSKHQRW\SHLVGXHWRDµFKHPLFDO OHVLRQ¶RIWKH901E\&UHUHFRPELQDVHDQGQRW
GXHWR&UHPHGLDWHG75ȕNQRFNGRZQLQWKH901WKHQWKHµQRQ-IOR[HG¶&UHLQMHFWHGPLFHVKRXOG
also become obese and hyperphagic (see 5.2). 
The work that has been presented has shown the specificity of TRȕ knock down in the VMN to 
the manifestation of the hyperphagic/obese phenotype since injection of rAAV-Cre into the LV 
did not result in a change in food intake or body weight. Although in situ hybridisation studies 
remain to be performed on rAAV-Cre-LV brains, given the results of the in situ hybridisation 
studies described and the confirmation by PCR of Cre recombinase excision of the TRȕflox allele, 
it would seem unlikely that the transgene was either not expressed or that its product was 
inactive in this group of mice. Determination of the specificity of TRȕ action in the VMN in the 
regulation of food intake and body weight further supports the use of the tissue specific rAAV-
Cre approach. Confirmation that TRȕ knock down solely within the VMN results in the observed 
phenotype is in agreement with the conclusions of the classical studies of the middle of the last 
FHQWXU\ WKDW SURSRVHG WKH LPSRUWDQFH RI WKH901 DV D µVDWLHW\ FHQWUH¶ D FRQFHSW ZKLFK KDV
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contemporarily been confirmed by molecular biology and transgenic studies (Chee et al., 2010, 
Dhillon et al., 2006, Kennedy, 1950, Majdic et al., 2002, Unger et al., 2007, Xu et al., 2003).  
Body weight depends on the balance of energy taken in and energy expenditure. If the former 
exceeds the latter then weight gain occurs. Energy expenditure was therefore measured by 
quantitation of UCP-1 mRNA in BAT, which showed no difference between the experimental 
and the control groups. The results of the pair-feeding study are in keeping with this as they 
demonstrate the key role of increased food intake to the development of obesity following intra-
90175ȕNQRFNGRZQ In this study, the experimental mice did not become obese when pair-
fed to the mean food intake of controls, but the rapid rise in body weight on the restoration of 
free feeding, accompanied by a marked increase in food intake adds substantial credence to the 
conclusion that hyperphagia in all or in large part accounts for the obesity that occurs following 
75ȕNQRFNGRZQLQWKH901 
This contrasts with the findings of Lopez et al, who have reported that ICV administration of T3 
increases expression of UCP-1 mRNA in BAT, an effect which is abolished by intra-VMN 
injection of AAV encoding a dominant negative form of TR (Lopez et al., 2010). While the 
limitations of the findings of Lopez et al have been discussed in 3.15, their work nonetheless 
implies that there may be a connection between the intra-VMN liganded-TR complex and BAT 
thermogenesis and this warrants further investigation (see 5.2).  
Increased food intake appears to be the primary determinant of the elevated body weight of intra-
90175ȕNQRFNGRZQPLFHDOWKRXJKWKHPHFKDQLVPE\ZKLFKWKHK\SHUSKDJLDRFFXUVLQWKLV
PRGHO UHPDLQV WREHHOXFLGDWHG6LQFH75ȕ LV DQXFOHDU WUDQVFULSWLRQ IDFWRU75ȕNQRFNGRZQ
could result in an alteration in the expression of neuropeptides which regulate feeding. For this 
reason, qPCR was performed in order to look for changes in the expression of four well-
characterised hypothalamic mediators of food intake. There was no difference in the mRNA 
expression of NPY, AgRP, POMC or BDNF. It remains a possibility, that in the examination of 
whole hypothalami, changes in mRNA expression in individual nuclei may be muted. In 
addition, changes in mRNA expression are not directly proportional to protein expression 
because of the effect of post-transcriptional processing. Therefore, while these results do not 
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entirely discount the role of these peptides, they do make their involvement significantly less 
likely.  
On review of the appetite circuits within the VMN and the connections of the VMN with other 
hypothalamic nuclei and CNS centres (see 1.2.2.3.1.2 and 1.2.2.3.2) there remain numerous 
other neuropeptides and receptors, the expression of which, could conceivably be disrupted by 
75ȕ NQRFN GRZQ LQ WKH 901 7KH P51$ H[SUHVVLRQ RI VRPH RI WKHVH SURWHLQV ZLOO EH
examined by future qPCR analysis (see 5.2). ,W LVDOVRSRVVLEOH WKDW75ȕNQRFNGRZQGLVUXSWV
neuropeptide release from the VMN and this will also be investigated in future work (see 5.2).  
In summary, the work presented in this thesis, confirms the hypothesis that 75ȕ LQ WKH901
plays a significant physiological role in the regulation of food intake and body weight. This work 
is the first to characterise WKHHVVHQWLDOIXQFWLRQRI75ȕLQWKH901LQWKHUHJXODWLRQof energy 
KRPHRVWDVLV E\ GHPRQVWUDWLQJ WKDW 75ȕ NQRFN GRZQ LQ WKH901 UHVXOWV LQ K\SHUSKDJLD DQG
obesity. These novel findings will be further characterised by planned future work.  
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5.2 FUTURE WORK 
The work described in thesis demonstrates the novel and robust phenotype of hyperphagia and 
REHVLW\ZKLFK UHVXOWV IURP75ȕ NQRFN GRZQ LQ WKH9011HYHUWKHOHVV WKHUH UHPDLQ VHYHUal 
areas which require further clarification. 
,QRUGHUWRVXEVWDQWLDWHWKHFRQFOXVLRQWKDW75ȕNQRFNGRZQRFFXUVLQWKH901IROORZLQJLQWUD-
nuclear injection of rAAV-Cre, in situ hybridisation will be carried out following the successful 
design of a radio-labelled probe WKDWLVFRPSOHPHQWDU\WRSDUWRIWKHH[FLVHG75ȕflox allele.  
,W LV LPSRUWDQW WR GHPRQVWUDWH WKDW WKH REVHUYHG SKHQRW\SH LV GXH WR 75ȕ NQRFN GRZQ LQ WKH
901DQGWKDWLWLVQRWVHFRQGDU\WRµFKHPLFDOOHVLRQLQJ¶RIWKH901E\&UHUHFRPELQDVH7KLV
will be addressed by a study identical to that described in 3.3 except that the mice will wild type 
mice in which the THRB JHQHKDVQRWEHHQµIOR[HG¶5HFRPELQDQW$$9-GFP will be injected 
bilaterally into the VMN of the control group. It would be predicted that if the observed 
phenotype is due to a Cre induced damage of the VM1WKHQWKHµQRQ-IOR[HG¶&UHLQMHFWHGPLFH
should also become obese and hyperphagic. 
While it has been shown by the injection of rAAV-Cre into the LV that the phenotype described 
appears to be specific to the VMN, in situ hybridisation remains to be performed on rAAV-Cre-
LV brains in order to verify injection accuracy and transgene expression. In addition, so as to 
further explore the specificity of the VMN to the phenotype, rAAV-Cre will be injected into two 
RWKHU&16DUHDVZKLFKKLJKO\H[SUHVV75ȕ and which have been implicated in the regulation of 
food intake, the lateral septal nucleus and the paraventricular thalamic nucleus (Bradley et al., 
1989, Coury, 1967, Date et al., 1999, Landry et al., 2007, Perez et al., 2011, Allen Institute for 
Brain Science, 2011). In these pilot studies (rAAV-Cre, n=5; rAAV-GFP, n WKHHIIHFWRI75ȕ
knock down on food intake and body weight will be measured over sixty three days and any 
resultant phenotype will be investigated.  
The contribution of energy expenditure and locomotor activity to the obese phenotype remains to 
be defined. In the behavioural analysis, there was a significant reduction in nocturnal locomotor 
activity in intra-901 75ȕ NQRFk down mice, however this study was performed after the 
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development of the obese phenotype, making it difficult to determine if reduced activity 
contributes to the obesity or vice versa. In order to clarify this, a behavioural analysis will be 
performed at day twenty one post-rAAV-Cre injection, when the transgene has been expressed 
but before the phenotype has developed.  
This cohort will also be used for assessment of energy expenditure using the comprehensive 
laboratory animal monitoring system (CLAMS) (Columbus Instruments, Columbus, OH, USA) 
which permits in vivo measurement of oxygen consumption, carbon dioxide production and 
locomotor activity as previously described (Smith et al., 2006). Since obesity can affect energy 
expenditure, this study will be conducted following transgene expression but before the mice 
become obese.  
MRI quantitation of WAT mass and WAT tissue distribution showed that obese intra-90175ȕ
knock down mice have significantly more total, subcutaneous and internal WAT compared with 
rAAV-GFP injected controls. Interestingly, despite having a higher quantity of internal WAT, 
MRI spectroscopy did not show an increase in hepatic or skeletal muscle fat deposition in the 
rAAV-Cre group. Liver and skeletal muscle samples were taken at the time of mouse killing and 
the fat content of these tissues will be assessed by histological analysis following oil red O 
staining, which will facilitate the clarification of this issue. 
The increase in internal fat content in intra-90175ȕNQRFNGRZQPLFHKDV LPSOLFDWLRQV IRU
glucose tolerance and insulin sensitivity (Fox et al., 2007). Although plasma insulin has been 
shown to be significantly higher in the obese rAAV-Cre animals, formal in vivo assessment of 
glucose homeostasis is required, and a GTT (glucose tolerance test) and an ITT (insulin tolerance 
test) will be performed in the mice used for the behavioural and CLAMS studies. Of note, the 
GTT and ITT will involve fasting the animals and therefore the behavioural analysis will be 
performed prior to the GTT/ITT, with a washout period in between in order to prevent 
interference with the behavioural study. 
The mechanism of hyperphagia resulting from 75ȕNQRFNGRZQLQWKH901ZLOOFRQWLQXHWREH
investigated. The mRNA expression of other hypothalamic mediators of food intake such as 
CART, SF-1, ObR and MC4R (see 1.2.2) will be investigated by qPCR. In addition, the release 
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of hypothalamic peptides known to influence energy homeostasis will be investigated by static 
incubation of hypothalamic explants as previously described (Stanley et al., 1999). 
7KHZRUN GHVFULEHG LQ WKLV WKHVLV GHPRQVWUDWHV WKH HVVHQWLDO UROH RI 75ȕ LQ WKH901 LQ WKH
mediation of food intake and body weight. The profound hyperphagia and obesity which arise 
following intra-VMN 75ȕ knock down are as pronounced as some of the most prominent 
transgenic models of disruption within hypothalamic appetite circuits. Although the findings 
described are not immediately translatable to the treatment of human obesity, as our 
understanding of the central energy regulating pathways develops, so too does the possibility of 
targeted anti-obesity drug therapy. Future work will further augment our understanding of the 
UROHRI75ȕLQWKH901DVDNH\SOD\HULQWKHUHJXODWLRQRIHQHUJ\KRPHRVWDVLV 
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APPENDIX I: SOLUTIONS USED IN THIS THESIS 
ABC Buffer 
Combine solutions A, B and C in the following proportions: 100:250:150 and store at      
 -20ºC. 
Solution A 
Add 1ml of 125mM MgCl2 and 1.25M Tris-HCl (pH 8.0) to 18µl mercaptoethanol, 5µl 
100mM dATP, 5µl 100mM dTTP and 5µl dGTP. 
Solution B 
2M Hepes (pH6.6) titrated with 4M NaOH. 
Solution C 
Random oligonucleotides (112µg/ml). 
 
5% Acetic acid in 95% ethanol 
Make up 400ml 95% ethanol by adding 380ml 99.7-100% ethanol to 20ml GDW. Make 
up 20ml 5% acetic acid by adding 4ml 5% acetic acid to 16ml GDW. Combine 380ml 
95% ethanol with 20ml 5% acetic acid. 
 
Amasino wash 
Mix 250ml 1M Na phosphate buffer (pH 7.2), 2ml 500mM EDTA and 100ml 20% SDS 
with 650ml GDW. 
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5M Ammonium acetate 
Dissolve 385g CH3.COONH4 in 600ml autoclaved GDW then make up to 1L. 
 
Ampicillin (100mg/ml) 
'LVVROYH J DPSLFLOOLQ LQ PO*': VWHULOLVH E\ SDVVDJH WKURXJK D ȝP ILOWHU DQG
distribute in 1ml aliquots. 
 
2.5mM Aurintricarboxylic acid (ATA) 
 Dissolve 0.1183g ATA in 100ml GDW. 
 
%DNHU¶V\HDVWtRNA (10mg/ml)  
Make up with GDW, aliquot and store at -20°C. 
 
Caesium chloride saturated propan-2-ol 
Vigorously mix 100g CsCl2, 100ml GDW and 100ml propan-2-ol and leave to settle. 
 
2M Calcium chloride (CaCl2)  
Dissolve 5.88g CaCl2.H2O in 20ml GDW and sterilise by passing through a 0.2µm filter. 
Store in 1ml aliquots at -20°C. 
 
1% Cresyl violet solution 
Add 1ml cresyl Violet to 99ml GDW, then pass through a Whatman GF/C filter. 
 
100x 'HQKDUW¶VVROXWLRQ 
Dissolve 10g ficoll, 10g polyvinylpyrrolidone (PVP) and 10g BSA (Pentax fraction V) 
and make up to 500ml with GDW. Aliquot and store at -20°C.  
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Denaturing solution (DNA)  
Dissolve 43.5g NaCl in 430 ml GDW. Add 25ml 10M NaOH and make up to 500ml with 
GDW. 
 
1M Dithiothreitol (DTT) 
Dissolve 154g C4H10O2S2 in 1L GDW. 
 
DNA/RNA loading Buffer 
Mix 3.125ml 80% glycerol, 50µl 0.5M C10H14H2O8Na2.H2O and 6.075ml autoclaved 
water, then add 10mg orange G. 
 
70% Ethanol in GDW 
To make 1L, add 700ml 99.7-100% ethanol to 300ml GDW. 
 
75% Ethanol in GDW 
 To make 1L, add 750ml 99.7-100% ethanol to 250ml GDW. 
 
95% Ethanol in GDW 
To make 1L, add 950ml 99.7-100% ethanol to 50ml GDW. 
 
0.5M Ethylenediaminetetra-acetic acid (EDTA) (pH 8.0) 
Dissolve 181.6g C10H14H2O8Na.2H2O in 800ml GDW and adjust to pH 8.0 with 1M 
NaOH. Make up to 1L with GDW. 
 
4% Formaldehyde solution 
 Add 100ml 40% formaldehyde to 900ml GDW. 
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4% Formaldehyde in 0.01M PBS 
 Add 8ml 40% formaldehyde solution to 400ml 0.01M PBS. 
 
Formamide (de-ionised) 
Add 2.7g duolite MB to 100ml formamide and stir until the duolite turns brown 
(approximately one hour). Remove the duolite by passing through Whatman GF/C filters, 
aliquot and store at -20°C. 
 
Glucose-Tris-EDTA (GTE) buffer  
Mix 2.5 ml 1M Tris-HCl (pH 8.0), 2ml 0.5M C10H14H2O8Na2.2H2O and 5ml 18% 
glucose and make up to 100ml with GDW. Sterilise by passing through a 0.2µm filter.  
 
10% Glycerol solution 
Add 10ml glycerol to 90ml of distilled water. 
 
1x Hepes buffered saline (HeBS) (pH 7.05) 
Dissolve 0.8g NaCl, 37.5mg KCl, 10.5mg, Na2HPO4, 0.11g dextrose and 0.5g Hepes in a 
total volume of 90mls GDW. Adjust to pH 7.05 with 0.5M NaOH and add GDW to a 
final volume of 100ml. Sterilise by passing through a 0.2µm filter and store in 5 ml 
aliquots at -20oC. 
 
Hybridisation buffer for northern blot analysis and for dot-blot analysis 
Add 0.5g dried milk powder and 0.5ml 500mM EDTA to 48ml GDW and leave at 37°C 
to dissolve. Allow to cool then add 25ml 1M Na phosphate buffer, 25ml 20% SDS and 
1ml 2.5M ATA. 
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Hybridisation buffer for in situ hybridisation 
Prepare dextran sulphate solution by the addition of 1.5ml GDW to 1g dextran sulphate 
and incubate in a water bath at 60°C for two hours. In a total volume of 4ml add together 
POIRUPDPLGHO01D&OOW51$PJPOO['HQKDUW¶V, 50µl 
1M Tris (pH 8.0), 40µl 1M dithiothreitol (DTT), 10µl 0.5M EDTA (pH 8.0), 1.1ml GDW 
and 1ml (50%) dextran sulphate. 
 
Hybridisation buffer for oligo dT labelling 
Add 25ml 5xSSPE and 0.2g 0.2% milk powder to 75ml GDW and dissolve at 37oC. Add 
200µl nonidet and incubate on ice until dissolved.  
 
LB agar plates  
Add 7g agar to 500ml LB and melt by autoclaving. 
 
Lysis buffer (pH 8.5) 
Add 8.765g NaCl to 6.055g NH2C(CH2OH)3. Adjust to pH 8.5 with HCl and make up to 
1L. 
 
Luria-Bertani (LB) culture medium (pH 7.5) 
Dissolve 10g NaCl, 10g tryptone and 5g yeast extract. Adjust to pH 7.5 with 10M NaOH. 
Sterilise by autoclaving. 
 
2M Magnesium chloride (MgCl2)  
Dissolve 406.6g MgCl2.6H2O in 1L GDW. 
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20x 3-(N-Morpholino) propanesulphonic acid (MOPS) buffer (pH 7.0) 
Dissolve 83.6g 3-(N-Morpholino) propanesulphonic acid (MOPS), 8.1g NaAc, 7.4g 
C10H14H2O8Na2.2H2O and 2.5ml formaldehyde in 800ml GDW. Adjust to pH 7.0 with 
10M NaOH and make up to 1L.  
 
Neutralising solution (pH 7.5) 
Dissolve 43.5g NaCl and 60.2g NH2C(CH2OH)3 in 430 ml GDW and adjust to pH 7.5 
with 70ml HCl.  
 
Phenol: chloroform: iso-amyl alcohol (pH 8.0) 
Mix equilibrated phenol, chloroform and iso-amyl alcohol in the ratio 25:24:1 and store 
under 0.1M Tris-HCl (pH 8.0). 
 
Phosphate buffered saline (PBS)  
0.1M PBS (10x) 
Dissolve 80g NaCl, 2g KCl, 14.4g Na2HPO4 and 2.4g KH2PO4 in 800ml GDW.  
0.01M PBS (1x) 
Add 100ml 0.1M PBS to 900ml GDW. 
 
5M Potassium acetate (KAc) 
Dissolve 294.4g CH3COOK in 500ml GDW. Add 115ml glacial acetic acid and make up 
to 1L with GDW.  
 
3M Potassium hydroxide  
 Dissolve 198g KOH in 1L GDW. 
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Proteinase K (20mg/ml) 
 Dissolve 20mg in 1ml GDW, distribute into 100µl aliquots and store at -20°C. 
 
RNA denaturing buffer (DENAT) 
 Mix 1ml formamide, 300µl formaldehyde and 100µl 20x MOPS. 
 
RNase A (10mg/ml)  
Dissolve 100mg RNase A in 10ml 10mM Tris-HCl (pH 7.5) and 15mM NaCl and boil 
for fifteen minutes. Allow to cool, distribute into 1ml aliquots and store at -20°C. 
 
RNase buffer for in situ hybridisation 
Add together 40ml 5M NaCl, 2ml 2M Tris-HCl (pH 8.0), 0.8ml 0.5M EDTA and 
PO *': DQG ZDUP LQ D & ZDWHUEDWK $GG ȝJPORNase A five minutes 
before use. 
 
20x Saline sodium citrate (SSC) buffer (pH 7.0) 
Dissolve 1.735g NaCl and 882g Na3C6H5O7.2H2O in 8L GDW. Adjust to pH 7.0 and 
make up to 10L. 
 
Sephadex G50 
Add 8g fine grade Sephadex G50 beads (diameter: 20-80µm), 2ml 100x TE and 0.1ml 
20% SDS to 200ml GDW and autoclave to expand the beads. 
 
2M Sodium acetate (pH 5.2) 
Dissolve 164.1g CH3COONa in 800ml GDW, adjust to pH 5.2 with glacial acetic acid 
and make up to 1L with GDW. 
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3M Sodium acetate (pH 4.6) 
Dissolve 246.1g CH3COONa in 800ml GDW, adjust to pH 4.6 with glacial acetic acid 
and make up to 1L with GDW. 
 
3M Sodium chloride  
Dissolve 175.3g NaCl in 1L GDW. 
 
5M Sodium chloride  
 Dissolve 292.2g NaCl in 1L GDW. 
 
20% (w/v) Sodium dodecyl sulphate (SDS) 
Add 200g SDS to 800ml GDW and heat to 60°C while stirring. Allow to cool and make 
up to 1L with GDW. 
 
0.2M Sodium hydroxide/1%SDS  
Add 3ml 10M NaOH to 140ml GDW, mix and add 7.5ml 20% SDS. 
 
10M Sodium hydroxide 
Dissolve 400g NaOH in 500ml GDW. Make up to 1Lwith GDW. 
 
1M Sodium phosphate buffer (pH 6.8) 
Dissolve 138g NaH2PO4.H2O in 1L GDW. Dissolve 142g Na2HPO4 in 1L GDW. Mix 
423 ml NaH2PO4.H2O solution with 577ml Na2HPO4 solution. 
Solution A for dot-blot analysis 
Add together 10µl 2M Tris-Hcl (pH 8.0), 0.5µl MgCl2 and 1µl DNase I. Make up to 1ml 
with 988.5µl GDW. 
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Solution B for dot-blot analysis 
Add together 90µl 2M Tris-HCl (pH 8.0), 360µl 5M NaCl, 360µl 0.5M EDTA, 450µl 
20% SDS and 50µl proteinase K (20mg/ml). Make up to 20ml with 18 ml GDW. 
 
20x Sodium chloride, sodium hydrogen phosphate, EDTA (SSPE) buffer (pH 7.7) 
Dissolve 1.753g NaCl, 14.2g Na2HPO4 and 7.4g C10H14H2O8Na2.2H2O in 700ml GDW, 
adjust to pH 7.7 with 10M NaOH and make up to 1L with GDW. 
 
20% Sucrose solution 
 Dissolve 20g sucrose in 80ml GDW. 
 
0.1M Triethanolamine (TEA) buffer (pH 8.0) 
Dissolve 18.6g C6H15NO3.HCl in 800ml GDW. Add HCl to pH 8.0 and make up to 1L 
with GDW. 
 
50x Tris-acetate-EDTA (TAE) buffer  
Dissolve 242g NH2C(CH2OH)3 in 843ml GDW then add 57ml glacial acetic acid and 
100ml 0.5M C10H14H2O8Na2.2H2O. 
 
100x Tris-EDTA (TE) buffer (pH 7.5) 
Dissolve 121.1g NH2C(CH2OH)3 and 3.7g C10H14H2O8Na2.2H2O in 800ml GDW. Adjust 
to pH 7.5 with hydrochloric acid and make up to 1L with GDW. 
 
Tris-EDTA-Sodium chloride (TES) buffer  
Mix 25ml 1M Tris-HCl (pH 8.0), 5ml 5M NaCl and 5ml C10 H14H2O8Na2.2H2O. Make up 
to 500ml with distilled water. 
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1M Tris (hydroxymethyl) aminomethane-hydrochloric acid (Tris-HCl) (pH 7.5)  
Dissolve 121.1g NH2C(CH2OH)3 in 800ml GDW. Adjust to pH 7.5 with HCl and make 
up to 1L.  
 
1M Tris (hydroxymethyl) aminomethane-hydrochloric acid (Tris-HCl) (pH 8.0)  
Dissolve 121.1g NH2C(CH2OH)3 in 800ml GDW. Adjust to pH 8.0 with HCl and make 
up to 1L.  
 
Universal wash buffer  
Mix 10ml 20% SDS with 10ml 20x SSPE and make up to 1L with 980ml GDW. 
 
Versene  
Dissolve 16g NaCl, 0.4g KCl, 2.88g Na2HPO4.2H2O, 1.2g C10H14H2O8Na2.2H2O and 
0.4g KH2PO4 in 1L GDW, add 3ml phenol red and make up to 2L with GDW. Sterilise 
by autoclaving. 
 
Yeast-tryptone (YT) culture medium (pH 7.0) 
Add 5g NaCl, 16g bacto-tryptone and 10g yeast extract to 900ml GDW. Add NaOH to 
pH 7.0 and sterilise by autoclaving. 
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APPENDIX II: DRUG REGIMENS FOR STEREOTAXIC SURGERY 
Amoxicillin/flucloxacillin antibiotic mixture 
Five hundred milligrams amoxicillin powder for injection were reconstituted in 20ml 
water for injection. Five hundred milligrams flucloxacillin powder for injection were 
reconstituted in 10ml water for injection. The amoxicillin and flucloxacillin solutions 
were mixed in a 1:1 ratio and 0.2ml administered by ip injection. 
 
Atipamezole hydrochloride (Antisedan)  
Atipamezole hydrochloride (Antisedan) (5mg/ml) was diluted 1:10 with water for 
injection and 0.1ml administered by sc injection. 
 
Buprenorphine hydrochloride (Temgesic) 
Buprenorphine hydrochloride (Temgesic) (0.3mg/ml) was diluted 1:10 with water for 
injection and 0.1ml administered by sc injection. 
 
Carprofen (Rimadyl)  
Carprofen (Rimadyl) (50mg/ml) was diluted 1:25 with water for injection and 0.1ml 
administered by sc injection. 
 
Kaetamine/xylazine anaesthesia 
Ketamine (Ketaset) (100mg/ml) was diluted 1:3 with water for injection. Xylazine 
(Rompun) (23mg/ml) was diluted 1:10 with water for injection. The ketamine and 
xylazine solutions were mixed in a 1:1 ratio and 0.2ml/25g mouse body weight 
administered by ip injection. 
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APPENDIX III: OLIGONUCLEOTIDE PRIMERS 
All oligonucleotide primers were supplied by Oswel DNA Service, University of Southampton, 
Southampton, UK 
 
Oligonucleotide primers for sequencing sub-cloned pTR-CGW plasmid containing Cre 
recombinase transgene: 
Accession number 774944: AGC-TCT-CGA-GAA-GCT-TGG-TCG-AGT-GCC-ATG 
Accession number 774945: AGC-TCG-TAC-GTA-GAG-CAA-TCA-TTT-ACG-CGT 
 
Oligonucleotide primers for AAV plasmid sequencing: 
Accession number 830346: TGA-CCT-CCA-TAG-AAG-ACA-CC 
Accession number 830347: GGT-AAG-ATG-CTC-AAC-TGC-AG 
 
Oligonucleotide primers for TRȕflox/flox genotyping and to confirm Cre mediated excision of 
75ȕflox allele: 
Accession number ße5S1: CAG CCA CTG GAA GCA GAA G 
Accession number ßi5AS5: AAC GTC ACT GTT GTG GTG TAC AGG 
 
Oligonucleotide primers to confirm Cre mediated H[FLVLRQRI75ȕflox allele: 
$FFHVVLRQQXPEHUȕH6&$7&7$7*77**&$7**&$$&AGA.CT 
Accession number ßi5AS5: AAC GTC ACT GTT GTG GTG TAC AGG 
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Oligonucleotide primers for UCP-1 DNA probe: 
Accession number BC012701: AGC TGG ATC CAA GGC CAG GCT TCC AGT ACT 
Accession number BC012702: AGC TGA ATT CGG TTT GAT CCC ATG CAG ATG 
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APPENDIX IV: NUCLEOTIDE SEQUENCE OF THE CRE RECOMBINASE TRANSGENE SUB-CLONED 
INTO PTR-CGW PLASMID  
Sequencing of pTR-CGW-Cre-GFP plasmids was performed by the DNA Sequencing Service, 
Medical Research Council Genomics Core Laboratory, Imperial College London, UK, using 
specific oligonucleotide primers (APPENDIX III). Sequence data was uploaded onto the 
nucleotide basic local alignment search tool (BLAST) (National Center for Biotechnology 
Information (NCBI), Bethesda, MD USA) in order to compare the plasmid sequence with gene 
sequences held on the NCBI gene database. The submitted queries were ninety eight percent 
homologous to the Cre recombinase gene sequence (FIGURE A4.1). 
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FI GURE A4.1 RESULTS OF NUCLEOTIDE SEQUENCE IDENTIFICATION SEARCH USING THE 
NUCLEOTIDE BASIC LOCAL ALIGNMENT SEARCH TOOL DATABASE (NCBI, BETHESDA, MD, 
USA) 
µQuery¶ indicates the sequence of the pTR-CGW-Cre-GFP plasmid. µSbjct¶ indicates the Cre 
recombinase gene sequence. The numbers indicate nucleotide position within the sequence. The 
submitted queries were ninety eight percent homologous to the Cre recombinase gene sequence. 
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APPENDIX V: LIST OF SUPPLIERS 
Allen Institute for Brain Science, Seattle, Washington, USA 
Allentown, New Jersey, USA 
Applied Biosystems, Warrington, UK 
ATCC, Middlesex, UK 
Bayer, Newbury, UK 
Bilaney Consultants Ltd., Sevenoaks, Kent, UK 
Biochrom, Cambridge, UK 
Bioline, London, UK 
Braun Medical Ltd., Sheffield, UK 
Bright Instrument Company, Huntingdon, Cambridgeshire, UK 
Carl Zeiss, Jena, Germany 
Centaur Services, Somerset, UK 
Clark Electromedical Instruments, Pangbourne, UK 
Columbus Instruments, Columbus, Ohio, USA  
CP Pharmaceuticals, Wrexham, UK 
Crystal Chem, Illinois, USA 
DJB Labcare, Buckinghamshire, UK 
Eli Lilly, Basingstoke, UK 
Ethicon, Gargrave, Yorkshire, UK 
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Fisher Scientific, Loughborough, Leicestershire, UK 
GE healthcare, Buckinghamshire, UK 
Gibco, Paisley, UK 
GraphPad Software Inc., San Diego, California, USA 
Harvard Apparatus, Edenbridge, UK 
Helena Biosciences, Sunderland, Tyne and Wear, UK 
Invitrogen, Paisley, UK 
Jet X-Ray, London, UK 
Kemprotec Ltd., Middlesbrough, UK 
Kodak, Hemel Hempstead, Hertfordshire, UK 
Life Sciences Technology, Eggenstein, Germany 
Merial, Harlow, UK 
Microfield Scientific Ltd., Dartmouth, UK 
Molecular Dynamics, Amersham, UK 
MP Biomedicals, Orangeburg, New York, USA 
National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA 
National Institutes of Health (NIH), Bethesda, Maryland, USA  
New England Biolabs, Hertfordshire, UK 
Novagen, Nottingham, UK 
Orbital Biosciences, Topsfield, MA, USA  
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Oswel DNA Service, University of Southampton, Southampton, UK 
Parke-Davis, Gwent, UK 
Promega, Southampton, UK 
Randox laboratories Ltd., Co. Antrim, UK 
Sarstedt, Leicester, UK 
Schering-Plough Ltd., Hertfordshire, UK 
Special Diets Services (SDS), Witham, Essex, UK 
Seton Scholl Healthcare Ltd., Gloucester, UK 
Techne Inc., Burlington, New Jersey, USA 
Thermo Shandon Ltd., Cheshire, UK 
Sigma-Aldrich, Dorset, UK 
StataCorp LP, Texas, USA 
Surgipro II, Johnson and Johnson, UK 
Techne Inc., Burlington, New Jersey, USA 
Thermo Electron Corporation, San Jose, California, USA 
TomoVision, Quebec, Canada 
Varian Medical Systems Ltd., West Sussex, UK 
VWR International, Leicestershire, UK 
Wallac, Waltham, Massachusetts, USA 
